	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
S107-PMC1888711	PMC1888711	5/2007	S107-PMC1888711	['supplementation with Vitamins C and E HAS BEEN SHOWN to have no effect on eclampsia, ALBEIT among well-nourished women [34,35].']	[('INCOMPLETE_EVIDENCE', 38), ('ANOMALY_CURIOUS_FINDING', 85)]	2	[('CHEBI_27300', 'vitamin D', 21, 'vitamins C'), ('PR_000004900', 'complement C3', 30, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 36, 'E')]
S6-PMC2581757	PMC2581757	11/2008	S6-PMC2581757	['a significant reduction in the incidence of Preeclampsia was FOUND in women AT RISK who were taking Vitamins C and E supplements [1].']	[('INCOMPLETE_EVIDENCE', 61), ('IMPORTANT_CONSIDERATION', 76)]	2	[('GO_0007128', 'meiotic prophase I', 44, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 100, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 115, 'E')]
S13-PMC2581757	PMC2581757	11/2008	S13-PMC2581757	['HOWEVER, in a recent review, antioxidant therapy HAS BEEN SUGGESTED and that the prophylactic supplementation of Vitamins C and E to Pregnant women is ASSOCIATED with reduced incidence of preeclampsia and decreased Placental and Endothelial dysfunction [9].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 49), ('SUPERFICIAL_RELATIONSHIP', 151)]	3	[('CHEBI_27300', 'vitamin D', 113, 'vitamins C'), ('PR_000004900', 'complement C3', 122, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 128, 'E'), ('GO_0007565', 'female pregnancy', 133, 'pregnant'), ('UBERON_0001987', 'placenta', 215, 'placental'), ('UBERON_0001986', 'endothelium', 229, 'endothelial')]
S170-PMC2581757	PMC2581757	11/2008	S170-PMC2581757	['from our results we INFER the positive EFFECT of Vitamins C and E on retaining sod activity during Preeclampsia.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 20), ('SUPERFICIAL_RELATIONSHIP', 39)]	2	[('CHEBI_27300', 'vitamin D', 49, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 64, 'E'), ('GO_0007128', 'meiotic prophase I', 99, 'preeclampsia')]
S179-PMC2581757	PMC2581757	11/2008	S179-PMC2581757	['a comparison of these two groups REVEALED a significant difference (22–29%), which SHOWS that Vitamins C and E consumption PREVENTED the fall in Grx activity.']	[('INCOMPLETE_EVIDENCE', 33), ('INCOMPLETE_EVIDENCE', 83), ('SUPERFICIAL_RELATIONSHIP', 123)]	3	[('CHEBI_27300', 'vitamin D', 94, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 109, 'E'), ('PR_000008290', 'eukaryotic peptide chain release factor GTP-binding subunit ERF3A', 145, 'GRx')]
S187-PMC2581757	PMC2581757	11/2008	S187-PMC2581757	['[1] HAVE REPORTED that a significant reduction in the incidence of Preeclampsia was FOUND in women AT RISK who were taking a Vitamins C and E supplements.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 84), ('IMPORTANT_CONSIDERATION', 99)]	3	[('GO_0007128', 'meiotic prophase I', 67, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 125, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 140, 'E')]
S193-PMC2581757	PMC2581757	11/2008	S193-PMC2581757	['[9] SUGGEST the prophylactic use of Vitamins C and E before the 20th.']	[('INCOMPLETE_EVIDENCE', 4)]	1	[('CHEBI_27300', 'vitamin D', 36, 'vitamins C'), ('PR_000004900', 'complement C3', 45, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 51, 'E')]
S198-PMC2581757	PMC2581757	11/2008	S198-PMC2581757	['the activities of antioxidant enzymes were also INFLUENCED by the use of Vitamins C and E. the reduction of sod activity during the development of Preeclampsia was controlled as a CONSEQUENCE of Vitamin consumption: the decrease was FOUND TO BE 14% WHEREAS it was 23% in patients who had not used Vitamins C and E. the most prominent EFFECT of the use of these Vitamins was FOUND TO BE ASSOCIATED with the activity of Glutathione reductase.']	[('SUPERFICIAL_RELATIONSHIP', 48), ('PROBABLE_UNDERSTANDING', 180), ('ANOMALY_CURIOUS_FINDING', 233), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 249), ('SUPERFICIAL_RELATIONSHIP', 334), ('ANOMALY_CURIOUS_FINDING', 374), ('SUPERFICIAL_RELATIONSHIP', 386)]	7	[('CHEBI_27300', 'vitamin D', 73, 'vitamins C'), ('PR_000004900', 'complement C3', 82, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 88, 'E'), ('GO_0007128', 'meiotic prophase I', 147, 'preeclampsia'), ('CHEBI_33229', 'vitamin (role)', 195, 'vitamin'), ('CHEBI_27300', 'vitamin D', 297, 'vitamins C'), ('PR_000004900', 'complement C3', 306, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 312, 'E'), ('CHEBI_33277', 'gamma-tocotrienol', 361, 'vitamins'), ('CHEBI_16856', 'glutathione', 418, 'glutathione')]
S200-PMC2581757	PMC2581757	11/2008	S200-PMC2581757	['THUS, we conclude that use of Vitamins C and E DEFINITELY Controls certain IMPORTANT biochemical indices during the development of Preeclampsia, and that FURTHER STUDIES ARE NEEDED to DEVELOP STRATEGIES for the PREVENTION of Preeclampsia in women at high RISK.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 47), ('IMPORTANT_CONSIDERATION', 75), ('FUTURE_WORK', 154), ('FUTURE_WORK', 162), ('FUTURE_WORK', 184), ('FUTURE_WORK', 192), ('SUPERFICIAL_RELATIONSHIP', 211), ('IMPORTANT_CONSIDERATION', 255)]	9	[('CHEBI_27300', 'vitamin D', 30, 'vitamins C'), ('PR_000004900', 'complement C3', 39, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 45, 'E'), ('GO_0065007', 'biological regulation', 58, 'controls'), ('GO_0007128', 'meiotic prophase I', 131, 'preeclampsia'), ('GO_0007128', 'meiotic prophase I', 225, 'preeclampsia')]
S117-PMC2722583	PMC2722583	1/2009	S117-PMC2722583	['iron deficiency is an IMPORTANT RISK FACTOR for increased maternal mortality, low Birth weight and Preterm Delivery (brabin et al 2001) and the availability of calcium, Iodine, Folate and Vitamins A and D MAY Modulate fetal development (bartley et al 2005).']	[('IMPORTANT_CONSIDERATION', 22), ('SUPERFICIAL_RELATIONSHIP', 32), ('INCOMPLETE_EVIDENCE', 205)]	3	[('GO_0007567', 'parturition', 82, 'birth'), ('GO_0007565', 'female pregnancy', 99, 'preterm'), ('GO_0007567', 'parturition', 107, 'delivery'), ('CHEBI_24859', 'iodine atom', 169, 'iodine'), ('CHEBI_30863', '5-azaorotic acid', 177, 'folate'), ('CHEBI_27300', 'vitamin D', 188, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 203, 'D'), ('GO_0065007', 'biological regulation', 209, 'modulate')]
S42-PMC2779500	PMC2779500	11/2009	S42-PMC2779500	['for example, ALTHOUGH reduced mortality HAS BEEN SHOWN in hiv-positive children receiving Vitamin A supplementation [30], the administration of Vitamin A supplements to women has BEEN IMPLICATED in increased Vaginal Viral shedding (no effect on risk was observed from Vitamins B, C, and E) [31], a heightened risk of Mother-To-Child Hiv Transmission [32], and hastened progression of child mortality [30].']	[('ANOMALY_CURIOUS_FINDING', 13), ('INCOMPLETE_EVIDENCE', 40), ('ANOMALY_CURIOUS_FINDING', 179), ('SUPERFICIAL_RELATIONSHIP', 184)]	4	[('CHEBI_27300', 'vitamin D', 90, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin A'), ('UBERON_0001987', 'placenta', 208, 'vaginal'), ('NCBITaxon_1', 'root', 216, 'viral'), ('CHEBI_27300', 'vitamin D', 268, 'vitamins B'), ('PR_000000037', 'BMP receptor type-2', 277, 'B'), ('CHEBI_18245', 'carboxylato group', 280, 'C'), ('PR_000004900', 'complement C3', 280, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 287, 'E'), ('GO_0048870', 'cell motility', 317, 'mother-to-child'), ('GO_0007228', 'positive regulation of hh target transcription factor activity', 333, 'HIV transmission')]
S23-PMC2821652	PMC2821652	2/2010	S23-PMC2821652	['THUS, in the Human fetus, Vitamin D Metabolism in all LIKELIHOOD begins with 25(Oh)D. as a result, the nutritional Vitamin D status of the Human fetus/neonate is totally DEPENDENT on the Vitamin D stores of the mother [11]; THUS, IF the mother is hypovitaminotic D, her fetus will experience depleted Vitamin D exposure throughout Gestation [14].']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 54), ('SUPERFICIAL_RELATIONSHIP', 170), ('PROBABLE_UNDERSTANDING', 224), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 230)]	5	[('NCBITaxon_9606', 'Homo sapiens', 13, 'human'), ('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 26, 'vitamin D metabolism'), ('CHEBI_71657', 'versiconol acetate', 77, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 139, 'human'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 263, 'D'), ('CHEBI_27300', 'vitamin D', 301, 'vitamin D'), ('GO_0007565', 'female pregnancy', 331, 'gestation')]
S77-PMC2821652	PMC2821652	2/2010	S77-PMC2821652	"[""in developing a definition of adherence by Serum 25(Oh)D levels, SEVERAL ASSUMPTIONS were made a priori about WHAT types of PATTERNS of 25(Oh)D levels would be exhibited by adherent and nonadherent patients BASED ON CURRENT KNOWLEDGE about the Metabolism Of Vitamin D.\nassumption 1\nBASED ON KNOWN pharmacokinetics of Vitamin D [64], adherent patients' 25(Oh)D levels would be expected to rise over time, eventually reaching a steady state after 2 months of therapy; nonadherent patients' 25(Oh)D levels would be expected to be erratic and to exhibit variable PATTERNS that would differ significantly from adherent patients' 25(Oh)D levels over the same dosing interval.""]"	[('INCOMPLETE_EVIDENCE', 65), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 73), ('EXPLICIT_QUESTION', 110), ('SUPERFICIAL_RELATIONSHIP', 124), ('INCOMPLETE_EVIDENCE', 207), ('PROBABLE_UNDERSTANDING', 207), ('SUPERFICIAL_RELATIONSHIP', 207), ('INCOMPLETE_EVIDENCE', 216), ('PROBABLE_UNDERSTANDING', 282), ('SUPERFICIAL_RELATIONSHIP', 282), ('INCOMPLETE_EVIDENCE', 291), ('SUPERFICIAL_RELATIONSHIP', 559)]	12	[('UBERON_0001977', 'blood serum', 43, 'serum'), ('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 49, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 136, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 142, 'D'), ('GO_0019458', 'methionine catabolic process via 2-oxobutanoate', 244, 'metabolism of vitamin D'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 317, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 325, 'D'), ('CHEBI_71657', 'versiconol acetate', 352, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 358, 'D'), ('CHEBI_71657', 'versiconol acetate', 488, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 488, '25'), ('PR_000011614', 'opioid growth factor receptor', 491, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 494, 'D'), ('CHEBI_71657', 'versiconol acetate', 624, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 624, '25(OH ... D')]
S111-PMC2874518	PMC2874518	6/2010	S111-PMC2874518	['women in our cohort were receiving adequate amounts of these Micronutrients from their diet alone, as assessed by the 24-hour dietary Recall (table 2), confirming the inverse Supplement HYPOTHESIS, that women who least NEED Supplements are most LIKELY to take them.22\nOTHER STUDIES have SUGGESTED POTENTIAL adverse EFFECTS of SOME Supplements, specifically those containing antioxidant Vitamins such as Vitamins C and E, on Pregnancy outcome when taken by women with adequate dietary Micronutrient intake.']	[('INCOMPLETE_EVIDENCE', 186), ('IMPORTANT_CONSIDERATION', 219), ('PROBABLE_UNDERSTANDING', 245), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 268), ('INCOMPLETE_EVIDENCE', 268), ('INCOMPLETE_EVIDENCE', 287), ('INCOMPLETE_EVIDENCE', 297), ('SUPERFICIAL_RELATIONSHIP', 315), ('INCOMPLETE_EVIDENCE', 326)]	9	[('CHEBI_33839', 'macromolecule', 61, 'micronutrients'), ('GO_0060033', 'anatomical structure regression', 134, 'recall'), ('CHEBI_16158', 'steroid sulfate', 175, 'supplement'), ('CHEBI_33341', 'titanium atom', 224, 'supplements'), ('CHEBI_33341', 'titanium atom', 331, 'supplements'), ('CHEBI_33277', 'gamma-tocotrienol', 386, 'vitamins'), ('CHEBI_27300', 'vitamin D', 403, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 418, 'E'), ('GO_0007565', 'female pregnancy', 424, 'pregnancy'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 484, 'micronutrient')]
S114-PMC2874518	PMC2874518	6/2010	S114-PMC2874518	['ANOTHER STUDY FOUND that use of supplements for Vitamins C and E was ASSOCIATED with an INCREASED RISK of premature rupture of membranes.24unfortunately, this information was NOT RECORDED in our study.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 14), ('SUPERFICIAL_RELATIONSHIP', 69), ('IMPORTANT_CONSIDERATION', 88), ('FULL_UNKNOWN', 175)]	5	[('CHEBI_27300', 'vitamin D', 48, 'vitamins C'), ('PR_000004900', 'complement C3', 57, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 63, 'E')]
S95-PMC3004407	PMC3004407	12/2010	S95-PMC3004407	['the odds of Vitamin D deficiency (AS measured by 25(Oh)D concentration) did NOT APPEAR TO change as a function of Gestational age; women in their later stages of Pregnancy had a SIMILAR odds of Vitamin D deficiency and insufficiency for a given race/ethnicity than women who had their 25(Oh)D concentrations measured earlier in Pregnancy ( p = .43).']	[('PROBABLE_UNDERSTANDING', 34), ('ANOMALY_CURIOUS_FINDING', 76), ('ANOMALY_CURIOUS_FINDING', 80), ('SUPERFICIAL_RELATIONSHIP', 178)]	4	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('GO_0007565', 'female pregnancy', 114, 'gestational'), ('GO_0007565', 'female pregnancy', 162, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 285, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 291, 'D'), ('GO_0007565', 'female pregnancy', 328, 'pregnancy')]
S10-PMC3034879	PMC3034879	12/2010	S10-PMC3034879	['DESPITE DISCREPANT S-25-Ohd at baseline (median 36.3 vs. 52.5\xa0nmol/l, p \u2009<\u20090.001), the values at 14\xa0months were SIMILAR (63 vs. 66\xa0nmol/l, p \u2009=\u20090.58) in low d and high d. Serum 25-ohd increased more in low D ( p \u2009<\u20090.001) DESPITE SIMILAR total intake of Vitamin D (mean 12.3\xa0μg/day).']	[('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 8), ('SUPERFICIAL_RELATIONSHIP', 112), ('ANOMALY_CURIOUS_FINDING', 222), ('SUPERFICIAL_RELATIONSHIP', 230)]	5	[('CHEBI_16786', 'vestitone', 19, 'S-'), ('1', 'A1BG (human)', 20, '-'), ('CHEBI_72765', 'verruculogen', 21, '25-OHD'), ('UBERON_0001977', 'blood serum', 171, 'Serum'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 206, 'D'), ('CHEBI_27300', 'vitamin D', 254, 'vitamin D')]
S106-PMC3034879	PMC3034879	12/2010	S106-PMC3034879	['1\n\ntotal intake of Vitamin D CORRELATED positively with Serum 25-Ohd in high D ( r \u2009=\u20090.505, p \u2009<\u20090.001), but not in low d ( r \u2009=\u20090.219, p \u2009=\u20090.168).']	[('SUPERFICIAL_RELATIONSHIP', 29)]	1	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('UBERON_0001977', 'blood serum', 56, 'serum'), ('CHEBI_72765', 'verruculogen', 62, '25-OHD'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 77, 'D')]
S189-PMC3034879	PMC3034879	12/2010	S189-PMC3034879	['there was a positive ASSOCIATION between total intake of Vitamin D and 25-Ohd in the entire group and in high d, but NOT among those infants in low D whose Vitamin D status during Pregnancy was worse.']	[('SUPERFICIAL_RELATIONSHIP', 21), ('ANOMALY_CURIOUS_FINDING', 117)]	2	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_72765', 'verruculogen', 71, '25-OHD'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 148, 'D'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin D'), ('GO_0007565', 'female pregnancy', 180, 'pregnancy')]
S191-PMC3034879	PMC3034879	12/2010	S191-PMC3034879	['given that more than 20% of the infants had S-25-Ohd below 50 nmol/l, DESPITE compliance with supplementation, higher intake of vitamin D is RECOMMENDED in order to obtain all the POTENTIAL health benefits of Vitamin D [43,44].']	[('ANOMALY_CURIOUS_FINDING', 70), ('FUTURE_WORK', 141), ('INCOMPLETE_EVIDENCE', 180)]	3	[('CHEBI_86929', 'S b G-5,5-G b S A CH2', 44, 'S-25-OHD'), ('PR_000001900', 'neuropilin-1', 44, 'S-25-OHD'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 136, 'D'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D')]
S145-PMC3171895	PMC3171895	9/2011	S145-PMC3171895	['a CONSIDERABLE INTEREST exists regarding PREVENTION of Maternal and Perinatal Morbidity with Vitamins C and E. HOWEVER, the most RECENT meta-analysis of ten trials (6533 women) published in 2008 of antioxidant supplementation (including Vitamin C and e but also OTHER supplements such as Lycopene) SHOWED no difference in the relative risk (rr) of Preeclampsia (rr 0.73, 95% ci 0.51 to 1.06), Preterm Birth (before 37 weeks) (rr 1.10, 95% ci 0.99 to 1.22), sga infants (rr 0.83, 95% ci 0.62 to 1.11), or any baby death (rr 1.12, 95% ci 0.81 to 1.53) [7].']	[('ANOMALY_CURIOUS_FINDING', 2), ('ANOMALY_CURIOUS_FINDING', 15), ('IMPORTANT_CONSIDERATION', 15), ('SUPERFICIAL_RELATIONSHIP', 41), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 111), ('INCOMPLETE_EVIDENCE', 129), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 262), ('INCOMPLETE_EVIDENCE', 298)]	8	[('GO_0007618', 'mating', 55, 'maternal ...'), ('GO_0019230', 'proprioception', 68, 'perinatal morbidity'), ('UBERON_0012101', 'perinatal stage', 68, 'perinatal'), ('CHEBI_27300', 'vitamin D', 93, 'vitamins C'), ('PR_000004900', 'complement C3', 102, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 108, 'E'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin C'), ('CHEBI_15948', 'lycopene', 288, 'lycopene'), ('GO_0007128', 'meiotic prophase I', 348, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 393, 'preterm'), ('GO_0007567', 'parturition', 401, 'birth')]
S147-PMC3171895	PMC3171895	9/2011	S147-PMC3171895	['a couple of subsequent RECENT multicentre double-blinded randomised trials of a combination of Vitamin C and E [130,131] also FOUND that supplementation did not reduce the rate of Preeclampsia or Gestational hypertension and, like the Vitamins in Preeclampsia trial in 2006 [132], increased the risk of fetal loss or Perinatal death and preterm prelabour rupture of Membranes.']	[('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 126)]	2	[('CHEBI_27300', 'vitamin D', 95, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 109, 'E'), ('GO_0007128', 'meiotic prophase I', 180, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 196, 'gestational'), ('CHEBI_28371', 'vitamin K epoxide', 235, 'Vitamins'), ('GO_0007128', 'meiotic prophase I', 247, 'Preeclampsia'), ('GO_0036268', 'swimming', 317, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 317, 'perinatal'), ('UBERON_0000922', 'embryo', 366, 'membranes')]
S148-PMC3171895	PMC3171895	9/2011	S148-PMC3171895	['ANOTHER RECENT multicentre placebo-controlled TRIAL of Vitamin C and E in women with type-1 diabetes in Pregnancy (Dapit) also REPORTED no differences in the rates of Preeclampsia between supplemented or placebo groups [133].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 46), ('INCOMPLETE_EVIDENCE', 127)]	4	"[('CHEBI_27300', 'vitamin D', 55, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 69, 'E'), ('GO_0007565', 'female pregnancy', 104, 'pregnancy'), ('CHEBI_73285', ""3-iodo-4-aminobenzyl-5'-N-methylcarboxamidoadenosine"", 115, 'DAPIT'), ('GO_0007128', 'meiotic prophase I', 167, 'preeclampsia')]"
S149-PMC3171895	PMC3171895	9/2011	S149-PMC3171895	['FURTHER INVESTIGATIONS are REQUIRED AS the concentrations of these Vitamins REMAIN significantly reduced in women with Preeclampsia, but in the absence OF FURTHER EVIDENCE, routine supplementation with higher dose Vitamin C and E is not RECOMMENDED AS they CAN be POTENTIALLY dangerous in high concentrations.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 8), ('IMPORTANT_CONSIDERATION', 27), ('PROBABLE_UNDERSTANDING', 36), ('INCOMPLETE_EVIDENCE', 76), ('ANOMALY_CURIOUS_FINDING', 152), ('INCOMPLETE_EVIDENCE', 155), ('FUTURE_WORK', 237), ('PROBABLE_UNDERSTANDING', 249), ('INCOMPLETE_EVIDENCE', 257), ('INCOMPLETE_EVIDENCE', 264)]	11	[('CHEBI_33277', 'gamma-tocotrienol', 67, 'vitamins'), ('GO_0007128', 'meiotic prophase I', 119, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 214, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 228, 'E')]
S43-PMC3309463	PMC3309463	6/2011	S43-PMC3309463	['it HAS BEEN PROPOSED that developmental Vitamin D deficiency MAY CONTRIBUTE to the increased risk of schizophrenia in dark-skinned migrants and those living in crowded urban settings.28both dark skin and urban residence are ASSOCIATED with an INCREASED risk of hypovitaminosis D.29developmental Vitamin D deficiency MAY also UNDERLIE the well-replicated season of birth EFFECT FOUND in schizophrenia (those Born in winter and spring have a small but significant increased risk of schizophrenia).30vitamin D is a potent pro-differentiation agent and CAN INFLUENCE Brain functioning via many DIFFERENT pathways.31the Vitamin D receptor and the enzyme required for the manufacture of the hormonally active form of Vitamin D have BEEN IDENTIFIED in the Human Brain,32AND THERE IS EVIDENCE from Rodent MODELS DEMONSTRATING that transient Prenatal Vitamin D deficiency results in persistent changes in Adult Brain structure, neurochemistry and behavior.33our species has evolved in settings where Vitamin D is abundant, and migration to colder climates and urban-related lifestyle factors have left modern Humans at increased risk of hypovitaminosis D.\ninspired by the conceptual framework described above, we PROPOSE that the absence of adequate Vitamin D levels during development deprives the Organism of expected instructions from the environment.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 61), ('SUPERFICIAL_RELATIONSHIP', 65), ('SUPERFICIAL_RELATIONSHIP', 224), ('IMPORTANT_CONSIDERATION', 243), ('INCOMPLETE_EVIDENCE', 316), ('SUPERFICIAL_RELATIONSHIP', 325), ('SUPERFICIAL_RELATIONSHIP', 370), ('INCOMPLETE_EVIDENCE', 377), ('INCOMPLETE_EVIDENCE', 549), ('SUPERFICIAL_RELATIONSHIP', 553), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 590), ('ANOMALY_CURIOUS_FINDING', 726), ('INCOMPLETE_EVIDENCE', 731), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 761), ('INCOMPLETE_EVIDENCE', 767), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 797), ('INCOMPLETE_EVIDENCE', 797), ('INCOMPLETE_EVIDENCE', 804), ('INCOMPLETE_EVIDENCE', 1204)]	21	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 277, 'D'), ('CHEBI_27300', 'vitamin D', 295, 'vitamin D'), ('GO_0007567', 'parturition', 407, 'born'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 505, 'D'), ('UBERON_0000955', 'brain', 563, 'brain'), ('CHEBI_27300', 'vitamin D', 615, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 711, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 749, 'human'), ('UBERON_0000955', 'brain', 755, 'brain'), ('NCBITaxon_33208', 'Metazoa', 790, 'rodent'), ('GO_0007565', 'female pregnancy', 833, 'prenatal'), ('CHEBI_27300', 'vitamin D', 842, 'vitamin D'), ('UBERON_0007023', 'adult organism', 896, 'adult'), ('UBERON_0000955', 'brain', 902, 'brain'), ('CHEBI_27300', 'vitamin D', 991, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 1100, 'humans'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1144, 'D'), ('CHEBI_27300', 'vitamin D', 1241, 'vitamin D'), ('NCBITaxon_1', 'root', 1290, 'organism')]
S155-PMC3347007	PMC3347007	4/2012	S155-PMC3347007	['OTHER STUDIES also FOUND that non-smokers had higher intakes of Vitamin D [19,29] and that non-smokers were more LIKELY to use vitamin D supplements [17,27].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 19), ('PROBABLE_UNDERSTANDING', 113)]	3	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 135, 'D')]
S3-PMC3356951	PMC3356951	4/2012	S3-PMC3356951	['high prevalence of Vitamin D insufficiency is a PARTICULARLY IMPORTANT PUBLIC HEALTH ISSUE BECAUSE hypovitaminosis D is an INDEPENDENT RISK FACTOR for total mortality in the general population.']	[('ANOMALY_CURIOUS_FINDING', 48), ('IMPORTANT_CONSIDERATION', 61), ('IMPORTANT_CONSIDERATION', 71), ('PROBLEM_COMPLICATION', 85), ('PROBABLE_UNDERSTANDING', 91), ('SUPERFICIAL_RELATIONSHIP', 123), ('SUPERFICIAL_RELATIONSHIP', 135)]	7	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 115, 'D')]
S15-PMC3356951	PMC3356951	4/2012	S15-PMC3356951	['black People Absorb more uvb in the Melanin of their skin than do white People and, THEREFORE, require more sun exposure to produce the same amount of vitamin D.[4]\nthe high prevalence of Vitamin D insufficiency is a PARTICULARLY IMPORTANT PUBLIC HEALTH ISSUE BECAUSE hypovitaminosis D is an INDEPENDENT RISK FACTOR for total mortality in the general population.']	[('PROBABLE_UNDERSTANDING', 84), ('ANOMALY_CURIOUS_FINDING', 217), ('IMPORTANT_CONSIDERATION', 230), ('IMPORTANT_CONSIDERATION', 240), ('PROBLEM_COMPLICATION', 254), ('PROBABLE_UNDERSTANDING', 260), ('SUPERFICIAL_RELATIONSHIP', 292), ('SUPERFICIAL_RELATIONSHIP', 304)]	8	[('NCBITaxon_10088', 'Mus <genus>', 6, 'people'), ('GO_0040011', 'locomotion', 13, 'absorb'), ('CHEBI_25179', 'melanins', 36, 'melanin'), ('NCBITaxon_10088', 'Mus <genus>', 72, 'people'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 159, 'D'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 284, 'D')]
S115-PMC3365381	PMC3365381	3/2011	S115-PMC3365381	['Imprinting with receptor level acting Vitamins A and D INFLUENCED the Brain biogenic amine levels of f1 progenies (tekes et al.2009a,b,c) as well as the hormone Production Of Immune Cells (csaba et al.2007).']	[('SUPERFICIAL_RELATIONSHIP', 55)]	1	[('GO_0071514', 'genetic imprinting', 0, 'Imprinting'), ('CHEBI_27300', 'vitamin D', 38, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 47, 'A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 53, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 53, 'D'), ('UBERON_0000955', 'brain', 70, 'brain'), ('GO_0002001', 'renin secretion into blood stream', 161, 'production of immune cells'), ('CL_0000738', 'leukocyte', 175, 'immune cells'), ('UBERON_0002405', 'immune system', 175, 'immune')]
S66-PMC3417531	PMC3417531	7/2012	S66-PMC3417531	"[""(91)childreninfectious diseasehigh rate of simkania negevensis among canadian inuit infants hospitalized with Lower Respiratory Tract infections (92)childrennutritioniron deficiency and anaemia prevalence and ASSOCIATED etiologic RISK FACTORS in first nations and inuit communities in northern ontario and nunavut (93)childrennutritionfood insecurity among inuit preschoolers: nunavut inuit child health survey, 2007–2008 (59)childrennutritionvitamin D status of inuit preschoolers reflects season and Vitamin D intake (56)childrenenvironment/environmental exposures; infectious diseaseeffect of Prenatal exposure to Polychlorinated Biphenyls on incidence of acute Respiratory infections in preschool inuit children (25)childrenchronic disease; interventions/programmingthe benefits of sound field amplification in classrooms of inuit students of nunavik: a pilot project (73)childrensocial DETERMINANTS of health; tobaccocultural, socioeconomic, and health indicators among inuit preschoolers: nunavut inuit child health survey, 2007–2008 (9)childreninfectious disease; tobaccoindoor air quality and the risk of Lower Respiratory Tract infections in young canadian inuit children (41)childreninfectious disease; interventions/programmingheat recovery ventilators prevent Respiratory disorders in inuit children (40)childrengenetics; nutritionadaptation of inuit children to a low-calcium diet (83)childreninfectious disease; health care, policy, Human resourcesbronchiolitis in inuit children from a canadian central arctic community, 1995–1996 (69)youthchronic diseasecauses and CONTRIBUTIONS to differences in Life expectancy for inuit nunangat and canada, 1994–2003 (82)youthinfectious diseaseotitis media and Hearing loss among 12–16 year-old inuit of inukjuak, quebec, canada (35)youthinjuryinjury mortality risk assessment and targeting the subpopulations for prevention in the northwest territories, canada (86)youthnutritionage differences in Vitamin A intake among canadian inuit (55)youthmental health and wellbeingcompleted suicides among the inuit of northern quebec, 1982–1996: a case-control study (77)youthmental health and wellbeing; social determinants of healthsuicidality in a sample of arctic households (76)youthinfectious disease; interventions/programminghiv testing experiences of aboriginal youth in canada: service IMPLICATIONS (74)youthinfections disease; social determinants of healthdeterminants of Sexually Transmitted infections among canadian inuit adolescent populations (30)youthinfections disease; mental health and wellbeingyouth sexual health in nunavut: a needs-based survey of knowledge, attitudes and behaviour (31)maternalbirth outcomesreclaiming Birth, health, and community: midwifery in the inuit villages of nunavik, canada (68)maternalenvironment/environmental exposuresorganochlorine levels in maternal and Umbilical Cord Blood Plasma in arctic canada (49)maternalenvironment/environmental exposuresexposure of the inuit population of nunavik (arctic quebec) to lead and mercury (48)maternalnutritiondietary assessment of indigenous canadian arctic women with a focus on Pregnancy and Lactation (54)maternalnutritioncontribution of selected traditional and market Foods to the diet of nunavik inuit women (57)maternalbirth outcomes; tobaccomaternal smoking at first Prenatal visit as a MARKER of risk for adverse Pregnancy outcomes in the qikiqtaaluk (baffin) region (8)maternalnutrition; environment/environmental exposuresfish Consumption and Blood Lipids in 3 ethnic groups of quebec (canada) (51)maternalhealth care, policy, Human resources; Birth outcomesconverging epistemologies: CRITICAL ISSUES in canadian inuit Childbirth and Pregnancy (65)maternalenvironment/environmental exposures; nutritiondeterminants of Polychlorinated Biphenyls and Methylmercury exposure in inuit women of Childbearing age (50)maternalhealth care, policy, Human resources; interventions/programmingthe outcome of Perinatal Care in inukjuak, nunavik, canada 1998–2002 (70)maternalhealth care, policy, Human resources; Birth outcomesthe inuulitsivik maternities: culturally appropriate midwifery and epistemological accommodation (66)maternalinfectious disease; interventions/programmingoncogenic human papillomavirus infection and Cervical lesions in aboriginal women in nunavut, canada (94)maternalchronic disease; social determinants of health; tobacco; mental health and Wellbeingthe health of cree, inuit and southern quebec women: similarities and differences (79)maternalnutrition; social DETERMINANTS of health; environment/environmental exposuresfood insecurity among inuit women exacerbated by socioeconomic stresses and climate change (60)children; youthchronic diseasethe RELATIONSHIP between socio-economic and geographic factors and asthma among canada's aboriginal populations (81)children; youthinfectious diseasehospitalization due to pneumonia among innu, inuit and non-aboriginal communities, newfoundland and labrador, canada (24)children; maternalbirth outcomesheart defects and other malformations in the inuit in canada: a baseline study (62)children; maternalbirth outcomesbirth outcomes in the inuit-inhabited areas of canada (95)children; maternalbirth outcomesdegree of rural isolation and Birth outcomes (63)children; maternalbirth outcomesrisks of adverse Pregnancy outcomes among inuit and north american indian women in quebec, 1985–97 (64)children; maternalenvironment/environmental exposuresprenatal exposure to Methylmercury and Pcbs AFFECTS distinct stages of information processing: an event-related POTENTIAL study with inuit children (44)children; maternalenvironment/environmental exposuresthe RELATION of lead neurotoxicity to the event-related potential p3b component in inuit children from arctic quebec (47)children; maternalenvironment/environmental exposuresthyroid hormone levels of Pregnant inuit women and their infants exposed to environmental contaminants (96)children; maternalenvironment/environmental exposuresneuromotor functions in inuit preschool children exposed to Pb, Pcbs, and hg (43)children; maternalenvironment/environmental exposuresbeneficial EFFECTS of a polyunsaturated Fatty Acid on infant development: EVIDENCE from the inuit of arctic quebec (52)children; maternalenvironment/environmental exposuresthe RELATION of environmental contaminants exposure to behavioural indicators in inuit preschoolers in arctic quebec (46)children; maternalinfectious diseaseneonatal Vitamin A deficiency and its IMPACT on acute Respiratory infections among preschool inuit children (33)children; maternalnutritionanaemia and iron status in inuit infants from northern quebec (97)children; maternalbirth outcomes; nutritioncongenital Heart defects in canadian inuit: is more Folic Acid making a difference?""]"	[('SUPERFICIAL_RELATIONSHIP', 209), ('SUPERFICIAL_RELATIONSHIP', 230), ('SUPERFICIAL_RELATIONSHIP', 891), ('SUPERFICIAL_RELATIONSHIP', 1581), ('IMPORTANT_CONSIDERATION', 2342), ('SUPERFICIAL_RELATIONSHIP', 3334), ('IMPORTANT_CONSIDERATION', 3635), ('IMPORTANT_CONSIDERATION', 3644), ('SUPERFICIAL_RELATIONSHIP', 4527), ('SUPERFICIAL_RELATIONSHIP', 4715), ('SUPERFICIAL_RELATIONSHIP', 5499), ('INCOMPLETE_EVIDENCE', 5567), ('SUPERFICIAL_RELATIONSHIP', 5664), ('SUPERFICIAL_RELATIONSHIP', 6139), ('INCOMPLETE_EVIDENCE', 6202), ('SUPERFICIAL_RELATIONSHIP', 6304), ('SUPERFICIAL_RELATIONSHIP', 6495), ('EXPLICIT_QUESTION', 6787)]	18	[('UBERON_0004905', 'articulation', 110, 'lower respiratory tract'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 451, 'D'), ('CHEBI_27300', 'vitamin D', 502, 'vitamin D'), ('GO_0007565', 'female pregnancy', 596, 'prenatal'), ('CHEBI_53421', 'poly(oxymethylene) macromolecule', 617, 'polychlorinated biphenyls'), ('UBERON_0001004', 'respiratory system', 665, 'respiratory'), ('UBERON_0004905', 'articulation', 1113, 'lower respiratory tract'), ('UBERON_0001004', 'respiratory system', 1272, 'respiratory'), ('NCBITaxon_9606', 'Homo sapiens', 1447, 'human'), ('UBERON_0000104', 'life cycle', 1613, 'life'), ('GO_0007605', 'sensory perception of sound', 1714, 'hearing'), ('CHEBI_27300', 'vitamin D', 1952, 'vitamin A'), ('GO_0019095', 'pole plasm mitochondrial rRNA localization', 2429, 'sexually transmitted'), ('GO_0007567', 'parturition', 2689, 'birth'), ('UBERON_0002331', 'umbilical cord', 2855, 'umbilical cord'), ('UBERON_0000178', 'blood', 2870, 'blood'), ('UBERON_0001969', 'blood plasma', 2876, 'plasma'), ('GO_0007565', 'female pregnancy', 3119, 'pregnancy'), ('GO_0007595', 'lactation', 3133, 'lactation'), ('CHEBI_33290', 'food', 3212, 'foods'), ('GO_0007565', 'female pregnancy', 3314, 'prenatal'), ('GO_0007565', 'female pregnancy', 3361, 'pregnancy'), ('GO_0007631', 'feeding behavior', 3477, 'consumption'), ('UBERON_0000178', 'blood', 3493, 'blood'), ('CHEBI_18059', 'lipid', 3499, 'lipids'), ('NCBITaxon_9606', 'Homo sapiens', 3577, 'human'), ('GO_0007567', 'parturition', 3594, 'birth'), ('GO_0007623', 'circadian rhythm', 3669, 'childbirth'), ('GO_0007565', 'female pregnancy', 3684, 'pregnancy'), ('CHEBI_53421', 'poly(oxymethylene) macromolecule', 3768, 'polychlorinated biphenyls'), ('CHEBI_33963', 'metallocene', 3798, 'methylmercury'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 3839, 'childbearing'), ('NCBITaxon_9606', 'Homo sapiens', 3889, 'human'), ('GO_0036356', 'cyclic 2,3-diphosphoglycerate synthetase activity', 3946, 'perinatal care'), ('UBERON_0012101', 'perinatal stage', 3946, 'perinatal'), ('NCBITaxon_9606', 'Homo sapiens', 4033, 'human'), ('GO_0007567', 'parturition', 4050, 'birth'), ('UBERON_0005434', 'cervical region', 4263, 'cervical'), ('GO_0035706', 'T-helper 1 cell chemotaxis', 4406, 'wellbeingThe'), ('GO_0007567', 'parturition', 5248, 'birth'), ('GO_0007565', 'female pregnancy', 5316, 'pregnancy'), ('CHEBI_33963', 'metallocene', 5476, 'methylmercury'), ('CHEBI_26199', 'polyprenol', 5494, 'PCBs'), ('GO_0007565', 'female pregnancy', 5860, 'pregnant'), ('CHEBI_37983', 'sulfur-35 atom', 6054, 'Pb'), ('CHEBI_26199', 'polyprenol', 6058, 'PCBs'), ('CHEBI_35366', 'fatty acid', 6168, 'fatty acid'), ('CHEBI_27300', 'vitamin D', 6466, 'vitamin A'), ('UBERON_0001004', 'respiratory system', 6511, 'respiratory'), ('UBERON_0000948', 'heart', 6716, 'heart'), ('CHEBI_30751', 'formic acid', 6757, 'folic acid')]
S15-PMC3427192	PMC3427192	4/2012	S15-PMC3427192	['vdrs are Expressed on a variety of Airway Immune Cells, where they function as classic Nuclear Steroid Hormone receptors and ultimately Regulate the transcription of numerous Genes associated with inflammation and Immunomodulation.27vitamin d also plays an IMPORTANT ROLE in Respiratory infection by facilitating Toll-Like Receptor Signaling through increased Synthesis of Human Cathelicidin Antimicrobial peptide,28-30which is cleaved to generate the active Cationic peptide, Ll-37.31,32vitamin D also exerts direct EFFECTS on target cells independent of Gene transcription33and MAY THEREFORE be of relevance to Airway inflammatory disorders.34while Vitamin D can suppress il-1735and Il-4-mediated Expression of Il-13,35,36it CAN also shift the th1/th2 balance toward th2 dominance.37THESE CONTRADICTORY actions MAY BE DUE to the direct actions of Vitamin D on cd4+T Cells to promote an Il-10-secreting T-Regulatory population.38\n\nBiosynthesis Of Vitamin D\nBiosynthesis Of Vitamin D begins PRIMARILY with absorption of solar ultravoilet-b (uvb) radiation and secondarily via Consumption of Vitamin D-rich and fortified foods, such as oily fish, fortified grains and dairy products.26following exposure to uvb radiation, 7-Dehydrocholesterol within the skin is converted to Previtamin D3( fig.']	[('IMPORTANT_CONSIDERATION', 257), ('SUPERFICIAL_RELATIONSHIP', 267), ('SUPERFICIAL_RELATIONSHIP', 517), ('INCOMPLETE_EVIDENCE', 580), ('PROBABLE_UNDERSTANDING', 584), ('INCOMPLETE_EVIDENCE', 727), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 783), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 791), ('INCOMPLETE_EVIDENCE', 813), ('IMPORTANT_CONSIDERATION', 820), ('PROBABLE_UNDERSTANDING', 991)]	11	[('GO_0010467', 'gene expression', 9, 'expressed'), ('UBERON_0001005', 'respiratory airway', 35, 'airway'), ('CL_0000738', 'leukocyte', 42, 'immune cells'), ('UBERON_0002405', 'immune system', 42, 'immune'), ('GO_0005634', 'nucleus', 87, 'nuclear'), ('CHEBI_26764', 'steroid hormone', 95, 'steroid hormone'), ('GO_0065007', 'biological regulation', 136, 'regulate'), ('SO_0000704', 'gene', 175, 'genes'), ('GO_0050900', 'leukocyte migration', 214, 'immunomodulation'), ('UBERON_0001004', 'respiratory system', 275, 'respiratory'), ('GO_0002770', 'T cell inhibitory signaling pathway', 313, 'Toll-like receptor signaling'), ('GO_0009057', 'macromolecule catabolic process', 360, 'synthesis'), ('NCBITaxon_9606', 'Homo sapiens', 373, 'human'), ('PR_000006009', 'alpha-catulin', 379, 'cathelicidin'), ('CHEBI_65381', 'albizoside C', 392, 'antimicrobial'), ('CHEBI_36916', 'cation', 459, 'cationic'), ('PR_000009809', 'leukocyte immunoglobulin-like receptor subfamily B member 2', 477, 'LL-37'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 496, 'D'), ('SO_0000704', 'gene', 556, 'gene'), ('UBERON_0001005', 'respiratory airway', 613, 'airway'), ('CHEBI_27300', 'vitamin D', 651, 'vitamin D'), ('PR_000001470', 'interleukin-28B', 685, 'IL-4'), ('GO_0010467', 'gene expression', 699, 'expression'), ('PR_000001470', 'interleukin-28B', 713, 'IL-13'), ('CHEBI_27300', 'vitamin D', 849, 'vitamin D'), ('CL_0000084', 'T cell', 866, 'T cells'), ('PR_000001470', 'interleukin-28B', 888, 'IL-10'), ('CL_0000895', 'naive thymus-derived CD4-positive, alpha-beta T cell', 904, 'T'), ('CL_0000232', 'erythrocyte', 906, 'regulatory'), ('GO_0065007', 'biological regulation', 906, 'regulatory'), ('GO_0033593', 'BRCA2-MAGE-D1 complex', 932, 'Biosynthesis of vitamin D'), ('CHEBI_27300', 'vitamin D', 948, 'vitamin D'), ('GO_0033593', 'BRCA2-MAGE-D1 complex', 958, 'Biosynthesis of vitamin D'), ('CHEBI_27300', 'vitamin D', 974, 'vitamin D'), ('GO_0007631', 'feeding behavior', 1076, 'consumption'), ('CHEBI_27300', 'vitamin D', 1091, 'vitamin D'), ('CHEBI_17500', '7alpha-hydroxycholesterol', 1221, '7-dehydrocholesterol'), ('PR_000014709', 'neuroserpin', 1274, 'previtamin D3')]
S35-PMC3427192	PMC3427192	4/2012	S35-PMC3427192	['HOWEVER, it is IMPORTANT TO NOTE that a large percentage of children were lost to follow-up, and THUS the resulting sample of mothers had higher concentrations of 25(Oh)D and were older, less LIKELY to smoke during Pregnancy, and more educated.63therefore WHILE there MAY BE therapeutic window for vitamin D supplementation in early Life, FURTHER STUDIES ARE NEEDED to more clearly understand the RISKS of high Vitamin D intake and bioavailability during the early childhood years.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 15), ('PROBABLE_UNDERSTANDING', 97), ('PROBABLE_UNDERSTANDING', 192), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 256), ('INCOMPLETE_EVIDENCE', 268), ('FUTURE_WORK', 339), ('FUTURE_WORK', 347), ('IMPORTANT_CONSIDERATION', 397)]	9	[('CHEBI_71657', 'versiconol acetate', 163, '25(OH)D'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 306, 'D'), ('UBERON_0000104', 'life cycle', 333, 'life'), ('CHEBI_27300', 'vitamin D', 411, 'vitamin D')]
S52-PMC3427192	PMC3427192	4/2012	S52-PMC3427192	['in these sub-analyses, Vitamin D3Supplementation was ASSOCIATED with a decreased risk of exacerbations compared with Placebo, with a relative risk of 0.17.75similarly, in a more RECENT randomized, double-blind 6-mo trial where 800 µg of inhaled Budesonide was administered daily to a small group of 48 children with asthma in the presence or absence of 500 iu/day of Vitamin D3, children receiving supplemental Vitamin D did not have a reduction in 25(Oh)D during the winter months and also had a reduced risk of asthma exacerbations triggered by acute Respiratory Viral infections.73these INITIAL FINDINGS SUGGEST that Vitamin D supplementation MAY have therapeutic benefit children with asthma, ALTHOUGH ADDITIONAL randomized, double-blind, placebo-controlled STUDIES ARE NEEDED.']	[('SUPERFICIAL_RELATIONSHIP', 53), ('INCOMPLETE_EVIDENCE', 178), ('INCOMPLETE_EVIDENCE', 590), ('INCOMPLETE_EVIDENCE', 607), ('INCOMPLETE_EVIDENCE', 646), ('ANOMALY_CURIOUS_FINDING', 697), ('FUTURE_WORK', 706), ('FUTURE_WORK', 762)]	8	[('CHEBI_52915', 'phosphatediyl group', 23, 'vitamin D3supplementation'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 23, 'vitamin D3supplementation'), ('CHEBI_26130', 'biological pigment', 117, 'placebo'), ('CHEBI_3219', 'bupropion', 245, 'budesonide'), ('CHEBI_33279', 'vitamin D5', 367, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 367, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 411, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 449, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 455, 'D'), ('UBERON_0001004', 'respiratory system', 553, 'respiratory'), ('NCBITaxon_1', 'root', 565, 'viral'), ('CHEBI_27300', 'vitamin D', 620, 'vitamin D')]
S7-PMC3427250	PMC3427250	8/2012	S7-PMC3427250	['of all women, 74.1% (95%ci\u200a=\u200a71.8–76.5%) were Vitamin D insufficient (25-(Oh)D <30 ng/ml), 44.6% (95%ci\u200a=\u200a41.9–47.3%) were Vitamin D deficient (25-(oh)d <20 ng/ml), WHILE 12.1% (95%ci\u200a=\u200a10.3–13.8%) were severely Vitamin D deficient (25-(Oh)D <10 ng/ml).']	[('ANOMALY_CURIOUS_FINDING', 165)]	1	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_30254', 'sulfidocarbon(.1+)', 70, '25-(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 77, 'D'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 212, 'vitamin D'), ('CHEBI_72657', '19,20-DiHDPA', 233, '25-(OH)D')]
S67-PMC3470091	PMC3470091	9/2012	S67-PMC3470091	['caption (table-wrap): table 3:\n\nthe number and (percentage) frequency distribution of Vitamin D status in the intervention group (ig) and control group (cg) before and after interventiongroupsvitamin D status (nmol/l)igcgbeforeafterbeforeaftersevere deficient (<12.5)0000moderate deficient (12.5-24.9)15(62.5%)09(42.9%)10(47.6%)mild deficient (25-34.9)4(16.7%)1(4.2%)7(33.3%)3(14.3%)optimal (>35)5(20.8%)23(95.8%)4(19%)6(28.6%)\n\ndiscussion\nif Vitamin D deficiency is DEFINED as Serum concentration of 25(Oh) Vitamin D3 lower than 35 nmol/l,12ABOUT 80% of the mothers with gdm in the present study were suffering to some degrees from Vitamin D deficiency.']	[('PROBABLE_UNDERSTANDING', 467), ('INCOMPLETE_EVIDENCE', 542)]	2	[('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 200, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 200, 'D'), ('CHEBI_27300', 'vitamin D', 443, 'vitamin D'), ('UBERON_0001977', 'blood serum', 478, 'serum'), ('CHEBI_30778', 'gallic acid', 501, '25(OH)'), ('CHEBI_33279', 'vitamin D5', 508, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 508, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 633, 'vitamin D')]
S92-PMC3501517	PMC3501517	11/2012	S92-PMC3501517	['results\n\nbaseline characteristics of Vitamin D sufficient and deficient Mice\nvitamin D deficiency (vdd) and sufficiency (vds) was CONFIRMED in 6-week old Mice.']	[('INCOMPLETE_EVIDENCE', 130)]	1	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 72, 'mice'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 85, 'D'), ('NCBITaxon_10088', 'Mus <genus>', 154, 'mice')]
S120-PMC3586494	PMC3586494	2/2013	S120-PMC3586494	['in comparing Vitamin levels in term and preterm infants, term babies had significantly higher levels of Vitamins A, C, and e. the authors concluded that for Vitamins A and E, neonatal levels are DEPENDENT on maternal levels and that preterm babies have fewer Lipid-soluble antioxidant Vitamins in their Serum compared to term infants THUS MAY BE more susceptible to oxidative stress [52].']	[('SUPERFICIAL_RELATIONSHIP', 195), ('PROBABLE_UNDERSTANDING', 334), ('INCOMPLETE_EVIDENCE', 339)]	3	[('CHEBI_33229', 'vitamin (role)', 13, 'vitamin'), ('CHEBI_27300', 'vitamin D', 104, 'vitamins A'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 104, 'vitamins A'), ('PR_000004900', 'complement C3', 116, 'C'), ('CHEBI_27300', 'vitamin D', 157, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 166, 'A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 172, 'E'), ('CHEBI_18059', 'lipid', 259, 'lipid'), ('CHEBI_33277', 'gamma-tocotrienol', 285, 'vitamins'), ('UBERON_0001977', 'blood serum', 303, 'serum')]
S13-PMC3616124	PMC3616124	4/2013	S13-PMC3616124	['hp phenotype does not influence Preeclampsia RISK, or identify a subset of women who MAY BENEFIT from Vitamin C and E supplementation to prevent Preeclampsia.']	[('IMPORTANT_CONSIDERATION', 45), ('INCOMPLETE_EVIDENCE', 85), ('IMPORTANT_CONSIDERATION', 89)]	3	[('GO_0007128', 'meiotic prophase I', 32, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 116, 'E'), ('GO_0007128', 'meiotic prophase I', 145, 'preeclampsia')]
S139-PMC3616124	PMC3616124	4/2013	S139-PMC3616124	['hp phenotype, Prenatal/multivitamin use at randomization, and Plasma Ascorbate\nhp phenotype INFLUENCES Plasma Ascorbate concentration[35], PROVIDING a POTENTIAL mechanism by which hp phenotype MIGHT INFLUENCE treatment response to Vitamin C and E. we EXAMINED the RELATIONSHIP between hp phenotype and Plasma Ascorbate in a pre-planned analysis.']	[('SUPERFICIAL_RELATIONSHIP', 92), ('PROBABLE_UNDERSTANDING', 139), ('INCOMPLETE_EVIDENCE', 151), ('INCOMPLETE_EVIDENCE', 193), ('SUPERFICIAL_RELATIONSHIP', 199), ('QUESTION_ANSWERED_BY_THIS_WORK', 251), ('SUPERFICIAL_RELATIONSHIP', 264)]	7	[('GO_0007565', 'female pregnancy', 14, 'Prenatal'), ('UBERON_0001969', 'blood plasma', 62, 'Plasma'), ('CHEBI_2874', 'Asimicin', 69, 'Ascorbate'), ('UBERON_0001969', 'blood plasma', 103, 'plasma'), ('CHEBI_22651', 'ascorbate', 110, 'ascorbate'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 245, 'E'), ('UBERON_0001969', 'blood plasma', 302, 'plasma'), ('CHEBI_22651', 'ascorbate', 309, 'ascorbate')]
S173-PMC3616124	PMC3616124	4/2013	S173-PMC3616124	['THEREFORE, we EXAMINED the POTENTIAL for hp phenotype to INFLUENCE the effectiveness of Vitamin C and E in preventing Preeclampsia and SERIOUS COMPLICATIONS of pah.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('INCOMPLETE_EVIDENCE', 27), ('SUPERFICIAL_RELATIONSHIP', 57), ('IMPORTANT_CONSIDERATION', 135), ('IMPORTANT_CONSIDERATION', 143)]	6	[('CHEBI_27300', 'vitamin D', 88, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 102, 'E'), ('GO_0007128', 'meiotic prophase I', 118, 'preeclampsia')]
S174-PMC3616124	PMC3616124	4/2013	S174-PMC3616124	['daily Vitamin C and E did not prevent Preeclampsia or SERIOUS COMPLICATIONS of pah in low risk primiparous women of any hp phenotype.']	[('IMPORTANT_CONSIDERATION', 54), ('PROBLEM_COMPLICATION', 62)]	2	[('CHEBI_27300', 'vitamin D', 6, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 20, 'E'), ('GO_0007128', 'meiotic prophase I', 38, 'preeclampsia')]
S186-PMC3616124	PMC3616124	4/2013	S186-PMC3616124	['first, Cardiovascular disease studies SUGGEST that Vitamin E alone has DIFFERENT EFFECTS from Vitamin C and E combined[18],[19],[27].']	[('INCOMPLETE_EVIDENCE', 38), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 71), ('SUPERFICIAL_RELATIONSHIP', 81)]	3	[('UBERON_0004535', 'cardiovascular system', 7, 'cardiovascular'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 108, 'E')]
S189-PMC3616124	PMC3616124	4/2013	S189-PMC3616124	['HOWEVER, the pro-oxidant EFFECTS of Vitamin C[28]combined with the reduced antioxidant capacity of Hp 2-2 MAY have CONTRIBUTED to accelerated Coronary Artery narrowing in diabetic Hp 2-2 post-menopausal women taking Vitamins C and E[21].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 25), ('INCOMPLETE_EVIDENCE', 106), ('SUPERFICIAL_RELATIONSHIP', 115)]	4	[('CHEBI_27300', 'vitamin D', 36, 'vitamin C'), ('PR_000008793', 'heat shock factor protein 4', 99, 'Hp 2-2'), ('UBERON_0005985', 'coronary vessel', 142, 'coronary'), ('UBERON_0001637', 'artery', 151, 'artery'), ('PR_000008443', 'huntingtin-associated protein 1', 180, 'Hp 2'), ('CHEBI_27300', 'vitamin D', 216, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 231, 'E')]
S191-PMC3616124	PMC3616124	4/2013	S191-PMC3616124	['in PARTIAL SUPPORT of this HYPOTHESIS, we OBSERVED a 3-fold increase in Preeclampsia risk in hp 2-2 hispanic women receiving Vitamin C and E. the original rct combined Vitamins C and E, an approach used in Cardiovascular disease prevention trials[47],[48],[49]that was successful in SMALL clinical trials.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 42), ('INCOMPLETE_EVIDENCE', 283)]	5	[('GO_0007128', 'meiotic prophase I', 72, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 139, 'E'), ('CHEBI_27300', 'vitamin D', 168, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 183, 'E'), ('UBERON_0004535', 'cardiovascular system', 206, 'cardiovascular')]
S203-PMC3616124	PMC3616124	4/2013	S203-PMC3616124	['conclusions\nIN CONTRAST TO our HYPOTHESIS, our secondary analysis of a large rct INDICATES that hp phenotype does not influence preeclampsia risk, or identify a subset of nulligravidas for whom Vitamins C and E would reduce Preeclampsia RISK in white, black or hispanic women.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 12), ('INCOMPLETE_EVIDENCE', 31), ('INCOMPLETE_EVIDENCE', 81), ('IMPORTANT_CONSIDERATION', 237)]	4	[('CHEBI_27300', 'vitamin D', 194, 'vitamins C'), ('PR_000004900', 'complement C3', 203, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 209, 'E'), ('GO_0007128', 'meiotic prophase I', 224, 'preeclampsia')]
S8-PMC3629265	PMC3629265	4/2013	S8-PMC3629265	"[""while these infants had several RISK FACTORS for Vitamin D deficiency, they were all receiving Cow's milk based formula supplemented with 400 iu/l of vitamin D.\n\nconclusion\nTHIS report SUGGESTS that CURRENT practice with regards to Vitamin D supplementation MAY BE INADEQUATE, especially for high-risk infants.""]"	[('SUPERFICIAL_RELATIONSHIP', 32), ('QUESTION_ANSWERED_BY_THIS_WORK', 173), ('INCOMPLETE_EVIDENCE', 185), ('INCOMPLETE_EVIDENCE', 199), ('INCOMPLETE_EVIDENCE', 258), ('IMPORTANT_CONSIDERATION', 265), ('PROBLEM_COMPLICATION', 265)]	7	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 95, 'cow'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 158, 'D'), ('CHEBI_27300', 'vitamin D', 232, 'vitamin D')]
S198-PMC3641012	PMC3641012	4/2013	S198-PMC3641012	['Vitamin D supplementation had a significant suppressive EFFECT on maternal pth concentration, such that the rise in pth observed in the placebo group was completely attenuated in the vitamin D group (figure\xa04), and the average pth concentration was lower in the Vitamin D group at Delivery (figure\xa02; table\xa04).']	[('SUPERFICIAL_RELATIONSHIP', 56)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 191, 'D'), ('CHEBI_27300', 'vitamin D', 262, 'vitamin D'), ('GO_0007567', 'parturition', 281, 'delivery')]
S93-PMC3659910	PMC3659910	1/2013	S93-PMC3659910	['HOWEVER, hypervitaminosis D has NEVER OCCURRED when physiologic amounts of Vitamin D are Ingested.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 32)]	2	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 26, 'D'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0007631', 'feeding behavior', 89, 'ingested')]
S129-PMC3659910	PMC3659910	1/2013	S129-PMC3659910	['[28] a study on rodents SHOWED that hypovitaminosis D Trabecular Bone loss, and CONCLUDED that Vitamin D is INDISPENSABLE for normal bone mineralization during the Reproductive period in Rats.']	[('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 80), ('IMPORTANT_CONSIDERATION', 108)]	3	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 52, 'D'), ('UBERON_0002483', 'trabecular bone tissue', 54, 'trabecular bone'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('GO_0000003', 'reproduction', 164, 'reproductive'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 187, 'rats')]
S10-PMC3668200	PMC3668200	5/2013	S10-PMC3668200	['HOWEVER, measuring 1,25-Oh2-D levels AS a PREDICTOR of Vitamin D status CAN LEAD TO ERRONEOUS CONCLUSIONS BECAUSE, compared with 25(Oh)D levels, 1,25-Oh2-D levels CAN be normal or EVEN elevated DESPITE Vitamin D deficiency due to secondary hyperparathyroidism.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 37), ('SUPERFICIAL_RELATIONSHIP', 42), ('INCOMPLETE_EVIDENCE', 72), ('PROBABLE_UNDERSTANDING', 76), ('QUESTION_ANSWERED_BY_THIS_WORK', 81), ('PROBLEM_COMPLICATION', 84), ('PROBLEM_COMPLICATION', 84), ('PROBABLE_UNDERSTANDING', 94), ('PROBABLE_UNDERSTANDING', 106), ('PROBLEM_COMPLICATION', 106), ('INCOMPLETE_EVIDENCE', 163), ('ANOMALY_CURIOUS_FINDING', 180), ('ANOMALY_CURIOUS_FINDING', 194)]	14	[('CHEBI_78731', '9(R)-HPETE', 21, '25-OH2-D'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 129, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 135, 'D'), ('CHEBI_78731', '9(R)-HPETE', 147, '25-OH2-D'), ('CHEBI_27300', 'vitamin D', 202, 'vitamin D')]
S11-PMC3668200	PMC3668200	5/2013	S11-PMC3668200	['in exclusively breastfed infants, 25(Oh)D Serum levels were low during the winter DESPITE supplementation3), whereas Serum levels of 1,25-Oh2-D and Vitamin D-Binding Protein were higher in the winter than in the summer4).']	[('ANOMALY_CURIOUS_FINDING', 82)]	1	[('CHEBI_71657', 'versiconol acetate', 34, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 34, '25'), ('PR_000006444', 'diacylglycerol kinase delta', 40, 'D'), ('UBERON_0001977', 'blood serum', 42, 'serum'), ('UBERON_0001977', 'blood serum', 117, 'serum'), ('CHEBI_17996', 'chloride', 134, ','), ('CHEBI_34309', '21-Fluoroprogesterone', 135, '25-OH2'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 142, 'D'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 148, 'vitamin D-binding protein')]
S41-PMC3668200	PMC3668200	5/2013	S41-PMC3668200	['THEREFORE, daily supplementation with 400 iu of Vitamin D during the last Trimester of Pregnancy HAS BEEN practiced, ALBEIT with MINIMAL EFFECT on circulating 25(Oh)D concentrations in the mother and infant at term.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 97), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 117), ('ANOMALY_CURIOUS_FINDING', 117), ('INCOMPLETE_EVIDENCE', 129), ('SUPERFICIAL_RELATIONSHIP', 137)]	6	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 74, 'trimester'), ('GO_0007565', 'female pregnancy', 87, 'pregnancy'), ('CHEBI_30778', 'gallic acid', 159, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 165, 'D')]
S12-PMC3672018	PMC3672018	5/2013	S12-PMC3672018	['THE PRESENT STUDY addresses these ISSUES in RELATION to Vitamin D.\n\nVitamin D\nvitamin D is a fat-soluble Vitamin that is NECESSARY for the Human body.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('PROBLEM_COMPLICATION', 34), ('SUPERFICIAL_RELATIONSHIP', 44), ('IMPORTANT_CONSIDERATION', 121)]	5	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 68, 'Vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 86, 'D'), ('CHEBI_33229', 'vitamin (role)', 105, 'vitamin'), ('NCBITaxon_9606', 'Homo sapiens', 139, 'human')]
S48-PMC3672018	PMC3672018	5/2013	S48-PMC3672018	['objectives and HYPOTHESIS\nthe PRESENT STUDY relies on a unique societal experiment in which all Margarine and low fat Milk products Consumed by the danish population were fortified with vitamin D, during two distinct time periods: in 1961–1985 fortifying Margarine with Vitamin D was mandatory in denmark and in 1972–1976 low fat milk fortification was allowed.']	[('INCOMPLETE_EVIDENCE', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 30)]	2	[('CHEBI_6784', 'mestranol', 96, 'margarine'), ('UBERON_0001913', 'milk', 118, 'milk'), ('GO_0007631', 'feeding behavior', 132, 'consumed'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 194, 'D'), ('CHEBI_6784', 'mestranol', 255, 'margarine'), ('CHEBI_27300', 'vitamin D', 270, 'vitamin D')]
S117-PMC3691177	PMC3691177	6/2013	S117-PMC3691177	['the 95% confidence interval for our primary outcome measure was 0.49 to 1.50, so we are UNABLE TO confidently exclude EFFECTS of Prenatal vitamin D supplementation on RISK of wheezing, or on the development of atopy especially in mothers treated with daily Vitamin D. third, we DID NOT assess Vitamin D receptor polymorphisms or OTHER POTENTIALLY IMPORTANT genotypic variations.']	[('DIFFICULT_TASK', 88), ('SUPERFICIAL_RELATIONSHIP', 118), ('IMPORTANT_CONSIDERATION', 167), ('INCOMPLETE_EVIDENCE', 278), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 329), ('INCOMPLETE_EVIDENCE', 335), ('IMPORTANT_CONSIDERATION', 347)]	7	[('GO_0007565', 'female pregnancy', 129, 'prenatal'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 146, 'D'), ('CHEBI_27300', 'vitamin D', 257, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 293, 'vitamin D')]
S13-PMC3702245	PMC3702245	6/2013	S13-PMC3702245	['HOWEVER, sustained Vitamin D deficiency results in rickets in children and osteomalacia in Adults.28the COMMONLY evaluated BIOMARKERS of Vitamin D nutrition include Serum 25(Oh)D concentrations, the inverse RELATIONSHIP between 25(Oh)D and Parathyroid hormone, Intestinal calcium absorption, and assessment of Skeletal integrity.29WHILE there is an inverse RELATIONSHIP between Serum Parathyroid hormone and 25(Oh)D in nonpregnant states, this RELATIONSHIP HAS BEEN SHOWN in RECENT STUDIES to be weak during Pregnancy,6,18,30,31INDICATING that Serum Parathyroid hormone MAY BE a LESS RELIABLE BIOMARKER of maternal Vitamin D status during Pregnancy than Serum 25(Oh)d.32the maternal 25(Oh)D level does not vary significantly during Pregnancy unless there is a change in Vitamin D intake or Endogenous Synthesis.2,33,34HOWEVER, Serum 1,25(Oh)2D levels increase by 100%–200% starting in the first trimester in both the mother and the fetus.35–37the increase in maternal 1,25(Oh)2D, which originates mostly from the Kidneys, accounts for increased Intestinal calcium absorption during Pregnancy.38,39the increase in fetal 1,25(Oh)2D level SEEMS to BE RELATED to synthesis in Placental and Fetal Tissues.39,40\nan IMPORTANT aspect of Vitamin D nutrition in Pregnancy is that the Vitamin D status of the infant at Birth and in early infancy DEPENDS ON the vitamin d status of the mother during Pregnancy.41vitamin D stores in the infant start with transplacental Transfer of 25(Oh)D in early Pregnancy from mother to fetus.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 104), ('SUPERFICIAL_RELATIONSHIP', 123), ('SUPERFICIAL_RELATIONSHIP', 207), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 329), ('SUPERFICIAL_RELATIONSHIP', 357), ('SUPERFICIAL_RELATIONSHIP', 444), ('INCOMPLETE_EVIDENCE', 457), ('INCOMPLETE_EVIDENCE', 475), ('INCOMPLETE_EVIDENCE', 526), ('INCOMPLETE_EVIDENCE', 570), ('INCOMPLETE_EVIDENCE', 579), ('IMPORTANT_CONSIDERATION', 584), ('SUPERFICIAL_RELATIONSHIP', 593), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 816), ('ANOMALY_CURIOUS_FINDING', 1136), ('ANOMALY_CURIOUS_FINDING', 1145), ('SUPERFICIAL_RELATIONSHIP', 1148), ('IMPORTANT_CONSIDERATION', 1209), ('SUPERFICIAL_RELATIONSHIP', 1335)]	20	"[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('UBERON_0007023', 'adult organism', 91, 'adults'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('UBERON_0001977', 'blood serum', 165, 'serum'), ('CHEBI_30778', 'gallic acid', 171, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 177, 'D'), ('CHEBI_71657', 'versiconol acetate', 228, '25(OH)D'), ('UBERON_0001132', 'parathyroid gland', 240, 'parathyroid'), ('UBERON_0000160', 'intestine', 261, 'intestinal'), ('UBERON_0004288', 'skeleton', 310, 'skeletal'), ('UBERON_0001977', 'blood serum', 378, 'serum'), ('UBERON_0001132', 'parathyroid gland', 384, 'parathyroid'), ('CHEBI_71657', 'versiconol acetate', 408, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 411, 'OH ... D'), ('GO_0007565', 'female pregnancy', 508, 'pregnancy'), ('UBERON_0001977', 'blood serum', 544, 'serum'), ('UBERON_0001132', 'parathyroid gland', 550, 'parathyroid'), ('CHEBI_27300', 'vitamin D', 615, 'vitamin D'), ('GO_0007565', 'female pregnancy', 639, 'pregnancy'), ('UBERON_0001977', 'blood serum', 654, 'serum'), ('CHEBI_30778', 'gallic acid', 660, '25(OH)'), ('CHEBI_71657', 'versiconol acetate', 683, '25(OH)D'), ('GO_0007565', 'female pregnancy', 732, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 770, 'vitamin D'), ('GO_0042400', 'ectoine catabolic process', 790, 'endogenous synthesis'), ('UBERON_0001977', 'blood serum', 827, 'serum'), ('CHEBI_37958', 'dye', 833, '1,'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 835, '25(OH)2D'), ('CHEBI_37958', 'dye', 968, '1,'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 970, '25(OH)2D'), ('UBERON_0002113', 'kidney', 1013, 'kidneys'), ('UBERON_0000160', 'intestine', 1045, 'intestinal'), ('GO_0007565', 'female pregnancy', 1082, 'pregnancy'), ('CHEBI_37958', 'dye', 1119, '1,'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 1121, '25(OH)2D'), ('UBERON_0001987', 'placenta', 1172, 'placental'), ('UBERON_0005291', 'embryonic tissue', 1186, 'fetal tissues'), ('CHEBI_27300', 'vitamin D', 1229, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1252, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1274, 'vitamin D'), ('GO_0007567', 'parturition', 1308, 'birth'), ('GO_0007565', 'female pregnancy', 1388, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1408, 'D'), ('GO_0006412', 'translation', 1457, 'transfer'), ('CHEBI_71657', 'versiconol acetate', 1469, '25(OH)D'), ('GO_0007565', 'female pregnancy', 1486, 'pregnancy')]"
S15-PMC3702245	PMC3702245	6/2013	S15-PMC3702245	['IN GENERAL, Cord Blood 25(Oh)D concentrations are APPROXIMATELY 60%–89% of the maternal value.11,17,35,41–47THEREFORE, maintaining optimum Vitamin D nutrition during Pregnancy is ESSENTIAL for PREVENTION of hypovitaminosis D in the fetus and Vitamin D deficiency at Birth and in early infancy.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 50), ('ANOMALY_CURIOUS_FINDING', 106), ('IMPORTANT_CONSIDERATION', 179), ('SUPERFICIAL_RELATIONSHIP', 193)]	5	[('UBERON_0002240', 'spinal cord', 12, 'cord'), ('UBERON_0000178', 'blood', 17, 'blood'), ('CHEBI_71657', 'versiconol acetate', 23, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 23, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('GO_0007565', 'female pregnancy', 166, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 223, 'D'), ('CHEBI_27300', 'vitamin D', 242, 'vitamin D'), ('GO_0007567', 'parturition', 266, 'birth')]
S16-PMC3702245	PMC3702245	6/2013	S16-PMC3702245	['high prevalence of low Vitamin D intake in Pregnancy\nthe Vitamin D status in Adults, including Pregnant women, is based currently on measurement of Serum 25(Oh)D concentrations, BUT WHAT constitutes the “normal” OR “optimal” level is CONTROVERSIAL.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 178), ('EXPLICIT_QUESTION', 182), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 212), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 234)]	4	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('GO_0007565', 'female pregnancy', 43, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('UBERON_0007023', 'adult organism', 77, 'adults'), ('GO_0007565', 'female pregnancy', 95, 'pregnant'), ('UBERON_0001977', 'blood serum', 148, 'serum'), ('CHEBI_63056', 'zinc cation', 154, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 160, 'D')]
S19-PMC3702245	PMC3702245	6/2013	S19-PMC3702245	['there is a high prevalence of Vitamin D deficiency [Serum 25(Oh) D <50 nmol/l], and as shown intable 1, most women studied (>80%) have Serum 25(Oh)D concentrations <75 nmol/l, which are CONSIDERED “INSUFFICIENT”.8mean Serum 25(Oh)D concentrations are highest and the prevalence of Vitamin D deficiency is lowest in sun-enriched populations,51,57WHILE the lowest mean Serum 25(Oh)d and the highest prevalence of Vitamin D deficiency are REPORTED in sunshine-deprived populations.16,17,50,55,56the high prevalence of low Vitamin D ASSOCIATED with sunshine deprivation and INADEQUATE corrective Vitamin D intake SHOULD RAISE PUBLIC HEALTH CONCERN about the INCREASED RISK of adverse health EFFECTS of low Vitamin D status for the mother and fetus and poor Vitamin D nutrition in the infant at Birth.']	[('INCOMPLETE_EVIDENCE', 186), ('PROBLEM_COMPLICATION', 198), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 343), ('INCOMPLETE_EVIDENCE', 436), ('SUPERFICIAL_RELATIONSHIP', 529), ('IMPORTANT_CONSIDERATION', 570), ('FUTURE_WORK', 609), ('IMPORTANT_CONSIDERATION', 616), ('IMPORTANT_CONSIDERATION', 622), ('IMPORTANT_CONSIDERATION', 654), ('SUPERFICIAL_RELATIONSHIP', 687)]	11	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('UBERON_0001977', 'blood serum', 52, 'serum'), ('CHEBI_71657', 'versiconol acetate', 58, '25(OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 58, '25(OH) D'), ('UBERON_0001977', 'blood serum', 135, 'serum'), ('CHEBI_71657', 'versiconol acetate', 141, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 141, '25(OH)D'), ('UBERON_0001977', 'blood serum', 218, 'serum'), ('CHEBI_30778', 'gallic acid', 224, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 230, 'D'), ('CHEBI_27300', 'vitamin D', 281, 'vitamin D'), ('UBERON_0001977', 'blood serum', 367, 'serum'), ('CHEBI_30778', 'gallic acid', 373, '25(OH)'), ('CHEBI_27300', 'vitamin D', 411, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 519, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 592, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 702, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 753, 'vitamin D'), ('GO_0007567', 'parturition', 790, 'birth')]
S27-PMC3702245	PMC3702245	6/2013	S27-PMC3702245	['high resolution three-dimensional ultrasound assessment in a study from the uk FOUND greater splaying of the distal Femoral Metaphysis in the fetus when maternal Serum 25(Oh)D was <50 nmol/l,60AND the authors SUGGESTED that this FINDING is SIMILAR TO radiologic features in Vitamin D-deficient rickets.']	[('INCOMPLETE_EVIDENCE', 79), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 191), ('INCOMPLETE_EVIDENCE', 209), ('INCOMPLETE_EVIDENCE', 229), ('INCOMPLETE_EVIDENCE', 240)]	5	[('UBERON_0013751', 'metaphysis of radius', 116, 'femoral metaphysis'), ('UBERON_0001977', 'blood serum', 162, 'serum'), ('CHEBI_63056', 'zinc cation', 168, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 174, 'D'), ('CHEBI_27300', 'vitamin D', 274, 'vitamin D')]
S24-PMC3704911	PMC3704911	7/2013	S24-PMC3704911	['additionally, Prenatal DEFICIENCIES in Vitamins D and E HAVE BEEN ASSOCIATED with increased incidences of Respiratory difficulties, including wheezing and asthma, in the offspring [7], and maternal Vitamin D deficiencies HAVE BEEN RELATED to observed hyper-Locomotion in the Adult Rat [8].']	[('IMPORTANT_CONSIDERATION', 23), ('INCOMPLETE_EVIDENCE', 56), ('SUPERFICIAL_RELATIONSHIP', 66), ('INCOMPLETE_EVIDENCE', 221), ('SUPERFICIAL_RELATIONSHIP', 231)]	5	[('GO_0007565', 'female pregnancy', 14, 'prenatal'), ('CHEBI_27300', 'vitamin D', 39, 'vitamins D'), ('PR_000006444', 'diacylglycerol kinase delta', 48, 'D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 54, 'E'), ('UBERON_0001004', 'respiratory system', 106, 'respiratory'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('GO_0040011', 'locomotion', 257, 'locomotion'), ('UBERON_0007023', 'adult organism', 275, 'adult'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 281, 'rat')]
S143-PMC3717170	PMC3717170	5/2013	S143-PMC3717170	['on numerous earlier occasions, encouraging findings from observational studies were NOT CONFIRMED by well-designed clinical trials (e.g., hormone replacement therapy, β-Carotene, Vitamins C and E, and Folic Acid) and prevailing clinical practice was OVERTURNED.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 84), ('IMPORTANT_CONSIDERATION', 105), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 250)]	3	[('CHEBI_23042', 'carotene', 169, 'carotene'), ('CHEBI_27300', 'vitamin D', 179, 'vitamins C'), ('PR_000004900', 'complement C3', 188, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 194, 'E'), ('CHEBI_30751', 'formic acid', 201, 'folic acid')]
S164-PMC3728489	PMC3728489	7/2013	S164-PMC3728489	['fat-soluble Vitamins A and D play IMPORTANT ROLES in both Cell-Mediated and humoral Immune Responses (wintergerst et al.,2007).']	[('IMPORTANT_CONSIDERATION', 34), ('SUPERFICIAL_RELATIONSHIP', 44)]	2	[('CHEBI_27300', 'vitamin D', 12, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 27, 'D'), ('GO_0000911', 'cytokinesis by cell plate formation', 58, 'cell-mediated ... immune responses'), ('UBERON_0002405', 'immune system', 84, 'immune')]
S21-PMC3760821	PMC3760821	9/2013	S21-PMC3760821	['hypovitaminosis D is commonly SEEN in both Pregnant and non-Pregnant women worldwide[5]; with many FACTORS IMPACTING on Vitamin D status, including; exposure to sunlight, skin colour, season, latitude and obesity, among others[6].']	[('INCOMPLETE_EVIDENCE', 30), ('SUPERFICIAL_RELATIONSHIP', 99), ('SUPERFICIAL_RELATIONSHIP', 107)]	3	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 16, 'D'), ('GO_0007565', 'female pregnancy', 43, 'pregnant'), ('GO_0007565', 'female pregnancy', 60, 'pregnant'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D')]
S134-PMC3760821	PMC3760821	9/2013	S134-PMC3760821	['a similar significant positive ASSOCIATION was SEEN between 25ohd at trimester 2 and trimester 3 in both groups.10.1371/journal.pone.0074068.t003\n\ncaption (table-wrap): table 3\nmaternal and Cord Vitamin D levels and their RELATIONSHIP with maternal and neonatal outcome variables.variablecontrol groupt1dm group rp value rp value maternal Vitamin D booking Vitamin D trimester 20.92<0.0010.46<0.001vitamin D trimester 30.76<0.0010.380.005hba1cbooking−0.160.49−0.380.004 maternal Vitamin D trimester 2 Vitamin D trimester 30.66<0.0010.64<0.001hba1cbooking−0.110.55−0.410.001hba1ctrimester 20.060.76−0.280.03birth weight (g)0.390.010.020.87neonatal bmi sds0.170.31−0.240.07birth height sds−0.060.730.230.08 maternal Vitamin D trimester 3 hba1cbooking−0.160.35−0.250.05hba1ctrimester 2−0.130.42−0.220.08neonatal bmi sds0.110.43−0.300.02birth height sds−0.0020.990.280.03 Cord Vitamin D neonatal measure\u2003neonatal bmi sds0.290.17−0.310.03\u2003Birth height sds−0.190.390.260.06maternal hba1c\u2003booking−0.140.57−0.440.001\u2003trimester 2−0.390.12−0.290.03\u2003trimester 3−0.230.29−0.220.12maternal Vitamin D\u2003booking0.390.260.330.02\u2003trimester 20.250.320.46<0.001\u2003trimester 30.73<0.0010.84<0.001\ncorrelations between continuous variables were assessed by pearson’s coefficients for correlations.']	[('SUPERFICIAL_RELATIONSHIP', 31), ('INCOMPLETE_EVIDENCE', 47), ('SUPERFICIAL_RELATIONSHIP', 222)]	3	[('UBERON_0002240', 'spinal cord', 190, 'cord'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 339, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 357, 'Vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 406, 'D'), ('CHEBI_28384', 'vitamin K', 479, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 501, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 714, 'Vitamin D'), ('UBERON_0000948', 'heart', 868, 'Cord'), ('CHEBI_28384', 'vitamin K', 873, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 873, 'Vitamin D'), ('GO_0007567', 'parturition', 934, 'Birth'), ('CHEBI_27300', 'vitamin D', 1077, 'vitamin D')]
S110-PMC3798907	PMC3798907	8/2013	S110-PMC3798907	['this CONCERN is SUPPORTED by the RECENT report that high-dose Antenatal Vitamin C and E supplementation is ASSOCIATED with increased infant healthcare utilisation and cost of care [23].']	[('IMPORTANT_CONSIDERATION', 5), ('PROBLEM_COMPLICATION', 5), ('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 33), ('SUPERFICIAL_RELATIONSHIP', 107)]	5	[('GO_0007567', 'parturition', 62, 'antenatal'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 86, 'E')]
S100-PMC3827489	PMC3827489	10/2013	S100-PMC3827489	['it is NOT KNOWN, however, HOW much amount of Vitamin D supplementation is NEEDED for korean children and Pregnant women in order to maintain adequate concentrations of vitamin D. CONSIDERING the high prevalence of Vitamin D insufficiency or deficiency in koreans, ESPECIALLY children and adolscents6,22-24), this ISSUE NEEDS TO BE addressed URGENTLY by FUTURE STUDIES.']	[('FULL_UNKNOWN', 6), ('EXPLICIT_QUESTION', 26), ('IMPORTANT_CONSIDERATION', 74), ('INCOMPLETE_EVIDENCE', 179), ('IMPORTANT_CONSIDERATION', 264), ('PROBLEM_COMPLICATION', 313), ('IMPORTANT_CONSIDERATION', 319), ('IMPORTANT_CONSIDERATION', 341), ('FUTURE_WORK', 353)]	9	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007565', 'female pregnancy', 105, 'pregnant'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 176, 'D'), ('CHEBI_27300', 'vitamin D', 214, 'vitamin D')]
S146-PMC3829207	PMC3829207	11/2013	S146-PMC3829207	['again, strict monitoring IS NEEDED to prevent Vitamin A and D toxicity in case of excessive Supplements [39].']	[('FUTURE_WORK', 25)]	1	[('CHEBI_27300', 'vitamin D', 46, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 60, 'D'), ('CHEBI_33341', 'titanium atom', 92, 'supplements')]
S134-PMC4034700	PMC4034700	5/2014	S134-PMC4034700	['we SHOWED that administration of Vitamins C and E can block hr-mediated Sflt-1 secretion, via inhibition of P38 and Nf-Κb Signaling Pathways (cindrova-davies et al., 2007;cindrova-davies, 2009).']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('CHEBI_27300', 'vitamin D', 33, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 48, 'E'), ('PR_000014793', 'inactive tyrosine-protein kinase PRAG1', 72, 'sFlt-1'), ('GO_0007567', 'parturition', 108, 'p38 ...'), ('PR_000000123', 'ribosomal protein S6 kinase beta-1', 108, 'p38'), ('GO_0038032', 'termination of G protein-coupled receptor signaling pathway', 116, 'NF-κB signaling pathways'), ('GO_0071159', 'NF-kappaB complex', 116, 'NF-κB'), ('PR_000011111', 'N-terminal EF-hand calcium-binding protein 3', 116, 'NF-κB')]
S137-PMC4034700	PMC4034700	5/2014	S137-PMC4034700	['HOWEVER, DESPITE encouraging in vitro DATA and cohort trials, clinical trials aimed to treat women AT RISK of Preeclampsia with Vitamins C and E (poston et al., 2006;rumbold et al., 2006) SHOWED no reduction in the incidence of the disease.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 9), ('FUTURE_WORK', 38), ('IMPORTANT_CONSIDERATION', 99), ('INCOMPLETE_EVIDENCE', 188)]	5	[('GO_0007128', 'meiotic prophase I', 110, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 128, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 143, 'E')]
S476-PMC4113768	PMC4113768	7/2014	S476-PMC4113768	['overall reductions in Lung cancer RISKS in never-smokers in the women’s health initiative (1771 cases in 128,779 women) were seen with vitamin D intakes >400 iu/day (or = 0.37, 95% ci: 0.18–0.77); HOWEVER, rct data for the 12% of women given Vitamin D supplements SHOWED lower Lung cancer risk ONLY in those with low intakes of Retinol (or = 0.69, 95% ci, 0.5–0.96).']	[('IMPORTANT_CONSIDERATION', 34), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 197), ('ANOMALY_CURIOUS_FINDING', 197), ('INCOMPLETE_EVIDENCE', 264), ('ANOMALY_CURIOUS_FINDING', 294), ('INCOMPLETE_EVIDENCE', 294)]	6	[('UBERON_0002048', 'lung', 22, 'lung'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 143, 'D'), ('CHEBI_27300', 'vitamin D', 242, 'vitamin D'), ('UBERON_0002048', 'lung', 277, 'lung'), ('CHEBI_26536', 'retinoic acid', 328, 'retinol')]
S1079-PMC4113768	PMC4113768	7/2014	S1079-PMC4113768	['there APPEARED TO BE NO significant impact of hypovitaminosis D on the inflammatory marker crp, levels of which were SIMILAR among Vitamin D sufficient and deficient subjects.']	[('ANOMALY_CURIOUS_FINDING', 6), ('SUPERFICIAL_RELATIONSHIP', 117)]	2	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 62, 'D'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
S2086-PMC4113768	PMC4113768	7/2014	S2086-PMC4113768	['conclusions: groups AT RISK of hypovitaminosis D NEED to consume Vitamin D-rich or fortified Foods and would BENEFIT from taking a daily low dose Vitamin D supplement of 5–10 µg (200–400 iu) IN KEEPING WITH the iom specifications for total daily Vitamin D intake.']	[('IMPORTANT_CONSIDERATION', 20), ('IMPORTANT_CONSIDERATION', 49), ('IMPORTANT_CONSIDERATION', 109), ('INCOMPLETE_EVIDENCE', 191)]	4	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 47, 'D'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_33290', 'food', 93, 'foods'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 246, 'vitamin D')]
S2146-PMC4113768	PMC4113768	7/2014	S2146-PMC4113768	['Vitamin D deficiency was CONFIRMED by measuring the Serum Calcium and 25(Oh)D3, an indicator for Vitamin D status.vitamin D deficient Rats had undetectable Serum 25(Oh)D3And hypocalcaemia.']	[('INCOMPLETE_EVIDENCE', 25)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 52, 'serum'), ('CHEBI_22313', 'alkaline earth metal atom', 58, 'calcium'), ('CHEBI_62946', 'ammonium sulfate', 70, '25(OH)D3'), ('PR_000029655', '28S rRNA (cytosine-C(5))-methyltransferase', 70, '25(OH)D3'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 122, 'D'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 134, 'rats'), ('UBERON_0001977', 'blood serum', 156, 'serum'), ('CHEBI_76945', 'manool', 162, '25(OH)D3and')]
S2219-PMC4113768	PMC4113768	7/2014	S2219-PMC4113768	['randomized, double-blind, placebo-controlled trial of Vitamin D supplement in parkinson’s disease\n\nurashima, m.; suzuki, m.; yoshioka, m.; hashimoto, m.; murakami, m.; noya, m.; takahashi, d.\nbackground: in our PREVIOUS STUDY, higher Serum 25-Hydroxy Vitamin D (25Ohd) levels and the Vitamin D receptor (vdr) fokicc genotype were ASSOCIATED with milder parkinson’s disease (pd).']	[('INCOMPLETE_EVIDENCE', 211), ('SUPERFICIAL_RELATIONSHIP', 330)]	2	"[('CHEBI_28384', 'vitamin K', 54, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 234, 'serum'), ('CHEBI_67376', 'dihydrooroxylin A', 240, '25-hydroxy vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 259, 'D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 262, '25OHD'), ('CHEBI_27300', 'vitamin D', 284, 'vitamin D')]"
S19-PMC4160835	PMC4160835	9/2014	S19-PMC4160835	['Vitamin C and E, for the PREVENTION of pre-eclampsia.19\norganic agriculture is a production system that relies on ecological processes, biodiversity and cycles adapted to local conditions, aiming at sustaining the health of soils, ecosystems and People.20organically produced Food is produced without the application of synthetic Pesticides, synthetic fertilisers or Genetically modified Organisms.']	[('SUPERFICIAL_RELATIONSHIP', 25)]	1	[('CHEBI_27300', 'vitamin D', 0, 'vitamin C'), ('PR_000004900', 'complement C3', 8, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 14, 'E'), ('NCBITaxon_10088', 'Mus <genus>', 246, 'people'), ('CHEBI_33290', 'food', 276, 'food'), ('CHEBI_35392', 'glucarate(1-)', 330, 'pesticides'), ('SO_0000704', 'gene', 367, 'genetically'), ('NCBITaxon_1', 'root', 388, 'organisms')]
S189-PMC4169453	PMC4169453	9/2014	S189-PMC4169453	['DESPITE the AFOREMENTIONED CONTROVERSIES, the improvement in Vitamin D status in studied groups was achieved without any evidence of hypervitaminosis D, such as elevated 25(Oh)d, hypercalcemia, or increased hypercalciuria.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 12), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 27)]	4	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 150, 'D'), ('CHEBI_30778', 'gallic acid', 170, '25(OH)')]
S84-PMC4171568	PMC4171568	9/2014	S84-PMC4171568	['these levels increased significantly at 4-month follow-up after Omega-3 Epufa supplementation combined with Vitamin C and E and were ASSOCIATED with improvements in psychopathology and quality Of Life.']	[('SUPERFICIAL_RELATIONSHIP', 133)]	1	[('CHEBI_82678', '3beta-hydroxy-7-oxo-5beta-cholan-24-oic acid', 64, 'omega-3 EPUFA'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 122, 'E'), ('GO_0007608', 'sensory perception of smell', 193, 'of life')]
S22-PMC4192458	PMC4192458	9/2014	S22-PMC4192458	['furthermore, Serum Nutrient levels (such as elevated polyunsaturated Fatty Acids, and decreased Vitamins C and E, zinc, and iron) HAVE BEEN ASSOCIATED with increased inflammation, oxidative stress, and dyslipidemia [9,10].']	[('INCOMPLETE_EVIDENCE', 130), ('SUPERFICIAL_RELATIONSHIP', 140)]	2	[('UBERON_0001977', 'blood serum', 13, 'serum'), ('CHEBI_33284', 'nutrient', 19, 'nutrient'), ('CHEBI_35366', 'fatty acid', 69, 'fatty acids'), ('CHEBI_27300', 'vitamin D', 96, 'vitamins C'), ('PR_000004900', 'complement C3', 105, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 111, 'E')]
S187-PMC4193194	PMC4193194	10/2014	S187-PMC4193194	['the study, called combined antioxidants and Preeclampsia prediction studies (capps), had the OBJECTIVE of determining WHETHER Vitamin C and E COULD reduce the frequency of Pregnancy related hypertension.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 93), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 118), ('INCOMPLETE_EVIDENCE', 142)]	3	[('GO_0007128', 'meiotic prophase I', 44, 'Preeclampsia'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 140, 'E'), ('GO_0007565', 'female pregnancy', 172, 'pregnancy')]
S188-PMC4193194	PMC4193194	10/2014	S188-PMC4193194	['results from this STUDY SHOWED that the supplementation with Vitamin C and E in a low-risk cohort of women DEMONSTRATED no significant differences in maternal or newborn complications RELATED to hypertension during Pregnancy (roberts et al.,2010; weissgerber et al.,2013).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 18), ('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 107), ('SUPERFICIAL_RELATIONSHIP', 184)]	4	[('CHEBI_27300', 'vitamin D', 61, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 75, 'E'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy')]
S190-PMC4193194	PMC4193194	10/2014	S190-PMC4193194	['ALIGNED with this FINDINGS, the cochrane collaboration initiative have CONCLUDED on its latest review on Antioxidants for preventing pe that evidence from trials reviewed does NOT SUPPORT the use of Vitamin C and E during Pregnancy for the PREVENTION of Preeclampsia and other outcomes (rumbold et al.,2008; salles et al.,2012).']	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 18), ('INCOMPLETE_EVIDENCE', 71), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 176), ('SUPERFICIAL_RELATIONSHIP', 240)]	5	[('CHEBI_60641', 'methyl 5-aminolevulinate hydrochloride', 105, 'antioxidants'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 213, 'E'), ('GO_0007565', 'female pregnancy', 222, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 254, 'preeclampsia')]
S212-PMC4193194	PMC4193194	10/2014	S212-PMC4193194	['oral supplementation with Antioxidants like Vitamin C and E and EVEN N-Acetylcysteine HAVE BEEN PROVEN to be a failure on the prevention of the disease.']	[('ANOMALY_CURIOUS_FINDING', 64), ('INCOMPLETE_EVIDENCE', 86)]	2	[('CHEBI_60641', 'methyl 5-aminolevulinate hydrochloride', 26, 'antioxidants'), ('CHEBI_27300', 'vitamin D', 44, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 58, 'E'), ('CHEBI_44482', 'N-oxalylglycine', 69, 'n-acetylcysteine')]
S29-PMC4268639	PMC4268639	11/2014	S29-PMC4268639	['caption (table-wrap): table 1\n\nEMPHASIS of nutrition education classesnutrientspreconception1st trimester2nd trimester3rd trimesterpostnatal protein adequatecomplete, Carnitine, methionine, cysteine, 0.8 g/kgcomplete, adequate 1.1 g/kgcomplete, adequate 1.1 g/kgcomplete, adequate fat essential Fatty Acidsomega 3omega 3omega 3omega 3 Carbohydrate complexcomplexcomplex,fiber complexcomplex Minerals Iodine, iron, magnesium, zinc, calcium, Seleniumiodine, Seleniumiron, magnesium, calciumiron, zinc, magnesiumiron, calcium Vitamins methylation factorsvitamins d, b6, b12, folatevitamins e, D, cvitamins C, ab Vitamins, Vitamin D Phytonutrients full range of colors of fruits and vegetablescolors: oxidative reservecolors: Organ growthcolors: newborn preferencecolors: oxidant balance Probiotics immune balanceimmune balanceimmune balance\n\ncaption (table-wrap): table 2\n\nPrenatal supplements adjusted to levels of Hemoglobin, hematocrit, mean corpuscular volume, Vitamin D, Zinc, Carnitine, and mthfr statusvitamin a Mixed Carotenoids5000 iumethylcobalamin800 µgchromium (Chromium Niacinate)200 µgvitamin c250 mgbiotin100 µgmolybdenum (Molybdenum Glycinate)25 µgvitamin d32000 iupantothenic Acid (D-Calcium Pantothenate)25 mgomega-3 Fatty Acids620 mgvitamin E (Mixed)110 iuiron (iron Bisglycinate)25 mgepa400 mgthiamine (Mononitrate)5 mgiodine (Potassium Iodide)150 µgdha200 mgriboflavin (5 phosphate)5 mgzinc (Zinc Citrate)25 mgother omega-320 mgniacinamide25 mgselenium (l Selenomethionine)100 µgl-Carnitine as 1492 mg l-Carnitine tartrate1000 mgb6(Pyridoxal 5 Phosphate)15 mgcopper (Copper Gluconate)1.5 mgprobiotic blend: lactobacillus acidophilus 60 b cful-5-Methylfolate1000 µgmanganese (manganese gluconate)5 mg bifidobacterium lectis, lactobacillus plantarum, lactobacillus salivarius, streptococcus thermophilus\nabbreviations: cfu, colony-forming unit; Dha, Docosahexaenoic Acid; Epa, Eicosapentaenoic Acid; mthfr, Methylenetetrahydrofolate reductase.']	[('IMPORTANT_CONSIDERATION', 31)]	1	"[('CHEBI_17126', 'carnitine', 167, 'carnitine'), ('CHEBI_39327', '(1S)-cis-(alphaR)-cyhalothrin', 295, 'fatty acidsOmega'), ('CHEBI_16646', 'carbohydrate', 335, 'Carbohydrate'), ('CHEBI_25468', 'naphthaldehydes', 391, 'Minerals'), ('CHEBI_31719', 'ipriflavone', 400, 'Iodine'), ('CHEBI_9107', 'senecionine', 440, 'seleniumIodine'), ('CHEBI_30483', 'trihydridotellurate(1-)', 456, 'seleniumIron'), ('CHEBI_28371', 'vitamin K epoxide', 523, 'Vitamins'), ('PR_000006444', 'diacylglycerol kinase delta', 590, 'D'), ('PR_000004900', 'complement C3', 603, 'C'), ('CHEBI_33277', 'gamma-tocotrienol', 609, 'vitamins'), ('CHEBI_27300', 'vitamin D', 619, 'vitamin D'), ('CHEBI_36961', 'chalcocarbonic acid', 629, 'Phytonutrients'), ('UBERON_0000062', 'organ', 722, 'organ'), ('CHEBI_8474', 'propane-2-thiol', 784, 'Probiotics'), ('GO_0007565', 'female pregnancy', 870, 'Prenatal'), ('CHEBI_5679', 'herniarin', 913, 'Hemoglobin'), ('CHEBI_28384', 'vitamin K', 962, 'Vitamin D'), ('CHEBI_27377', ""Unsym-bis(4'-chlorophenyl)ethylene"", 973, 'Zinc'), ('CHEBI_17126', 'carnitine', 979, 'Carnitine'), ('CHEBI_60004', 'mixture', 1016, 'mixed'), ('CHEBI_77957', 'm-fluoro-L-phenylalanine', 1022, 'carotenoids5000'), ('CHEBI_53471', 'chromium(III) sulfate', 1071, 'chromium niacinate'), ('UBERON_0002365', 'exocrine gland', 1135, 'molybdenum'), ('CHEBI_32508', 'glycinate', 1146, 'glycinate'), ('CHEBI_37527', 'acid', 1190, 'acid'), ('CHEBI_38294', 'dicarba-nido-undecaborane(11)', 1196, 'd-calcium pantothenate'), ('CHEBI_78128', 'fatty acid anion 24:0', 1232, 'fatty acids620'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1257, 'E'), ('CHEBI_60004', 'mixture', 1260, 'mixed'), ('CHEBI_32499', 'amineptine', 1283, 'bisglycinate'), ('CHEBI_29440', 'methanuidyl', 1320, 'mononitrate'), ('CHEBI_8346', 'potassium iodide', 1344, 'potassium iodide'), ('CHEBI_46916', 'vinyl acetate', 1410, 'zinc citrate'), ('CHEBI_26630', 'selenocystathionine', 1474, 'selenomethionine'), ('CHEBI_17126', 'carnitine', 1499, 'carnitine'), ('CHEBI_17126', 'carnitine', 1522, 'carnitine'), ('CHEBI_16462', 'glycylpeptide', 1550, 'Pyridoxal 5 phosphate'), ('CHEBI_23401', 'coumaric acid', 1585, 'copper gluconate'), ('CHEBI_82350', '5-Nitroacenaphthene', 1661, '5-Methylfolate1000'), ('CHEBI_17874', 'dihydrozeatin', 1861, 'DHA'), ('CHEBI_36003', 'decenoic acid', 1866, 'docosahexaenoic acid'), ('CHEBI_34733', 'EPN', 1888, 'EPA'), ('CHEBI_36003', 'decenoic acid', 1893, 'eicosapentaenoic acid'), ('CHEBI_38725', 'mevinphos', 1923, 'methylenetetrahydrofolate')]"
S45-PMC4275593	PMC4275593	9/2014	S45-PMC4275593	['the supply of free or cheap Vitamin A and D tablets, milk, orange juice and cod Liver oil to expectant mothers and children through the wartime vitamin welfare scheme, with their perceived ROLE in the decline of maternal mortality, consolidated the IMPORTANCE of dietary supplements in Pregnancy.']	[('SUPERFICIAL_RELATIONSHIP', 189), ('IMPORTANT_CONSIDERATION', 249)]	2	[('CHEBI_27300', 'vitamin D', 28, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 42, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 42, 'D'), ('UBERON_0002107', 'liver', 80, 'liver'), ('GO_0007565', 'female pregnancy', 286, 'pregnancy')]
S141-PMC4377879	PMC4377879	3/2015	S141-PMC4377879	['there DOES NOT APPEAR TO BE EVIDENCE to RECOMMEND supplementation with Vitamins C and E.\n\n7.']	[('INCOMPLETE_EVIDENCE', 6), ('ANOMALY_CURIOUS_FINDING', 11), ('ANOMALY_CURIOUS_FINDING', 15), ('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 25), ('FUTURE_WORK', 40)]	6	[('CHEBI_27300', 'vitamin D', 71, 'vitamins C'), ('PR_000004900', 'complement C3', 80, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 86, 'E')]
S96-PMC4417995	PMC4417995	4/2015	S96-PMC4417995	['[44] reported that high Vitamin D values during Pregnancy MIGHT also be harmful with respect to Allergic disease development: children whose mothers had a 25(Oh)D concentration during Pregnancy of greater than 30\u2009ng/ml had an increased risk of atopic eczema on examination at 9 months compared with children whose mothers had a concentration of less than 12\u2009ng/ml.']	[('INCOMPLETE_EVIDENCE', 58)]	1	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0007565', 'female pregnancy', 48, 'pregnancy'), ('GO_0040011', 'locomotion', 96, 'allergic'), ('CHEBI_63056', 'zinc cation', 155, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 161, 'D'), ('GO_0007565', 'female pregnancy', 184, 'pregnancy')]
S242-PMC4448820	PMC4448820	5/2015	S242-PMC4448820	['in addition to Vitamins A and D, OTHER Nutrients MAY AFFECT the induction of Tregs.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 33), ('INCOMPLETE_EVIDENCE', 49), ('SUPERFICIAL_RELATIONSHIP', 53)]	3	[('CHEBI_27300', 'vitamin D', 15, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 30, 'D'), ('CHEBI_33284', 'nutrient', 39, 'nutrients'), ('CL_0000909', 'CD8-positive, alpha-beta memory T cell', 77, 'Tregs')]
S274-PMC4448820	PMC4448820	5/2015	S274-PMC4448820	['caption (boxed-text): text box 9\u2003\npotential pathways of intersection for Micronutrients\n\n● Myelomonocytic Cell Differentiation (Vitamins A and D)\n● Macrophage polarization (Vitamins a and d, zinc, Folic Acid)\n● B and T Cell Proliferation (zinc, Iron, Folic Acid, others)\n● T Cell Apoptosis (zinc, iron, Vitamin A, Vitamin E, others)\n● Regulation of Nf-Κb activity (Vitamins A, d, and e; zinc; iron; many others)\n● induction, and maintenance, of Treg Cells (Vitamins A and D, zinc, Folic Acid)\n● Regulation Of Gene Expression and/or activity of Protein Kinase C, cyclins, and cyclin-dependent kinases (e.g., as seen with iron): such defects in one or more of these factors MAY AFFECT or Modulate Lymphocyte Responses to stimuli\n\niv.']	[('INCOMPLETE_EVIDENCE', 672), ('SUPERFICIAL_RELATIONSHIP', 676)]	2	[('CHEBI_33839', 'macromolecule', 73, 'micronutrients'), ('CL_0000763', 'myeloid cell', 91, 'Myelomonocytic cell'), ('GO_0002270', 'plasmacytoid dendritic cell activation', 91, 'Myelomonocytic'), ('GO_0030154', 'cell differentiation', 106, 'cell differentiation'), ('CHEBI_27300', 'vitamin D', 128, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 137, 'A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 143, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 143, 'D'), ('CL_0000235', 'macrophage', 148, 'Macrophage'), ('CHEBI_33277', 'gamma-tocotrienol', 173, 'vitamins'), ('CHEBI_30751', 'formic acid', 197, 'folic acid'), ('CL_0000969', 'regulatory B cell', 211, 'B ...'), ('CL_0000084', 'T cell', 217, 'T cell'), ('GO_0008283', 'cell proliferation', 219, 'cell proliferation'), ('CHEBI_24870', 'ion', 245, 'iron'), ('CHEBI_30751', 'formic acid', 251, 'folic acid'), ('CL_0000084', 'T cell', 273, 'T cell'), ('GO_0006915', 'apoptotic process', 275, 'cell apoptosis'), ('CHEBI_27300', 'vitamin D', 303, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 314, 'vitamin E'), ('GO_0065007', 'biological regulation', 335, 'Regulation'), ('GO_0035773', 'insulin secretion involved in cellular response to glucose stimulus', 349, 'NF-κB'), ('GO_0071159', 'NF-kappaB complex', 349, 'NF-κB'), ('PR_000011111', 'N-terminal EF-hand calcium-binding protein 3', 349, 'NF-κB'), ('CHEBI_27300', 'vitamin D', 365, 'vitamins A'), ('CL_0000960', 'T3 B cell', 445, 'Treg cells'), ('CHEBI_27300', 'vitamin D', 457, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 472, 'D'), ('CHEBI_30751', 'formic acid', 481, 'folic acid'), ('GO_0010468', 'regulation of gene expression', 495, 'Regulation of gene expression'), ('SO_0000704', 'gene', 509, 'gene'), ('PR_000013390', '26S proteasome non-ATPase regulatory subunit 8', 544, 'protein kinase C'), ('GO_0065007', 'biological regulation', 686, 'modulate'), ('CL_0000542', 'lymphocyte', 695, 'lymphocyte'), ('GO_0060033', 'anatomical structure regression', 706, 'responses')]
S297-PMC4448820	PMC4448820	5/2015	S297-PMC4448820	['because Vitamins A and D share a Nuclear receptor (rxr), compete for coactivators and corepressors, and reciprocally Regulate the Expression of their receptors, a wide variety of combined EFFECTS on Gene Regulation LIKELY occurs (190–192).']	[('SUPERFICIAL_RELATIONSHIP', 188), ('PROBABLE_UNDERSTANDING', 215)]	2	[('CHEBI_27300', 'vitamin D', 8, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 23, 'D'), ('GO_0005634', 'nucleus', 33, 'nuclear'), ('GO_0065007', 'biological regulation', 117, 'regulate'), ('GO_0010467', 'gene expression', 130, 'expression'), ('SO_0000704', 'gene', 199, 'gene'), ('GO_0065007', 'biological regulation', 204, 'regulation')]
S299-PMC4448820	PMC4448820	5/2015	S299-PMC4448820	['the molecular actions of zinc APPEAR TO BE more COMPLEX than those of Vitamins A and D. in Humans, the zinc-containing proteome contains <3000 members (193).']	[('ANOMALY_CURIOUS_FINDING', 30), ('DIFFICULT_TASK', 48)]	2	[('CHEBI_27300', 'vitamin D', 70, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 85, 'D'), ('NCBITaxon_9606', 'Homo sapiens', 91, 'humans')]
S347-PMC4448820	PMC4448820	5/2015	S347-PMC4448820	['cell culture MODELS and a very SMALL NUMBER OF Human clinical STUDIES INDICATE that nutritional factors including Vitamins A and D AFFECT numerous Genes INVOLVED in Chromatin Remodeling or processes that are INVOLVED in epigenetic Regulation.']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 31), ('INCOMPLETE_EVIDENCE', 62), ('INCOMPLETE_EVIDENCE', 70), ('SUPERFICIAL_RELATIONSHIP', 131), ('SUPERFICIAL_RELATIONSHIP', 153), ('SUPERFICIAL_RELATIONSHIP', 208)]	7	[('NCBITaxon_9606', 'Homo sapiens', 47, 'human'), ('CHEBI_27300', 'vitamin D', 114, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 129, 'D'), ('SO_0000704', 'gene', 147, 'genes'), ('GO_0000785', 'chromatin', 165, 'chromatin'), ('GO_0006338', 'chromatin remodeling', 165, 'chromatin remodeling'), ('GO_0065007', 'biological regulation', 231, 'regulation')]
S1031-PMC4448820	PMC4448820	5/2015	S1031-PMC4448820	['plausible mechanisms and EXTANT EVIDENCE for 2 Micronutrients, Vitamins A and D, are presented in text box 36 .']	[('INCOMPLETE_EVIDENCE', 25), ('INCOMPLETE_EVIDENCE', 32)]	2	[('CHEBI_33839', 'macromolecule', 47, 'micronutrients'), ('CHEBI_27300', 'vitamin D', 63, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 72, 'A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 78, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 78, 'D')]
S1550-PMC4448820	PMC4448820	5/2015	S1550-PMC4448820	['HOWEVER, it was POSSIBLE to interpret these Micronutrients IF the systemic inflammatory response was less severe: for zinc when crp is <20 mg/l, for Selenium and Vitamins A and D when crp is <10 mg/l, and for Vitamins B-6 and C when crp is <5 mg/l.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 16), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 59)]	3	[('CHEBI_33839', 'macromolecule', 44, 'micronutrients'), ('CHEBI_27568', 'selenium atom', 149, 'selenium'), ('CHEBI_27300', 'vitamin D', 162, 'vitamins A'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 162, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 177, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 177, 'D'), ('CHEBI_27300', 'vitamin D', 209, 'vitamins B'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 209, 'vitamins B-6'), ('PR_000004900', 'complement C3', 226, 'C')]
S147-PMC4476607	PMC4476607	1/2015	S147-PMC4476607	['ALTHOUGH antioxidant treatments in Animal MODELS are encouraging, researchers PREMATURELY terminated a clinical trial utilizing high doses of Vitamins C and E in women with Alcohol-exposed Pregnancies BECAUSE of SAFETY CONCERNS (goh et al.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 42), ('INCOMPLETE_EVIDENCE', 42), ('PROBLEM_COMPLICATION', 78), ('PROBLEM_COMPLICATION', 201), ('IMPORTANT_CONSIDERATION', 212), ('IMPORTANT_CONSIDERATION', 219), ('PROBLEM_COMPLICATION', 219)]	9	[('NCBITaxon_33208', 'Metazoa', 35, 'animal'), ('CHEBI_27300', 'vitamin D', 142, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 157, 'E'), ('CHEBI_30879', 'alcohol', 173, 'alcohol'), ('GO_0007565', 'female pregnancy', 189, 'pregnancies')]
S98-PMC4499946	PMC4499946	7/2015	S98-PMC4499946	['our PREVIOUS pharmacokinetic FINDINGS among Pregnant women in dhaka [16,40] HAVE GENERALLY BEEN CONSISTENT with published ESTIMATES of the Vitamin D-to-25(Oh)D dose–response RELATIONSHIP in non-Pregnant Adults (i.e., an APPROXIMATELY 0.7 nmol/l increase in 25(Oh)D at steady state for each 1 μg/day of Vitamin D3[41,42]).']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 29), ('INCOMPLETE_EVIDENCE', 76), ('PROBABLE_UNDERSTANDING', 81), ('INCOMPLETE_EVIDENCE', 96), ('INCOMPLETE_EVIDENCE', 122), ('SUPERFICIAL_RELATIONSHIP', 174), ('INCOMPLETE_EVIDENCE', 220)]	8	[('GO_0007565', 'female pregnancy', 44, 'pregnant'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 155, 'OH)D'), ('GO_0007565', 'female pregnancy', 194, 'pregnant'), ('UBERON_0007023', 'adult organism', 203, 'adults'), ('CHEBI_63056', 'zinc cation', 257, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 263, 'D'), ('CHEBI_33279', 'vitamin D5', 302, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 302, 'vitamin D3')]
S13-PMC4624803	PMC4624803	10/2015	S13-PMC4624803	['results from two RECENT STUDIES on the ASSOCIATION between Vitamin D status and adhd diagnosis SHOWED an ASSOCIATION between low levels of D vitamin and an adhd diagnosis [5,6].']	[('INCOMPLETE_EVIDENCE', 17), ('SUPERFICIAL_RELATIONSHIP', 39), ('INCOMPLETE_EVIDENCE', 95), ('SUPERFICIAL_RELATIONSHIP', 105)]	4	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 139, 'D')]
S116-PMC4632418	PMC4632418	10/2015	S116-PMC4632418	['there are MAJOR causes behind Vitamin D deficiency during Pregnancy, such as INADEQUATE exposure to sunlight, low Vitamin D intake and more REQUIREMENTS for Vitamin D. Vitamin D supplementation during Pregnancy has beneficial EFFECTS on glycaemia, Insulin sensitivity [45], Insulin resistance [46] and Metabolic profiles [47].']	[('IMPORTANT_CONSIDERATION', 10), ('IMPORTANT_CONSIDERATION', 77), ('IMPORTANT_CONSIDERATION', 140), ('SUPERFICIAL_RELATIONSHIP', 226)]	4	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 168, 'Vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 176, 'D'), ('GO_0007565', 'female pregnancy', 201, 'pregnancy'), ('PR_000045358', 'insulin family protein', 248, 'insulin'), ('PR_000045358', 'insulin family protein', 274, 'insulin'), ('GO_0008152', 'metabolic process', 302, 'metabolic')]
S107-PMC4632423	PMC4632423	10/2015	S107-PMC4632423	['likewise concentrations of Anti-Oxidant Micronutrient Vitamins A, E and Selenium are often lower in smokers [30], PERHAPS BECAUSE of increased utilisation, and more of the obese women in our study were current smokers.']	[('INCOMPLETE_EVIDENCE', 114), ('PROBABLE_UNDERSTANDING', 122)]	2	[('CHEBI_74351', 'aclacinomycin T', 27, 'anti-oxidant'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 40, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 54, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 63, 'A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 66, 'E'), ('CHEBI_27568', 'selenium atom', 72, 'selenium')]
S20-PMC4691762	PMC4691762	12/2015	S20-PMC4691762	['objectives\nwith the ultimate GOAL of developing improved PUBLIC HEALTH GUIDELINES for Vitamin D supplementation of infants, we AIM TO DETERMINE IF Vitamin D supplementation in infants from 6 to 8\u2005weeks of age LEADS to a reduction in the following during the first year of Life:\nchallenge-proven Food allergy\nlower Respiratory infections\nFood sensitisation\ndoctor diagnosed eczema\nvitamin D deficiency\n\nmethods and analysis\n\ndesign\nvitality is a double-blind, randomised, placebo-controlled trial of Vitamin D supplementation during the first year of Life.']	[('IMPORTANT_CONSIDERATION', 29), ('IMPORTANT_CONSIDERATION', 57), ('IMPORTANT_CONSIDERATION', 71), ('FUTURE_WORK', 127), ('QUESTION_ANSWERED_BY_THIS_WORK', 127), ('QUESTION_ANSWERED_BY_THIS_WORK', 131), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 144), ('SUPERFICIAL_RELATIONSHIP', 209)]	8	[('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('UBERON_0000104', 'life cycle', 272, 'life'), ('CHEBI_33290', 'food', 295, 'food'), ('UBERON_0001004', 'respiratory system', 314, 'respiratory'), ('CHEBI_33290', 'food', 337, 'Food'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 388, 'D'), ('CHEBI_27300', 'vitamin D', 499, 'vitamin D'), ('UBERON_0000104', 'life cycle', 550, 'life')]
S21-PMC4719746	PMC4719746	1/2016	S21-PMC4719746	['the AIMS of THIS PAPER were TO INVESTIGATE ethnic DIFFERENCES in Vitamin D levels during Pregnancy, ASSESS RISK FACTORS for Vitamin D deficiency and explore the EFFECT of Vitamin D supplementation in women identified with low values during early Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 12), ('QUESTION_ANSWERED_BY_THIS_WORK', 28), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 50), ('QUESTION_ANSWERED_BY_THIS_WORK', 100), ('SUPERFICIAL_RELATIONSHIP', 107), ('SUPERFICIAL_RELATIONSHIP', 161)]	7	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 171, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 179, 'D'), ('GO_0007565', 'female pregnancy', 246, 'pregnancy')]
S137-PMC4728620	PMC4728620	1/2016	S137-PMC4728620	['furthermore, a trial that provided a teaspoonful of cod Liver oil (free of Vitamin A and D) from 9 to 12 month of age FOUND an increase in voluntary attention in a free play test after the intervention, ESPECIALLY in boys, compared with un-supplemented children [73].']	[('INCOMPLETE_EVIDENCE', 118), ('ANOMALY_CURIOUS_FINDING', 203)]	2	[('UBERON_0002107', 'liver', 56, 'liver'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 83, 'A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 89, 'D')]
S0-PMC4785305	PMC4785305	3/2016	S0-PMC4785305	['EFFECT of Vitamin D replacement on maternal and neonatal outcomes: a randomised controlled trial in Pregnant women with hypovitaminosis D. a protocol\n\nabstract\n\nintroduction\nthe Vitamin D RECOMMENDED doses during Pregnancy differ between societies.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('FUTURE_WORK', 188)]	2	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('GO_0007565', 'female pregnancy', 100, 'pregnant'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 136, 'D'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D'), ('GO_0007565', 'female pregnancy', 213, 'pregnancy')]
S23-PMC4785305	PMC4785305	3/2016	S23-PMC4785305	['maternal Vitamin D status during Pregnancy\nvitamin D deficiency during Pregnancy is PREVALENT worldwide, ESPECIALLY in developing countries.8in a systematic review of 18 studies conducted in western countries during the first Trimester, white caucasian Pregnant women were found to have a mean 25(Oh)D level between 29 and 73\u2005nmol/l.9mean 25(Oh)D levels were lower in non-caucasian Pregnant women, ranging between 15.2 and 43\u2005nmol/l.9in addition to ethnicity, higher latitude was a significant predisposing FACTOR for hypovitaminosis d.9similarly, in non-western countries, more than half of the Pregnant women who were beyond their first trimester had 25(Oh)D levels below 75\u2005nmol/l; these include countries such as india,10kuwait,11pakistan12and turkey.13even lower levels (<25\u2005nmol/l) HAVE BEEN REPORTED at Delivery in saudi arabia, iran and the united arab emirates.14furthermore, immigrant women were at PARTICULAR RISK.1516an OBSERVATIONAL study from the netherlands SHOWED significantly lower 25(Oh)D levels during the first Trimester in immigrant Pregnant women (turkish, moroccan and others), compared to western participants.17\n\nASSOCIATION between maternal Vitamin D status and maternal adverse outcomes\nVitamin D insufficiency during Pregnancy is ASSOCIATED with adverse maternal outcomes such as increased risk of Gestational diabetes mellitus (gdm), preeclampsia, caesarean-section Delivery and bacterial vaginosis.18in a recent meta-analysis of observational studies, the risk of gdm was FOUND TO BE increased by 40–84% in Pregnant women with low 25(Oh)D levels, defined as <50\u2005nmol/l or <75\u2005nmol/l, DEPENDING ON the studies.19–21while Preeclampsia risk was significantly increased in Vitamin D insufficient women,22c-section rates were INCONSISTENTLY AFFECTED by Vitamin D status.23HOWEVER, THESE FINDINGS REMAIN LIMITED by the inherent BIASES of OBSERVATIONAL studies, INCONSISTENT adjustment for CONFOUNDERS, in addition to the wide HETEROGENEITY in Vitamin D assays and Vitamin D cut-offs definition.']	[('IMPORTANT_CONSIDERATION', 84), ('IMPORTANT_CONSIDERATION', 105), ('SUPERFICIAL_RELATIONSHIP', 507), ('INCOMPLETE_EVIDENCE', 788), ('IMPORTANT_CONSIDERATION', 909), ('INCOMPLETE_EVIDENCE', 932), ('INCOMPLETE_EVIDENCE', 973), ('SUPERFICIAL_RELATIONSHIP', 1139), ('SUPERFICIAL_RELATIONSHIP', 1259), ('ANOMALY_CURIOUS_FINDING', 1503), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1615), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1752), ('SUPERFICIAL_RELATIONSHIP', 1767), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1796), ('INCOMPLETE_EVIDENCE', 1807), ('INCOMPLETE_EVIDENCE', 1822), ('INCOMPLETE_EVIDENCE', 1829), ('PROBLEM_COMPLICATION', 1853), ('INCOMPLETE_EVIDENCE', 1863), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1886), ('PROBLEM_COMPLICATION', 1914), ('DIFFICULT_TASK', 1951)]	22	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 51, 'D'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy'), ('GO_0009294', 'DNA mediated transformation', 226, 'trimester'), ('GO_0007565', 'female pregnancy', 253, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 294, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 294, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 339, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 345, 'D'), ('GO_0007565', 'female pregnancy', 382, 'pregnant'), ('GO_0007565', 'female pregnancy', 596, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 653, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 653, '25(OH)D'), ('GO_0007567', 'parturition', 810, 'delivery'), ('CHEBI_71657', 'versiconol acetate', 1000, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1000, '25(OH)D'), ('GO_0009294', 'DNA mediated transformation', 1032, 'trimester'), ('GO_0007565', 'female pregnancy', 1055, 'pregnant'), ('CHEBI_27300', 'vitamin D', 1168, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 1215, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1246, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1327, 'gestational'), ('GO_0007567', 'parturition', 1396, 'delivery'), ('GO_0007565', 'female pregnancy', 1538, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 1562, '25(OH)D'), ('GO_0007128', 'meiotic prophase I', 1651, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 1700, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1779, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1968, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1989, 'vitamin D')]
S25-PMC4785305	PMC4785305	3/2016	S25-PMC4785305	['the 2010 institute of medicine (iom) report on dietary reference intakes for Calcium and Vitamin D RECOMMENDED 600\u2005iu to Pregnant women as the recommended daily allowance (rda), the rda being the dose that is projected to allow at least 97.5% of the Pregnant women population to reach the DESIRABLE target 25(Oh)D level ≥50\u2005nmol/l.29this RECOMMENDATION was BASED ON OBSERVATIONAL studies, NONE of which were conducted in the middle east.29CONVERSELY, the Endocrine society 2011 GUIDELINES RECOMMENDED that 1500–2000\u2005iu daily of Vitamin D is NEEDED to reach a target 25(Oh)D level ≥75\u2005nmol/l (a RECOMMENDATION that was graded as weak with moderate quality of evidence).30the american college of obstetricians and gynecologists (acog) does not RECOMMEND screening for Vitamin D level in Pregnancy, and abides by the iom RECOMMENDATIONS.31moreover, the who 2012 guidelines on Vitamin D replacement during Pregnancy DID NOT RECOMMEND vitamin D supplementation as part of Prenatal care.32this was based ON a meta-analysis of Vitamin D trials during Pregnancy, which IDENTIFIED a LIMITED NUMBER of high-quality studies DEMONSTRATING a beneficial EFFECT of supplementation on maternal and neonatal outcomes, and CONCLUDED that FURTHER randomised controlled trials (rcts) ARE NEEDED.33in the uk, HOWEVER, Pregnant women are CONSIDERED AT RISK of Vitamin D deficiency, and supplementation with 400\u2005iu daily is REQUIRED.34\nit is NOT CLEAR WHETHER any of the above RECOMMENDED doses are applicable to non-western populations, with lower baseline Vitamin D levels, such as in lebanon and other middle eastern countries.']	[('FUTURE_WORK', 99), ('IMPORTANT_CONSIDERATION', 289), ('FUTURE_WORK', 338), ('INCOMPLETE_EVIDENCE', 357), ('INCOMPLETE_EVIDENCE', 366), ('INCOMPLETE_EVIDENCE', 389), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 437), ('PROBABLE_UNDERSTANDING', 478), ('FUTURE_WORK', 489), ('FUTURE_WORK', 541), ('IMPORTANT_CONSIDERATION', 541), ('FUTURE_WORK', 594), ('FUTURE_WORK', 742), ('FUTURE_WORK', 818), ('INCOMPLETE_EVIDENCE', 912), ('FUTURE_WORK', 920), ('ANOMALY_CURIOUS_FINDING', 998), ('ANOMALY_CURIOUS_FINDING', 998), ('INCOMPLETE_EVIDENCE', 1061), ('INCOMPLETE_EVIDENCE', 1074), ('INCOMPLETE_EVIDENCE', 1113), ('SUPERFICIAL_RELATIONSHIP', 1140), ('INCOMPLETE_EVIDENCE', 1205), ('FUTURE_WORK', 1220), ('FUTURE_WORK', 1264), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1288), ('IMPORTANT_CONSIDERATION', 1316), ('INCOMPLETE_EVIDENCE', 1316), ('IMPORTANT_CONSIDERATION', 1327), ('IMPORTANT_CONSIDERATION', 1401), ('FULL_UNKNOWN', 1419), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1429), ('FUTURE_WORK', 1454)]	33	[('CHEBI_31341', 'calcium dihydroxide', 77, 'Calcium'), ('CHEBI_28384', 'vitamin K', 89, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 89, 'Vitamin'), ('GO_0007565', 'female pregnancy', 121, 'pregnant'), ('GO_0007565', 'female pregnancy', 250, 'pregnant'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 309, 'OH)D'), ('PR_000013502', 'parvalbumin alpha', 311, ')D'), ('UBERON_0005063', 'left ventricular compact myocardium', 455, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 528, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 566, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 566, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 766, 'vitamin D'), ('GO_0007565', 'female pregnancy', 785, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 873, 'vitamin D'), ('GO_0007565', 'female pregnancy', 902, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 938, 'D'), ('GO_0007565', 'female pregnancy', 967, 'prenatal'), ('CHEBI_27300', 'vitamin D', 1020, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1044, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1297, 'pregnant'), ('CHEBI_27300', 'vitamin D', 1338, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1535, 'vitamin D')]
S12-PMC4829940	PMC4829940	5/2016	S12-PMC4829940	['the MAJOR circulating form and indicator of Vitamin D status, 25-Hydroxyvitamin D (25(Oh)D), is supplied by 25-hydroxylation of Vitamin D produced in the skin upon uvb radiation or Vitamin D from the diet[1].']	[('IMPORTANT_CONSIDERATION', 4)]	1	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 62, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 83, '25(OH)D'), ('CHEBI_33229', 'vitamin (role)', 128, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 136, 'D'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin D')]
S6211-PMC4896250	PMC4896250	4/2016	S6211-PMC4896250	['a438 Vitamin D level and the CORRELATION with Ige in children with allergic Respiratory diseases in guangzhou china\n\nhuimin huang1, baoqing sun2, yun chen3, peiyan zheng2, nili wei1, wenting luo4\n\n1the first affiliated hospital of guangzhou medical university, china;2first affiliated hospital guangzhou medical university;3guangzhou yuexiu district maternal and child health care hospital;4first affiliated hospital of guangzhou medical university, guangzhou institute of respiratory diseases\n\ncorrespondence: huimin huang – the first affiliated hospital of guangzhou medical university, china\nobjective: TO EXPLORE the Vitamin D(vit D) level and analyse the CORRELATION with Immunoglobulin e (Ige) in children with allergic Respiratory diseases in guangzhou china.']	[('SUPERFICIAL_RELATIONSHIP', 29), ('QUESTION_ANSWERED_BY_THIS_WORK', 606), ('SUPERFICIAL_RELATIONSHIP', 660)]	3	[('CHEBI_28384', 'vitamin K', 5, 'Vitamin D'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 46, 'IgE'), ('UBERON_0001004', 'respiratory system', 76, 'Respiratory'), ('CHEBI_27300', 'vitamin D', 621, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 635, 'D'), ('GO_0019814', 'immunoglobulin complex', 677, 'immunoglobulin'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 695, 'IgE'), ('UBERON_0001004', 'respiratory system', 726, 'respiratory')]
S13-PMC4897157	PMC4897157	5/2016	S13-PMC4897157	['among such FACTORS, there is GROWING RECOGNITION of the INFLUENCE of sunlight exposure and Vitamin D. since its immunomodulatory EFFECT was FIRST CONFIRMED, Vitamin D has emerged as a variable of interest in the pathogenesis of Allergic diseases; accordingly, there is also interest in sunlight exposure because of its ASSOCIATION with the generation of vitamin D. SEVERAL STUDIES HAVE SHOWN that Vitamin D has an EFFECT on the pathogenesis of allergic diseases56).']	[('SUPERFICIAL_RELATIONSHIP', 11), ('INCOMPLETE_EVIDENCE', 29), ('PROBABLE_UNDERSTANDING', 37), ('SUPERFICIAL_RELATIONSHIP', 56), ('SUPERFICIAL_RELATIONSHIP', 129), ('INCOMPLETE_EVIDENCE', 140), ('INCOMPLETE_EVIDENCE', 146), ('SUPERFICIAL_RELATIONSHIP', 319), ('INCOMPLETE_EVIDENCE', 365), ('INCOMPLETE_EVIDENCE', 381), ('SUPERFICIAL_RELATIONSHIP', 414)]	11	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('GO_0040011', 'locomotion', 228, 'allergic'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 362, 'D'), ('CHEBI_27300', 'vitamin D', 397, 'vitamin D')]
S28-PMC4944244	PMC4944244	7/2016	S28-PMC4944244	['THEREFORE, it is NECESSARY to determine the PREVALENCE of hypovitaminosis D among Pregnant women and assess its risk FACTORS to overcome the PROBLEMS caused by lack of Vitamin D.\n\nmethods\n\nsubjects and sampling\na cross-sectional study was conducted in petaling district, selangor.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 17), ('IMPORTANT_CONSIDERATION', 44), ('SUPERFICIAL_RELATIONSHIP', 117), ('IMPORTANT_CONSIDERATION', 141), ('PROBLEM_COMPLICATION', 141)]	6	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 74, 'D'), ('GO_0007565', 'female pregnancy', 82, 'pregnant'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D')]
S49-PMC4944244	PMC4944244	7/2016	S49-PMC4944244	['they also underwent skin color measurement using the fitzpatrick skin type chart measurement (fstcm) and mexameter (mx) 18; weight and height measurements and Blood test for Vitamin D. hypovitaminosis D was DEFINED as Serum 25(Oh)D\u2009<\u200950\xa0nmol/l.']	[('PROBABLE_UNDERSTANDING', 207)]	1	[('UBERON_0000178', 'blood', 159, 'blood'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 201, 'D'), ('UBERON_0001977', 'blood serum', 218, 'serum'), ('CHEBI_71657', 'versiconol acetate', 224, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 224, '25(OH)D')]
S75-PMC4944244	PMC4944244	7/2016	S75-PMC4944244	['caption (table-wrap): table 1\n\nsocio-demographic, Antenatal, skin characteristics and Vitamin D intake of first trimester Pregnant women ( n \u2009=\u2009396)independent variablesnpercentmean\u2009±\u2009sd /\xa0median (iqr 25\xa0%, 75\xa0%)a) socio-demographic factors\u2003age (year)28.06\u2009±\u20094.09 (min\u2009=\u200918, max\u2009=\u200940)\u2003ethnic groups\u2003\u2003malay30777.5\u2003\u2003chinese4411.2\u2003\u2003indian358.8\u2003\u2003others102.5\u2003educational status\u2003\u2003primary school164.0\u2003\u2003secondary school14937.6\u2003\u2003tertiary school23158.4\u2003working status\u2003\u2003working30176.0\u2003\u2003not working9524.0\u2003household members3 (2,4) (min\u2009=\u20092, max\u2009=\u200912)\u2003household income per monthrm3500 (2800,5000) (min\u2009=\u2009rm900, max\u2009=\u2009rm20 000)b) factors related to Antenatal\u2003Week Of Pregnancy10 (8,12) (min\u2009=\u20094, max\u2009=\u200912)\u2003gravidity2 (1,3) (min\u2009=\u20091, max\u2009=\u20099)\u2003parity0 (0,1) (min\u2009=\u20090, max\u2009=\u20096)\u2003smoking status\u2003\u2003yes30.8\u2003\u2003no39399.2\u2003last child Birth\u2003\u2003≤ 2\xa0years12461.1\u2003\u2003>2\xa0years7938.9\u2003\u2003not applicable (first Pregnancy)193\u2003still breastfeeding\u2003\u2003yes4122.9\u2003\u2003no13879.1\u2003\u2003not applicable (no child)217\u2003body mass index (bmi) before Pregnancy(kg/m2)22.69 (19.95, 26.36) (min\u2009=\u200914.29, max\u2009=\u200953.90)\u2003weight at first Antenatal visit (kg)57.70 (49.60,68.00) (min\u2009=\u200933.00, max\u2009=\u2009148.70)c) factors related to skin\u2003fitzpatrick skin classification\u2003\u2003skin type i -ii10326.0\u2003\u2003skin type iii17343.7\u2003\u2003skin type iv-vi12030.3\u2003Melanin indices (using mexameter 18) (0-999.000)302.17 (245.00, 302.17) (min\u2009=\u2009133.33, max\u2009=\u2009949.33)\u2003sun protection score (0-8)5 (4,5) (min\u2009=\u20090, max\u2009=\u20097)\u2003the length of time exposed to sunlight (minutes per week)37.50 (0,150) (min\u2009=\u20090, max\u2009=\u20091680)d) factors related to Vitamin D intake\u2003intake of Vitamin D in Food (iu/day)202.16 (124.94, 334.62) (min\u2009=\u200913.50, max\u2009=\u20091523.12)\u2003the number of respondents taking Antenatal Supplements\u2003\u2003taking Supplements containing Vitamin D4411.1\u2003\u2003taking supplements without Vitamin D intake61.5\u2003\u2003not taking supplement34687.4\u2003Calcium and Vitamin D supplement\u2003\u2003no38697.5\u2003\u2003yes102.5\u2003intake of Vitamin D from Food and supplements (iu/day)220.04 (137.88, 376.45) (min\u2009=\u200915.10, max\u2009=\u20091523.12)\u2003the level of Vitamin D taken from Food and supplements (iu/day)\u2003\u2003<200\xa0iu/day17844.90\u2003\u2003≥200\xa0iu/day21855.10\n\ncaption (table-wrap): table 2\n\nSerum Vitamin D (25(Oh)D) concentrations among first Trimester Pregnant women ( n \u2009=\u2009396)Serum Vitamin dnpercentmedian (iqr 25\xa0%, 75\xa0%)Serum concentration of 25 (Oh)D nmol/l27.11 (19.87,36.99) (min\u2009=\u20097.50, max\u2009=\u2009121.43)Serum concentration of 25 (Oh) D nmol/l (categorized)\u2003<25.00\xa0nmol/l17443.9\u200325-49.99\xa0nmol/l18446.5\u200350-74.99\xa0nmol/l338.3\u2003≥75\xa0nmol/l51.3serum concentration of 25 (Oh) D nmol/l (categorized)\u2003<50\xa0nmol/l35890.4\u2003≥50\xa0nmol/l389.6\ntable\xa03shows the association between each independent variable with hypovitaminosis d. age, ethnicity, education level, fitzpatrick classification, Melanin indices, sun protection score and Intake of Vitamin D from Food have ASSOCIATION with hypovitaminosis D ( p \u2009<\u20090.05).']	[('SUPERFICIAL_RELATIONSHIP', 2779)]	1	[('GO_0007567', 'parturition', 50, 'antenatal'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'pregnant'), ('GO_0003410', 'anterior rotation of the optic cup', 634, 'antenatal Week of pregnancy10'), ('GO_0007567', 'parturition', 806, 'Birth'), ('GO_0007565', 'female pregnancy', 869, 'pregnancy'), ('GO_0007565', 'female pregnancy', 984, 'pregnancy'), ('GO_0007567', 'parturition', 1064, 'antenatal'), ('CHEBI_25179', 'melanins', 1260, 'Melanin'), ('CHEBI_27300', 'vitamin D', 1528, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1555, 'vitamin D'), ('CHEBI_33290', 'food', 1568, 'food'), ('GO_0007567', 'parturition', 1667, 'antenatal'), ('CHEBI_33341', 'titanium atom', 1677, 'supplements'), ('CHEBI_33341', 'titanium atom', 1697, 'supplements'), ('CHEBI_72741', '2-arachidonyl-sn-glycero-3-phosphoethanolamine', 1720, 'vitamin D4411'), ('CHEBI_27300', 'vitamin D', 1764, 'vitamin D'), ('CHEBI_31341', 'calcium dihydroxide', 1815, 'Calcium'), ('CHEBI_27300', 'vitamin D', 1827, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1879, 'vitamin D'), ('CHEBI_33290', 'food', 1894, 'food'), ('CHEBI_27300', 'vitamin D', 1989, 'vitamin D'), ('CHEBI_33290', 'food', 2010, 'food'), ('UBERON_0001977', 'blood serum', 2114, 'Serum'), ('CHEBI_27300', 'vitamin D', 2120, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 2131, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 2131, '25 ... OH ... D'), ('GO_0009294', 'DNA mediated transformation', 2167, 'trimester'), ('GO_0007565', 'female pregnancy', 2177, 'pregnant'), ('UBERON_0001977', 'blood serum', 2203, 'Serum'), ('CHEBI_33229', 'vitamin (role)', 2209, 'vitamin'), ('UBERON_0001977', 'blood serum', 2249, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 2272, '25 (OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 2272, '25'), ('PR_000006444', 'diacylglycerol kinase delta', 2279, 'D'), ('UBERON_0001977', 'blood serum', 2333, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 2356, '25 (OH) D'), ('CHEBI_71657', 'versiconol acetate', 2489, '25 (OH) D'), ('CHEBI_25179', 'melanins', 2702, 'melanin'), ('GO_0007631', 'feeding behavior', 2744, 'intake'), ('CHEBI_27300', 'vitamin D', 2754, 'vitamin D'), ('CHEBI_33290', 'food', 2769, 'food'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 2812, 'D')]
S91-PMC4944244	PMC4944244	7/2016	S91-PMC4944244	['hypovitaminosis D is expected to be high AS PREVIOUS STUDIES RELATED to Vitamin D conducted in malaysia among children and malay women were also high.']	[('PROBABLE_UNDERSTANDING', 41), ('INCOMPLETE_EVIDENCE', 44), ('SUPERFICIAL_RELATIONSHIP', 61)]	3	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 16, 'D'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D')]
S94-PMC4944244	PMC4944244	7/2016	S94-PMC4944244	['this high prevalence of hypovitaminosis D was DUE TO age, Abdominal obesity and Metabolic syndrome AFFECTING Vitamin D levels.']	[('PROBABLE_UNDERSTANDING', 46), ('SUPERFICIAL_RELATIONSHIP', 99)]	2	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 40, 'D'), ('UBERON_0000916', 'abdomen', 58, 'abdominal'), ('GO_0008152', 'metabolic process', 80, 'metabolic'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D')]
S100-PMC4944244	PMC4944244	7/2016	S100-PMC4944244	['this is IN LINE WITH OUR STUDY, where the PREVALENCE of hypovitaminosis D (25 (Oh) D Serum <50\xa0nmol/l) in the first trimester was high (90.4\xa0%) and only 11.1\xa0% took supplements containing Vitamin D. moreover, most of them had just started the Supplements and the results MAY not have AFFECTED their Vitamin D status yet.']	[('INCOMPLETE_EVIDENCE', 8), ('QUESTION_ANSWERED_BY_THIS_WORK', 21), ('IMPORTANT_CONSIDERATION', 42), ('INCOMPLETE_EVIDENCE', 271), ('SUPERFICIAL_RELATIONSHIP', 284)]	5	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 72, 'D'), ('CHEBI_71657', 'versiconol acetate', 75, '25 (OH) D'), ('PR_000003010', 'moesin isoform 1', 78, '(OH ... D'), ('UBERON_0001977', 'blood serum', 85, 'serum'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 243, 'supplements'), ('CHEBI_27300', 'vitamin D', 299, 'vitamin D')]
S229-PMC4944244	PMC4944244	7/2016	S229-PMC4944244	['dietary Intake of Food containing Vitamin D was found to reduce hypovitaminosis D. nutrition education NEEDS TO BE EMPHASIZED among Pregnant women, ESPECIALLY those of malay and indian ethnicity, who Consume little or no milk, and those who work at desk jobs as INDICATED by high education levels.']	[('FUTURE_WORK', 103), ('IMPORTANT_CONSIDERATION', 109), ('IMPORTANT_CONSIDERATION', 148), ('INCOMPLETE_EVIDENCE', 262)]	4	[('GO_0007631', 'feeding behavior', 8, 'intake'), ('CHEBI_33290', 'food', 18, 'food'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 80, 'D'), ('GO_0007565', 'female pregnancy', 132, 'pregnant'), ('GO_0007631', 'feeding behavior', 200, 'consume')]
S11-PMC4973215	PMC4973215	8/2016	S11-PMC4973215	['several large OBSERVATIONAL studies and meta-analyses have DESCRIBED the ASSOCIATION of maternal Vitamin D deficiency with Pregnancy COMPLICATIONS such as pre-eclampsia, Gestational diabetes and premature Birth.10,11,12,13racial DISPARITIES in maternal and neonatal Vitamin D deficiency HAVE BEEN DESCRIBED.1,14,15vitamin D deficiency is MORE COMMON and more SEVERE in black mothers.10,15,16,17,18,19racial DISPARITIES are also SEEN with Pregnancy COMPLICATIONS such as Preterm birth, pre-eclampsia and Gestational diabetes, as well as adverse neonatal outcomes including low Birth weight and small-for-Gestational-age (sga) status.15,17,20,21HOWEVER, the MAJORITY of studies EXAMINED maternal Vitamin D levels during the first and second Trimesters of Pregnancy7,8,22,23and CORRELATED these levels to neonatal outcomes.']	[('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 59), ('SUPERFICIAL_RELATIONSHIP', 73), ('PROBLEM_COMPLICATION', 133), ('IMPORTANT_CONSIDERATION', 229), ('INCOMPLETE_EVIDENCE', 287), ('INCOMPLETE_EVIDENCE', 297), ('PROBABLE_UNDERSTANDING', 338), ('IMPORTANT_CONSIDERATION', 359), ('IMPORTANT_CONSIDERATION', 407), ('INCOMPLETE_EVIDENCE', 428), ('PROBLEM_COMPLICATION', 448), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 643), ('PROBABLE_UNDERSTANDING', 656), ('INCOMPLETE_EVIDENCE', 676), ('SUPERFICIAL_RELATIONSHIP', 775)]	16	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007565', 'female pregnancy', 123, 'pregnancy'), ('GO_0007565', 'female pregnancy', 170, 'gestational'), ('GO_0007567', 'parturition', 205, 'birth'), ('CHEBI_27300', 'vitamin D', 266, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 322, 'D'), ('GO_0007565', 'female pregnancy', 438, 'pregnancy'), ('GO_0007565', 'female pregnancy', 470, 'preterm'), ('GO_0007565', 'female pregnancy', 503, 'gestational'), ('GO_0007567', 'parturition', 576, 'birth'), ('GO_0007565', 'female pregnancy', 603, 'gestational'), ('CHEBI_27300', 'vitamin D', 694, 'vitamin D'), ('GO_0043033', 'isoamylase complex', 739, 'trimesters'), ('GO_0007565', 'female pregnancy', 753, 'pregnancy7')]
S17-PMC4976416	PMC4976416	7/2016	S17-PMC4976416	['HOWEVER when a stable formulation delivers a high concentration of nonesterified, OPTIMAL isomer of the antioxidant, Vitamins C and E inhibit the acute uv damage as well as chronic uv photoaging and skin cancer.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 82)]	2	[('CHEBI_27300', 'vitamin D', 117, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 132, 'E')]
S70-PMC4976416	PMC4976416	7/2016	S70-PMC4976416	['[51] in a healthy Adult who had been on a normal diet it would take an ESTIMATED 4 years to fully deplete body stores of Vitamin E.[52]\n\ntopical vitamin E in dermatology\ntopical Vitamin E has emerged as a popular treatment for a number of skin disorders OWING TO its antioxidant properties.']	[('INCOMPLETE_EVIDENCE', 71), ('PROBABLE_UNDERSTANDING', 254)]	2	[('UBERON_0007023', 'adult organism', 18, 'adult'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin E'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 153, 'E'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin E')]
S82-PMC4976416	PMC4976416	7/2016	S82-PMC4976416	['Vitamin E being a fat-soluble Vitamin, administration of a dose higher than daily REQUIREMENT results in accumulation inside the body, resulting in hypervitaminosis e. healthy Adults taking Vitamin E daily at a dose of 100 mg for more than 1 year are LIKELY to get hypervitaminosis E, manifesting as reduced Platelet Aggregation and interference with Vitamin K Metabolism resulting in bleeding tendencies.']	[('IMPORTANT_CONSIDERATION', 82), ('PROBABLE_UNDERSTANDING', 251)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin E'), ('PR_000017279', 'testis-specific basic protein Y 1', 0, 'Vitamin E'), ('CHEBI_33229', 'vitamin (role)', 30, 'vitamin'), ('UBERON_0007023', 'adult organism', 176, 'adults'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin E'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 282, 'E'), ('CL_0000233', 'platelet', 308, 'platelet'), ('GO_0070527', 'platelet aggregation', 308, 'platelet aggregation'), ('CHEBI_27300', 'vitamin D', 351, 'vitamin K'), ('GO_0007601', 'visual perception', 351, 'vitamin K'), ('GO_0008152', 'metabolic process', 361, 'metabolism')]
S177-PMC4992225	PMC4992225	8/2016	S177-PMC4992225	['caption (table-wrap): table 4\n\n25(Oh)D concentrations and depression scores in nulliparous and multiparous subgroupsvariables mean (sd)nulliparousmultiparousvitamin D groupcontrol groupn p -valuevitamin D groupcontrol groupn p -value*25(Oh)D at baseline (ng/ml)13.13(6.91)13.25 (6.55)41/510.9312.49 (9.08)9.31 (5.34)34/270.1525(Oh)D at Delivery (ng/ml)18.40 (11.38)12.49 (6.29)33/430.0116.58 (8.54)11.36 (5.47)28/250.02depression score at baseline8.41(3.52)8.73 (3.57)41/510.678.47 (4.35)8.48 (4.30)34/270.99depression score at 38-40w Gestation6.47(3.43)7.98 (3.74)38/460.065.80 (3.62)7.44 (4.28)30/270.12depression score at Postpartum (4w)4.59(3.24)7.27 (4.04)34/450.0024.60 (3.40)7.52 (4.70)30/270.01depression score at Postpartum (8w)4.18(3.79)7.24 (3.79)34/450.0014.20 (3.79)7.07 (4.37)30/270.01\n*mann–whitney u test\nwe EXAMINED the CORRELATION between change in Vitamin D concentrations and change in depression scores at 38–40 weeks of Gestation, 4 and 8 weeks Postpartum.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 824), ('SUPERFICIAL_RELATIONSHIP', 837)]	2	[('CHEBI_71657', 'versiconol acetate', 31, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 31, '25(OH)D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 165, 'D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 203, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 203, 'D'), ('CHEBI_71657', 'versiconol acetate', 234, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 240, 'D'), ('CHEBI_33010', 'chromide(1-)', 327, '(OH)D'), ('GO_0007567', 'parturition', 336, 'delivery'), ('GO_0007565', 'female pregnancy', 535, 'gestation6'), ('GO_0007565', 'female pregnancy', 625, 'postpartum'), ('GO_0007565', 'female pregnancy', 722, 'postpartum'), ('CHEBI_27300', 'vitamin D', 867, 'vitamin D'), ('GO_0007565', 'female pregnancy', 942, 'gestation'), ('GO_0007565', 'female pregnancy', 967, 'postpartum')]
S115-PMC4993554	PMC4993554	8/2016	S115-PMC4993554	['the women were asked to identify Micronutrients for which there was a risk ASSOCIATED with excessive intake, from a list including zinc, Vitamin A, magnesium, vitamin D, and Vitamin B6.']	[('SUPERFICIAL_RELATIONSHIP', 75)]	1	[('CHEBI_33839', 'macromolecule', 33, 'micronutrients'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 167, 'D'), ('CHEBI_33237', 'vitamin D4', 174, 'vitamin B6'), ('PR_000004690', 'B-cell lymphoma/leukemia 11A', 182, 'B6')]
S4-PMC5014971	PMC5014971	8/2016	S4-PMC5014971	['a majority INDICATED that Vitamin D insufficiency was a PROBLEM in their patient population (68.4%) and that most of their Pregnant patients would BENEFIT from vitamin D supplementation (66.3%).']	[('INCOMPLETE_EVIDENCE', 11), ('IMPORTANT_CONSIDERATION', 56), ('PROBLEM_COMPLICATION', 56), ('IMPORTANT_CONSIDERATION', 147)]	4	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007565', 'female pregnancy', 123, 'pregnant'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 168, 'D')]
S91-PMC5028238	PMC5028238	10/2016	S91-PMC5028238	['an indirect negative feedback LOOP, established in laboratory studies, allows Vitamin D levels to Regulate Dhcr7 activity and PREVENT hypervitaminosis D (that is, toxically high Vitamin d levels).54slos patients have high 7-Dehydrocholesterol levels.']	[('SUPERFICIAL_RELATIONSHIP', 30), ('SUPERFICIAL_RELATIONSHIP', 126)]	2	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('GO_0065007', 'biological regulation', 98, 'regulate'), ('PR_000006474', 'ATP-dependent RNA helicase A', 107, 'DHCR7'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 151, 'D'), ('CHEBI_33229', 'vitamin (role)', 178, 'vitamin'), ('CHEBI_17500', '7alpha-hydroxycholesterol', 222, '7-dehydrocholesterol')]
S26-PMC5035678	PMC5035678	4/2016	S26-PMC5035678	['objectives\nwe THEREFORE SOUGHT TO EXPLORE the EFFECT of Vitamin D supplementation in women with gdm and hypovitaminosis D, both on post-Partum Glucose levels and Insulin resistance, in a randomized clinical trial.']	[('PROBABLE_UNDERSTANDING', 14), ('QUESTION_ANSWERED_BY_THIS_WORK', 24), ('QUESTION_ANSWERED_BY_THIS_WORK', 31), ('SUPERFICIAL_RELATIONSHIP', 46)]	4	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 120, 'D'), ('GO_0007567', 'parturition', 136, 'partum'), ('CHEBI_17234', 'glucose', 143, 'glucose'), ('PR_000045358', 'insulin family protein', 162, 'insulin')]
S112-PMC5035678	PMC5035678	4/2016	S112-PMC5035678	['fifty eight percent of group c remained Vitamin D deficient, which INDICATES that the usual multivitamin that is prescribed for a majority of Pregnant women (containing 400 iu Vitamin D3) is not adequate to correct hypovitaminosis D. THEREFORE, Pregnant women NEED a higher dose of Vitamin D than that typically consumed.']	[('INCOMPLETE_EVIDENCE', 67), ('PROBABLE_UNDERSTANDING', 234), ('IMPORTANT_CONSIDERATION', 260)]	3	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007565', 'female pregnancy', 142, 'pregnant'), ('CHEBI_33279', 'vitamin D5', 176, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 176, 'vitamin D3'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 231, 'D'), ('GO_0007565', 'female pregnancy', 245, 'pregnant'), ('CHEBI_27300', 'vitamin D', 282, 'vitamin D')]
S132-PMC5035678	PMC5035678	4/2016	S132-PMC5035678	['they FOUND that high dose supplementation for a mean of 14 weeks during Pregnancy was not beneficial to the patients’ plasma Glucose level or Insulin resistance during Pregnancy, BUT that their babies BENEFITTED from the supplementation with decreased neonatal hypovitaminosis D. the authors CONCLUDED that the commencement of Vitamin D supplementation MAY HAVE been too late to cause any observable EFFECTS on Β-Cell function, and they SUGGESTED that earlier supplementation, EVEN before Pregnancy, MIGHT be EFFECTIVE.']	[('INCOMPLETE_EVIDENCE', 5), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 179), ('IMPORTANT_CONSIDERATION', 201), ('INCOMPLETE_EVIDENCE', 292), ('INCOMPLETE_EVIDENCE', 353), ('IMPORTANT_CONSIDERATION', 357), ('SUPERFICIAL_RELATIONSHIP', 400), ('INCOMPLETE_EVIDENCE', 437), ('ANOMALY_CURIOUS_FINDING', 477), ('INCOMPLETE_EVIDENCE', 500), ('SUPERFICIAL_RELATIONSHIP', 509)]	11	[('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('CHEBI_17234', 'glucose', 125, 'glucose'), ('PR_000045358', 'insulin family protein', 142, 'insulin'), ('GO_0007565', 'female pregnancy', 168, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 277, 'D'), ('CHEBI_27300', 'vitamin D', 327, 'vitamin D'), ('CL_0000623', 'natural killer cell', 411, 'β-cell'), ('GO_0007565', 'female pregnancy', 489, 'pregnancy')]
S143-PMC5035678	PMC5035678	4/2016	S143-PMC5035678	['in ANOTHER STUDY of the non-Pregnant population, and CONSISTENT with our results, davidson and colleagues FOUND that a mean supplement dose of 88,865 iu Vitamin D per week, in 56 subjects with hypovitaminosis D and pre-diabetes, had no effect on Insulin resistance and plasma Glucose levels at 3, 6, 9, and 12 months after intervention, compared to 53 subjects in a placebo group (31).']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 53), ('INCOMPLETE_EVIDENCE', 106)]	3	[('GO_0007565', 'female pregnancy', 28, 'pregnant'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 209, 'D'), ('PR_000045358', 'insulin family protein', 246, 'insulin'), ('CHEBI_17234', 'glucose', 276, 'glucose')]
S161-PMC5035678	PMC5035678	4/2016	S161-PMC5035678	['in conclusion, Prenatal Vitamin D supplementation in patients with gdm and hypovitaminosis D SAFELY and significantly increases maternal and neonatal Serum 25Ohd.']	[('IMPORTANT_CONSIDERATION', 93)]	1	"[('GO_0007565', 'female pregnancy', 15, 'prenatal'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 91, 'D'), ('UBERON_0001977', 'blood serum', 150, 'serum'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 156, '25OHD')]"
S17-PMC5051327	PMC5051327	9/2016	S17-PMC5051327	['introduction\nVitamin D is NECESSARY for optimal Skeletal function and deficiency is RELATED to rachitis.1\nit is, HOWEVER, IMPORTANT for bone Metabolism, as well as for optimal function of Striated and Smooth Muscle strength including Heart Muscle, and is RELATED to Postnatal muscle strength.2vitamin D supplementation has a positive IMPACT on muscle strength on Individuals with Vitamin D deficiency.134THE institute of medicine (iom), usa RECOMMENDS daily nutritional intake of Vitamin D of 600\u2005u, BUT OTHERS RECOMMEND higher doses.56a RECENT swedish STUDY SHOWED that the mean nutritional intake of Vitamin D was <200\u2005u/day.7ALTHOUGH Vitamin D is found in low amounts in the diet, mainly in oily fish and egg, the primary source of Vitamin D for Humans is skin conversion to Vitamin D from solar ultraviolet radiation.1pregnant women residing at high latitudes are AT RISK of Vitamin D deficiency BECAUSE of low solar intensity, especially during the winter months.18vitamin D deficiency is common in the nordic countries, ESPECIALLY among those not exposing themselves to the sun.8since fetal Vitamin D levels are directly RELATED to that of their mothers there is also a high LIKELIHOOD of fetal Vitamin D deficiency in our population.9\nBirth asphyxia is ASSOCIATED with Cardiovascular dysfunction, including low Ventricular output, lower left Ventricular Ejection fraction and increased troponin levels.1011congestive Heart failure MAY occur in severe cases of asphyxia.12intrauterine fetal distress is RELATED to an increase in Blood pressure, redistribution and a change in fetal Heart rate pattern.']	[('IMPORTANT_CONSIDERATION', 26), ('SUPERFICIAL_RELATIONSHIP', 84), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 113), ('IMPORTANT_CONSIDERATION', 122), ('SUPERFICIAL_RELATIONSHIP', 255), ('SUPERFICIAL_RELATIONSHIP', 334), ('INCOMPLETE_EVIDENCE', 401), ('FUTURE_WORK', 441), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 500), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 504), ('FUTURE_WORK', 511), ('INCOMPLETE_EVIDENCE', 538), ('INCOMPLETE_EVIDENCE', 559), ('ANOMALY_CURIOUS_FINDING', 627), ('IMPORTANT_CONSIDERATION', 868), ('PROBABLE_UNDERSTANDING', 900), ('ANOMALY_CURIOUS_FINDING', 1026), ('SUPERFICIAL_RELATIONSHIP', 1127), ('PROBABLE_UNDERSTANDING', 1181), ('SUPERFICIAL_RELATIONSHIP', 1260), ('INCOMPLETE_EVIDENCE', 1438), ('SUPERFICIAL_RELATIONSHIP', 1509)]	22	[('CHEBI_28384', 'vitamin K', 13, 'Vitamin D'), ('UBERON_0004288', 'skeleton', 48, 'skeletal'), ('GO_0008152', 'metabolic process', 141, 'metabolism'), ('UBERON_0002435', 'striatum', 188, 'striated'), ('UBERON_0001135', 'smooth muscle tissue', 201, 'smooth muscle'), ('UBERON_0001133', 'cardiac muscle tissue', 234, 'heart muscle'), ('GO_0007567', 'parturition', 266, 'postnatal'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 301, 'D'), ('NCBITaxon_1', 'root', 363, 'individuals'), ('CHEBI_27300', 'vitamin D', 380, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 480, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 602, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 637, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 735, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 749, 'humans'), ('CHEBI_27300', 'vitamin D', 778, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 879, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 978, 'D'), ('CHEBI_27300', 'vitamin D', 1097, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1201, 'vitamin D'), ('GO_0007567', 'parturition', 1242, 'Birth'), ('UBERON_0004535', 'cardiovascular system', 1276, 'cardiovascular'), ('UBERON_0002082', 'cardiac ventricle', 1318, 'ventricular'), ('UBERON_0002082', 'cardiac ventricle', 1349, 'ventricular'), ('UBERON_0000970', 'eye', 1361, 'ejection'), ('UBERON_0000948', 'heart', 1424, 'heart'), ('UBERON_0000178', 'blood', 1535, 'blood'), ('UBERON_0000948', 'heart', 1588, 'heart')]
S79-PMC5054480	PMC5054480	9/2016	S79-PMC5054480	['other causes are SIMILAR TO those encountered in the nonpregnant population, namely hyperthyroidism, Vitamin A or D toxicity, familial hypocalciuric hypercalcemia, acute or chronic Renal failure, granulomatous diseases, Milk–alkali syndrome, and malignancy.']	[('INCOMPLETE_EVIDENCE', 17)]	1	[('CHEBI_27300', 'vitamin D', 101, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 114, 'D'), ('UBERON_0002113', 'kidney', 181, 'renal'), ('UBERON_0001913', 'milk', 220, 'milk')]
S10-PMC5084041	PMC5084041	10/2016	S10-PMC5084041	['the DETERMINANTS of season-corrected change in 25(Oh)D were origin, sun-Seeking behaviour, clothing style, dietary Vitamin D intake, Vitamin D supplementation and recent travel <35° n. in CONCLUSION, season-corrected 25(Oh)D concentration increased during Pregnancy and DEPENDED PARTLY on lifestyle FACTORS.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('INCOMPLETE_EVIDENCE', 188), ('SUPERFICIAL_RELATIONSHIP', 270), ('INCOMPLETE_EVIDENCE', 279), ('SUPERFICIAL_RELATIONSHIP', 299)]	5	[('CHEBI_71657', 'versiconol acetate', 47, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 53, 'D'), ('GO_0007601', 'visual perception', 72, 'seeking'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 133, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 141, 'D'), ('CHEBI_71657', 'versiconol acetate', 217, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 217, '25(OH)D'), ('GO_0007565', 'female pregnancy', 256, 'pregnancy')]
S177-PMC5129897	PMC5129897	10/2016	S177-PMC5129897	['for example, 50% of the clinical trials with baseline 25(Oh)D concentration <50\xa0nmol/l FOUND beneficial EFFECTS of Vitamin D on BIOMARKERS of inflammation, WHEREAS ONLY 26% of those with higher baseline 25(Oh)D concentrations did.3the DIFFERENT results with respect to baseline 25(Oh)D concentration MAY BE DUE TO the LIMITED accuracy of clinical trials but COULD also be DUE TO CONSIDERABLY less BENEFIT for those with 25(Oh)D concentrations above 50\xa0nmol/l.']	[('INCOMPLETE_EVIDENCE', 87), ('SUPERFICIAL_RELATIONSHIP', 104), ('SUPERFICIAL_RELATIONSHIP', 128), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 156), ('ANOMALY_CURIOUS_FINDING', 156), ('ANOMALY_CURIOUS_FINDING', 164), ('INCOMPLETE_EVIDENCE', 164), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 235), ('INCOMPLETE_EVIDENCE', 300), ('PROBLEM_COMPLICATION', 307), ('INCOMPLETE_EVIDENCE', 318), ('INCOMPLETE_EVIDENCE', 358), ('PROBLEM_COMPLICATION', 372), ('ANOMALY_CURIOUS_FINDING', 379), ('IMPORTANT_CONSIDERATION', 397)]	15	[('CHEBI_71657', 'versiconol acetate', 54, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 54, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 203, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 203, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 278, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 284, 'D'), ('CHEBI_71657', 'versiconol acetate', 420, '25(OH)D')]
S78-PMC5146866	PMC5146866	12/2016	S78-PMC5146866	['caption (table-wrap): table 3\n\ncharacteristics of neonates during Birth hospitalization with respect to their cb Vitamin D statusparametricvitamin D satus p valuedeficiency n \u2009=\u200995insufficiency n \u2009=\u200979sufficiency n \u2009=\u200991gestational age (weeks)38.8(38.6–39.1)39.2(38.9–39.5)38.9(38.7–39.3)0.65birth weight (g)3301(3215–3387)3433(3322–3544)3306(3305–3406)0.35birth length (cm)48.8(48.1–49.6)49.5(49.0–50.0)48.3(47.2–49.5)0.53apgar 1\xa0min <72.1%(0.6–7.0)2.6%(0.7–8.9)6.5%(2.4–12.2)0.21nicu admission6.3%(0.87–11.7)5.1%(0–10.6)8.9%(2.4–15.3)0.62hypoglycemia (%)01.3%(0–4.4)1.1%(0–3.6)0.56neonatal jaundice (%)21.1%(12.6–29.6)13.9%(5.3–22.5)13.9%(6.4–21.4)0.27phototherapy (%)5.3%(0.3–10.3)1.3%(0–4.4)1.1%(0–3.6)0.13\ndata presented as mean or proportion (%) with 95% confidence intervals of mean or %\n\ndiscussion\nwe FOUND that up to 45% infants are AT RISK for deficient and 35% for INSUFFICIENT levels of Vitamin D. the APPROXIMATED probability of an infant being Born with a sufficient Vitamin D level as defined by the aap for children [8] is less than 40%.']	[('INCOMPLETE_EVIDENCE', 810), ('IMPORTANT_CONSIDERATION', 843), ('IMPORTANT_CONSIDERATION', 877), ('INCOMPLETE_EVIDENCE', 915)]	4	[('GO_0007567', 'parturition', 66, 'birth'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 147, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 147, 'D'), ('CHEBI_27300', 'vitamin D', 900, 'vitamin D'), ('GO_0007567', 'parturition', 959, 'born'), ('CHEBI_27300', 'vitamin D', 982, 'vitamin D')]
S21-PMC5155676	PMC5155676	12/2016	S21-PMC5155676	['in nonpregnant Adults, baseline 25(Oh)D concentration, body weight/adiposity and age are IMPORTANT DETERMINANTS of the incremental rise in 25(Oh)D after Vitamin D supplementation (13,14).']	[('IMPORTANT_CONSIDERATION', 89), ('SUPERFICIAL_RELATIONSHIP', 99)]	2	[('UBERON_0007023', 'adult organism', 15, 'adults'), ('CHEBI_71657', 'versiconol acetate', 32, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 32, '25(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 38, 'D'), ('CHEBI_30778', 'gallic acid', 139, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 145, 'D'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D')]
S112-PMC5155676	PMC5155676	12/2016	S112-PMC5155676	['HOWEVER, it is NOTABLE that there were marked DIFFERENCES in baseline 25(Oh)D concentrations between these investigations, and we OBSERVED that initial 25(Oh)D status was positively ASSOCIATED with both the LIKELIHOOD of achieving Vitamin D replete status and absolute 25(Oh)D status at 34 weeks of Gestation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 15), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 46), ('INCOMPLETE_EVIDENCE', 130), ('SUPERFICIAL_RELATIONSHIP', 182), ('PROBABLE_UNDERSTANDING', 207)]	7	[('CHEBI_71657', 'versiconol acetate', 70, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 76, 'D'), ('CHEBI_63056', 'zinc cation', 152, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 158, 'D'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 269, '25(OH)D'), ('GO_0007565', 'female pregnancy', 299, 'gestation')]
S113-PMC5155676	PMC5155676	12/2016	S113-PMC5155676	['IMPORTANTLY, the difference between the 25(Oh)D achieved at 34 weeks of Gestation in women randomized to Placebo compared with Cholecalciferol decreased with increasing baseline 25(Oh)D. this is CONSISTENT with PREVIOUS STUDIES in Adults, which HAVE SHOWN that the incremental response to Vitamin D supplementation is higher in Vitamin D insufficient than replete subjects (13,14) and that the increase in 25(Oh)D relative to supplementation dose is negatively ASSOCIATED with dose of vitamin D supplement (26).']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 195), ('INCOMPLETE_EVIDENCE', 211), ('INCOMPLETE_EVIDENCE', 245), ('SUPERFICIAL_RELATIONSHIP', 461)]	5	[('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('GO_0007565', 'female pregnancy', 72, 'gestation'), ('CHEBI_26130', 'biological pigment', 105, 'placebo'), ('CHEBI_52550', 'theopalauamide', 127, 'cholecalciferol'), ('CHEBI_33010', 'chromide(1-)', 180, '(OH)D'), ('UBERON_0007023', 'adult organism', 231, 'adults'), ('CHEBI_27300', 'vitamin D', 289, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 328, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 406, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 412, 'D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 493, 'D')]
S115-PMC5155676	PMC5155676	12/2016	S115-PMC5155676	['this mechanism MIGHT be IMPORTANT in preventing hypervitaminosis D. HOWEVER, studies comparing the effectiveness of DIFFERING doses of Vitamin D in Pregnancy HAVE SHOWN that 4000 iu/d CAN achieve a higher 25(Oh)D than 400 iu/d (10,28), BUT WHETHER these higher doses are of clinical benefit is YET to be DEMONSTRATED (4,29) and at the general population level, lower doses would be compatible with keeping 25(Oh)D below a concentration which MIGHT be concerning.']	[('INCOMPLETE_EVIDENCE', 15), ('IMPORTANT_CONSIDERATION', 24), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 68), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 116), ('INCOMPLETE_EVIDENCE', 158), ('INCOMPLETE_EVIDENCE', 184), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 236), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 240), ('ANOMALY_CURIOUS_FINDING', 294), ('INCOMPLETE_EVIDENCE', 304), ('INCOMPLETE_EVIDENCE', 442)]	11	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 65, 'D'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('GO_0007565', 'female pregnancy', 148, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 205, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 205, '25(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 211, 'D'), ('CHEBI_71657', 'versiconol acetate', 406, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 412, 'D')]
S8-PMC5368580	PMC5368580	4/2017	S8-PMC5368580	['circadian variance was significant except for fat-adjusted Vitamins A and E, with a higher CONTRIBUTION to total variance with supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 91)]	1	[('CHEBI_27300', 'vitamin D', 59, 'vitamins A'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 59, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 74, 'E')]
S185-PMC5368580	PMC5368580	4/2017	S185-PMC5368580	['the Regulation of fat-soluble Vitamins A and E APPEARS TO occur through a specific transport system independent from Lipid Transfer, but the mechanisms INVOLVED have not been revealed (36,37).']	[('SUPERFICIAL_RELATIONSHIP', 4), ('ANOMALY_CURIOUS_FINDING', 47), ('SUPERFICIAL_RELATIONSHIP', 152)]	3	[('GO_0065007', 'biological regulation', 4, 'regulation'), ('CHEBI_27300', 'vitamin D', 30, 'vitamins A'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 30, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 45, 'E'), ('CHEBI_18059', 'lipid', 117, 'lipid'), ('GO_0060986', 'endocrine hormone secretion', 117, 'lipid transfer')]
S31-PMC5405075	PMC5405075	4/2017	S31-PMC5405075	['the most cited adverse outcome of maternal Vitamin D deficiency is neonatal rickets, WHILE mild hypovitaminosis D COULD BE more pronounced in exclusively Breast-Fed infants, on the BASIS that Breast Milk constitutes a POOR source of Vitamin D compared with formulas (34–36).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 85), ('ANOMALY_CURIOUS_FINDING', 85), ('INCOMPLETE_EVIDENCE', 114), ('PROBABLE_UNDERSTANDING', 181), ('IMPORTANT_CONSIDERATION', 218)]	5	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 112, 'D'), ('GO_0007567', 'parturition', 154, 'breast'), ('UBERON_0000310', 'breast', 154, 'breast'), ('GO_0007631', 'feeding behavior', 161, 'fed'), ('UBERON_0001348', 'brown adipose tissue', 192, 'breast milk'), ('CHEBI_27300', 'vitamin D', 233, 'vitamin D')]
S129-PMC5513133	PMC5513133	7/2017	S129-PMC5513133	['germany, 2–14 [85]case control20 – women with peat Delivery43 – healthy Pregnant controls\u2003mohaghegh et al., iran, 2015 [89]case control41 -- women with pe 50 – healthy Pregnant controlstime of labor\u2003powe, usa, 2010 [86]nested case control39 -- developed pe 131 – healthy Pregnant controls1st Trimester\u2003robinson et al., usa, 2010 [25]case control50 -- women with eospe29\xa0weeks Gestation100 – healthy Pregnant controls\u2003schneuer et al., australia, 2014 [114]nested case control5109 Pregnant women (223 with pe and 29/223 with eospe)10–14\xa0weeks Gestation\u2003singla et al., india, 2015 [87]case control74 -- nulliparous women with pe>30\xa0weeks Gestation100 -- healthy nulliparous controls\u2003ullah et al., bangladesh, 2013 [82]case control33 -- women with pe>20\xa0weeks Gestation79 – normal Pregnancy controls\u2003wetta et al., uk, 2013 [96]case control100 -women with pe15–21\xa0weeks Gestation200 – healthy Pregnant controls\u2003woodham et al., usa, 2011 [15]nested case control41 – women with severe pe2nd trimester121 – uncomplicated birth controls\u2003xu et al., usa, 2014 [53]case control100 – women with pe≤ 24\xa0weeks Gestation100 – uncomplicated Birth controls\u2003yu et al., uk, 2012 [115]case control60 –late pe11–13\xa0weeks Gestation30 –early pe1000 – healthy controlsretrospective cohort study\u2003alvarez-fernandez et al., spain, 2014 [90]retrospective cohort257 -- women attending obstetric triage with suspicion of pe1st trimester and 20\xa0weeks of Gestation\u2003scholl et al., usa, 2013 [78]retrospective cohort1141 -- low income and minority Pregnant womenentry to care (mean 13.7\xa0±\xa05.7\xa0weeks)prospective cohort studies\u2003burris et al., usa, 2014 [94]prospective cohort1591 -- Pregnant women16.4–36.9\xa0weeks Gestation\u2003haugen et al., norway, 2000 [77]prospective cohort23,423 -- Pregnant womenvitamin D intake at weeks 15, 22, and 30 Gestation\u2003shand et al., canada, 2010 [37]prospective cohort221 -- women at risk for pe10–20\xa0weeks Gestation\u2003wei et al., canda 2012 [60]prospective cohort697 -- Pregnant women receiving Vitamin C and e supplementation for the PREVENTION of pe12–18\xa0weeks Gestation, 24-26 weeks Gestation\u2003wei, canada, 2013 [14]prospective cohort697 -- Pregnant women receiving Vitamin C and e supplementation for the PREVENTION of pe24–26\xa0weeks Gestation\u2003zhou, china, 2014 [116]prospective cohort74 – women with pe16–20 weeks\xa0Gestation\n\ncaption (table-wrap): table 3\n\nASSOCIATION between Vitamin D and pre-eclampsia (pe) in observational studiesauthor, location, yearkey findingsresultsaugust et al., usa, 1992 [88]↓ 1,25Oh2D in women with pe vs chronic htn and normal women1,25 Oh2D levels:pe: 37.8 +/− 15\xa0pg/ml chronic htn: 75 +/− 15\xa0pg/ml ( p \xa0<\xa00.05); normal women: 65 +/− 10\xa0pg/ml ( p \xa0<\xa00.05)fernandez- alonzo et al., spain, 2012 [97]↔ Pe and 25(Oh)D levels25(Oh)D: <49.9\xa0nmol/l: 28.6% (2/7 women); 49.9–74.9\xa0nmol/l: 42.9% (3/7 women); ≥ 74.9\xa0nmol/l: 28.6% (2/7 women) ( p \xa0=\xa00.91)pena hr, et al.']	[('SUPERFICIAL_RELATIONSHIP', 2026), ('SUPERFICIAL_RELATIONSHIP', 2199), ('SUPERFICIAL_RELATIONSHIP', 2350)]	3	[('GO_0007567', 'parturition', 51, 'delivery43'), ('GO_0007565', 'female pregnancy', 72, 'pregnant'), ('GO_0007565', 'female pregnancy', 168, 'pregnant'), ('GO_0007565', 'female pregnancy', 271, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 292, 'trimester'), ('GO_0007565', 'female pregnancy', 376, 'gestation100'), ('GO_0007565', 'female pregnancy', 399, 'pregnant'), ('GO_0007565', 'female pregnancy', 479, 'pregnant'), ('GO_0007565', 'female pregnancy', 541, 'gestation'), ('GO_0007565', 'female pregnancy', 635, 'gestation100'), ('GO_0007565', 'female pregnancy', 756, 'gestation79'), ('GO_0007565', 'female pregnancy', 777, 'pregnancy'), ('GO_0007565', 'female pregnancy', 865, 'gestation200'), ('GO_0007565', 'female pregnancy', 888, 'pregnant'), ('GO_0007565', 'female pregnancy', 1095, 'gestation100'), ('GO_0007567', 'parturition', 1124, 'birth'), ('GO_0007565', 'female pregnancy', 1199, 'gestation30'), ('GO_0007565', 'female pregnancy', 1422, 'gestation'), ('GO_0007565', 'female pregnancy', 1513, 'pregnant'), ('GO_0007565', 'female pregnancy', 1646, 'pregnant'), ('GO_0007565', 'female pregnancy', 1676, 'gestation'), ('GO_0007565', 'female pregnancy', 1746, 'pregnant'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1768, 'D'), ('GO_0007565', 'female pregnancy', 1801, 'gestation'), ('GO_0007565', 'female pregnancy', 1899, 'gestation'), ('GO_0007565', 'female pregnancy', 1961, 'pregnant'), ('CHEBI_27300', 'vitamin D', 1986, 'vitamin C'), ('GO_0007565', 'female pregnancy', 2054, 'gestation'), ('GO_0007565', 'female pregnancy', 2077, 'gestation'), ('GO_0007565', 'female pregnancy', 2134, 'pregnant'), ('CHEBI_27300', 'vitamin D', 2159, 'vitamin C'), ('GO_0007565', 'female pregnancy', 2227, 'gestation'), ('GO_0007565', 'female pregnancy', 2308, 'gestation'), ('CHEBI_27300', 'vitamin D', 2370, 'vitamin D'), ('CHEBI_72639', '13-HODE', 2501, '25OH2D'), ('CHEBI_72639', '13-HODE', 2558, '25 OH2D'), ('CHEBI_51383', 'hydridocarbon(3.)', 2724, 'PE'), ('CHEBI_71657', 'versiconol acetate', 2731, '25(OH)D'), ('CHEBI_33010', 'chromide(1-)', 2747, '(OH)D')]
S132-PMC5513133	PMC5513133	7/2017	S132-PMC5513133	['germany, 2–14 [85]↓ 25(Oh)D levels in pe in summer compared to controls, 1,25(Oh)2D ↓ only in winter25(Oh)D: pe:18.2\xa0±\xa017.1; control: 49.2\xa0±\xa029.2\xa0ng/ml, ( p \xa0<\xa00.001); 1,25(Oh)2D: 291\xa0±\xa0217 vs 612.3\xa0±\xa0455\xa0pmol/ml ( p \xa0<\xa00.05)mohaghegh et al., iran, 2015 [89]↓ mean 25(Oh)D in pe compared to Pregnant controls without pe25(Oh)D:Pe: 37.9\xa0±\xa033.9\xa0nmol/lcontrols: 58.2\xa0±\xa038.2\xa0nmol/l( p \xa0=\xa00.001)powe, usa, 2010 [86]↔ women with pe and controls with 25(Oh)D\xa0<\xa015.0\xa0nmol/ladjusted or: 1.3595% ci: 0.40 to 4.50robinson et al., usa, 2010 [25]↑ eospe in women with maternal 25(Oh)D levels <=19.6\xa0nmol/l compared to levels >19.6\xa0nmol/lor: 3.6095% ci: 1.71–7.58( p \xa0<\xa00.001)schneuer et al., australia, 2014 [114]↔ pe or eospe and low 25(Oh)D (< 25\xa0nmol/l)adjusted or- all pe: 0.4695% ci: 0.19–1.10adjusted or- eospe: 1.4095% ci: 0.20 to 9.89singla et al., india, 2015 [87]↓ mean Serum Vitamin D in women with pe vs controlspe: 24.2\xa0±\xa012.4\xa0nmol/l controls: 36.9\xa0±\xa016.7\xa0nmol/l;( p \xa0=\xa00.0001)ullah et al., bangladesh, 2013 [82]↑ pe per 25\xa0nmol/l decrease in 25(Oh)D leveladjusted or: 1.6695% ci: 1.05–3.02wetta et al., uk, 2013 [96]↔ between pe and 25-Oh D\xa0<\xa030\xa0ng/ml and <37.4\xa0nmol/l<30\xa0ng/ml adjusted or: 1.195% ci: 0.6–2.0adjusted or: 1.4 (<37.4\xa0nmol/l)95% ci: 0.7–3.0woodham et al., usa, 2011 [15]↓ severe pe in women with 10\xa0nmol/l increase in maternal 25(Oh)D leveladjusted or: 0.6295% ci: 0.51–0.76xu et al., usa, 2014 [53]↑ pe in women with Vitamin D deficiency (<37.5\xa0nmol/l)or: 4.495% ci: 1.8–10.8yu et al., uk, 2012 [115]↔ Serum Vitamin D raw values in pe and controls25(Oh)D levels: controls: 46.8\xa0nmol/l (27.8–70.0;)early pe: 32.2\xa0nmol/l (22.7–50.4); late pe: 39.2\xa0nmol/l (22.1–63.0) ( p \xa0=\xa00.231)alvarez-fernandez et al., spain, 2014 [90]↑ pe in women with 25(Oh)D levels <50\xa0nmol/l compared TO levels >50\xa0nmol/l after 20\xa0weeks of Gestationor: 4.695% ci:1.4–15( p \xa0=\xa00.010)scholl et al., usa, 2013 [78]↑ pe in women with 25(Oh)D\xa0<\xa049.9\xa0nmol/l and hyperparathyroidismadjusted or: 2.8695% ci: 1.28–6.41burris et al., usa, 2014 [94]↔ Pe and 25(Oh)D levels compared at each 25\xa0nmol/l increase in 25 (Oh)Dadjusted or: 1.1495% ci: 0.77–1.67haugen et al., norway, 2000 [77]↓ pe in women taking 10–15 mcg/d as compared with no supplementsadjusted or: 0.7395% ci: 0.58–0.92shand et al., canada, 2010 [37]↔ pe and 25(Oh)D levels <37.5\xa0nmol/ladjusted or: 0.9195% ci: 0.31–2.62wei et al., canda 2012 [60]↔ Pe and 25(Oh)D\xa0<\xa050\xa0nmol/ladjusted or: 1.2495% ci: 0.58–2.67( p \xa0=\xa00.58)wei, canada, 2013 [14]↑ pe and women with ↓ pigf levels and maternal 25(Oh)d\xa0<\xa050\xa0nmol/ladjusted or: 2.9795% ci: 1.23–7.20zhou, china, 2014 [116]↔ pe and 25(Oh)D levels25(Oh)D levelsgroup a ( n \xa0=\xa013): 41.4\xa0±\xa06.5\xa0nmol/l; group b ( n \xa0=\xa036): 62.1\xa0±\xa07.0\xa0nmol/l; group c ( n \xa0=\xa025): 89.6\xa0±\xa013.0\xa0nmol/l; ( p \xa0=\xa00.900)\na case-cohort study of women from 12 different united states (us) sites whose vitamin D levels were measured at ≤26\xa0weeks of Gestation SHOWED that 25(Oh)D levels greater than 50\xa0nmol/l were ASSOCIATED with a 40% reduction in risk for severe pe (0.65 [95% ci 0.43 to 0.98]), although there was no reduction in absolute and relative risk for the milder clinical subtypes of pe when 25(Oh)D levels were greater than 50\xa0nmol/l [79].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 1791), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2293), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2609), ('INCOMPLETE_EVIDENCE', 2914), ('SUPERFICIAL_RELATIONSHIP', 2969)]	5	"[('CHEBI_71657', 'versiconol acetate', 20, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 26, 'D'), ('CHEBI_73285', ""3-iodo-4-aminobenzyl-5'-N-methylcarboxamidoadenosine"", 75, '25(OH)2D ↓'), ('CHEBI_33010', 'chromide(1-)', 102, '(OH)D'), ('CHEBI_82784', 'PVP38-Ag NP', 168, '1,25(OH)2D'), ('CHEBI_71657', 'versiconol acetate', 265, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 265, '25'), ('PR_000011614', 'opioid growth factor receptor', 268, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 271, 'D'), ('GO_0007565', 'female pregnancy', 291, 'pregnant'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 322, 'OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 327, 'PE'), ('CHEBI_71657', 'versiconol acetate', 444, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 444, '25(OH)D'), ('CHEBI_33010', 'chromide(1-)', 566, '(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 725, 'OH)D'), ('UBERON_0001977', 'blood serum', 867, 'serum'), ('CHEBI_27300', 'vitamin D', 873, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 1043, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 1043, '25(OH ... D'), ('CHEBI_72765', 'verruculogen', 1134, '25-OH D'), ('CHEBI_71657', 'versiconol acetate', 1343, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1343, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 1434, 'vitamin D'), ('UBERON_0001977', 'blood serum', 1519, 'serum'), ('CHEBI_27300', 'vitamin D', 1525, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 1566, '(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 1759, 'OH)D'), ('GO_0007565', 'female pregnancy', 1830, 'gestationOR'), ('CHEBI_71657', 'versiconol acetate', 1920, '25(OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 2030, 'PE'), ('CHEBI_71657', 'versiconol acetate', 2037, '25(OH)D'), ('CHEBI_982', '2-Aceto-2-hydroxybutanoate', 2091, '25 (OH)DAdjusted'), ('CHEBI_71657', 'versiconol acetate', 2303, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 2303, '25(OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 2393, 'PE'), ('CHEBI_71657', 'versiconol acetate', 2400, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 2534, '25(OH'), ('CHEBI_71657', 'versiconol acetate', 2619, '25(OH)D'), ('CHEBI_33010', 'chromide(1-)', 2635, '(OH)D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 2865, 'D'), ('GO_0007565', 'female pregnancy', 2904, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 2926, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 3159, '25(OH)D')]"
S97-PMC5523023	PMC5523023	7/2017	S97-PMC5523023	['Prenatal supplementation of Vitamin C and E improved Pulmonary functions of newborns of smoking mothers (59), BUT in a large placebo-controlled study, this EFFECT was not confirmed (60).']	[('ANOMALY_CURIOUS_FINDING', 110), ('SUPERFICIAL_RELATIONSHIP', 156)]	2	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 28, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 42, 'E'), ('UBERON_0002048', 'lung', 53, 'pulmonary')]
S5-PMC5537904	PMC5537904	7/2017	S5-PMC5537904	['non-hispanic white race, lower Pre-Pregnancy bmi, higher Prenatal Vitamin D intake, and summer Births were ASSOCIATED with higher Cord Blood 25(Oh)D. higher 25(Oh)D was ASSOCIATED with lower Birthweight ( β = –6.22, p = 0.02), but as maternal bmi increased, this ASSOCIATION became increasingly positive in direction and magnitude ( β = 1.05, p = 0.04).']	[('SUPERFICIAL_RELATIONSHIP', 107), ('SUPERFICIAL_RELATIONSHIP', 169), ('SUPERFICIAL_RELATIONSHIP', 263)]	3	[('GO_0007568', 'aging', 31, 'pre'), ('GO_0007565', 'female pregnancy', 35, 'pregnancy'), ('GO_0007565', 'female pregnancy', 57, 'prenatal'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007567', 'parturition', 95, 'births'), ('UBERON_0002240', 'spinal cord', 130, 'cord'), ('UBERON_0000178', 'blood', 135, 'blood'), ('CHEBI_63056', 'zinc cation', 141, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 147, 'D'), ('CHEBI_71657', 'versiconol acetate', 157, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 157, '25(OH ... D'), ('GO_0007596', 'blood coagulation', 191, 'birthweight')]
S118-PMC5546866	PMC5546866	8/2017	S118-PMC5546866	['discussion\nTHIS STUDY ASSESSED the RELATIONSHIPS between common Genetic variants and the response to Vitamin D supplementation in Pregnancy; rs12785878 in dhcr7 was ASSOCIATED with 25(Oh)D status in early Pregnancy prior to Vitamin D supplementation, WHEREAS rs10741657 in Cyp2R1 and rs2282679 in gc were ASSOCIATED with both the achieved and change in 25(Oh)D concentration following supplementation with 1000 iu/d Cholecalciferol.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 22), ('SUPERFICIAL_RELATIONSHIP', 35), ('SUPERFICIAL_RELATIONSHIP', 165), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 251), ('SUPERFICIAL_RELATIONSHIP', 305)]	6	[('SO_0000704', 'gene', 64, 'genetic'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('GO_0007565', 'female pregnancy', 130, 'pregnancy'), ('CHEBI_30778', 'gallic acid', 181, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 187, 'D'), ('GO_0007565', 'female pregnancy', 205, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 224, 'vitamin D'), ('PR_000006110', 'cytochrome P450 27, mitochondrial', 273, 'CYP2R1'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 356, 'OH)D'), ('CHEBI_52550', 'theopalauamide', 416, 'cholecalciferol')]
S129-PMC5546866	PMC5546866	8/2017	S129-PMC5546866	['the Dhcr7 Gene encodes 7-Dhc reductase, which converts 7-Dhc back to Cholesterol, thereby reducing the availability of 7-Dhc for conversion to previtamin d. the ASSOCIATION of this Snp with only baseline 25(Oh)D is biologically CONSISTENT with the NOTION that the relative proportion of 25(Oh)D obtained from Vitamin D Biosynthesis in the skin AS OPPOSED TO dietary intake is lower following supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 161), ('INCOMPLETE_EVIDENCE', 228), ('INCOMPLETE_EVIDENCE', 248), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 344)]	4	[('PR_000006474', 'ATP-dependent RNA helicase A', 4, 'DHCR7'), ('SO_0000704', 'gene', 10, 'gene'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 23, '7-DHC'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 55, '7-DHC'), ('CHEBI_16113', 'cholesterol', 69, 'cholesterol'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 119, '7-DHC'), ('SO_0000694', 'SNP', 181, 'SNP'), ('CHEBI_71657', 'versiconol acetate', 204, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 287, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 293, 'D'), ('CHEBI_27300', 'vitamin D', 309, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 309, 'vitamin D biosynthesis')]
S26-PMC5634602	PMC5634602	10/2017	S26-PMC5634602	['preterm infants2008[2]Endocrine society healthy infants 0–1 year400–1000 iu>75 nmol/l (for non-Skeletal benefits)0–1 Vitamin D deficient (<50 nmol/l) 2000 iu/D for 6 weeks followed by maintenance dosing2011[9]\nvery LITTLE data is available regarding response to Vitamin D supplementation in the smallest and youngest infants (<1200 grams at Birth), a population that MIGHT see the most BENEFIT from normalized Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 215), ('INCOMPLETE_EVIDENCE', 367), ('IMPORTANT_CONSIDERATION', 386)]	3	[('UBERON_0005063', 'left ventricular compact myocardium', 22, 'Endocrine'), ('UBERON_0004288', 'skeleton', 95, 'skeletal'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 158, 'D'), ('CHEBI_27300', 'vitamin D', 262, 'vitamin D'), ('GO_0007567', 'parturition', 341, 'birth'), ('CHEBI_27300', 'vitamin D', 410, 'vitamin D')]
S89-PMC5634602	PMC5634602	10/2017	S89-PMC5634602	['a notable DIFFERENCE between THIS STUDY and ours is that in natarajan’s intervention the dose of Vitamin D supplementation was reduced to ACCOUNT FOR dietary intake of vitamin D and the total intake of Vitamin D was 400 iu or 800 iu.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 10), ('QUESTION_ANSWERED_BY_THIS_WORK', 29), ('PROBABLE_UNDERSTANDING', 138)]	3	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 176, 'D'), ('CHEBI_27300', 'vitamin D', 202, 'vitamin D')]
S94-PMC5659607	PMC5659607	10/2017	S94-PMC5659607	['an analysis of initial 25(Oh)D level and randomization group, SHOWED a lower risk of asthma/recurrent wheeze in women with 25(Oh)D level ≥ 30ng/ml and randomized to Vitamin D (women with initial 25(Oh)D <30 ng/ml and randomized to Placebo as reference), or = 0.58 (0.37–0.91), p = 0.02, i2= 0%, p = 0.35.']	[('INCOMPLETE_EVIDENCE', 62)]	1	[('CHEBI_71657', 'versiconol acetate', 23, '25(OH)D'), ('PR_000010220', 'mannose-binding protein C', 25, '('), ('PR_000006444', 'diacylglycerol kinase delta', 29, 'D'), ('CHEBI_30778', 'gallic acid', 123, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 129, 'D'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 195, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 195, '25(OH ... D'), ('CHEBI_26130', 'biological pigment', 231, 'placebo')]
S105-PMC5679631	PMC5679631	11/2017	S105-PMC5679631	['600 (reference)0 (reference)quintile 2680.01 (-0.21, 0.24)0.01 (-0.21, 0.22)quintile 349-0.11 (-0.35, 0.14)-0.18 (-0.41, 0.06)quintile 4510.02 (-0.22, 0.26)0.04 (-0.20, 0.28)quintile 558-0.06 (-0.30, 0.17)0.08 (-0.17, 0.33)p for linear trendp = 0.459\n&number of children colonized;\n#adjusted for: place and mode of Delivery, number of siblings, recruitment group, total bacterial counts, sex, vaginitis during the last month of Pregnancy, mode of infant nutrition and season of Blood sampling; quintile 5 is the highest quintile;\n* remained statistically significant after correction with fdr (q < 0.05)\n\nVitamin D supplementation of the infant\nthere was no influence of Vitamin D supplementation of the infant during the first month of Life on the prevalence of any of the bacterial species or groups (data not shown).table 5shows the ASSOCIATION between Vitamin D supplementation of the infant in the first month of Life and the log10cfus of the different bacteria in children colonized with the respective bacterial group or species (for a visualisation of the data in univariable boxplots see alsos3 fig).10.1371/journal.pone.0188011.t005\n\ncaption (table-wrap): table 5\nassociation between Vitamin D supplementation of the infant and log10colony forming units/g Feces of bacterial species or groups in Breast Fed infants (n = 616) colonized with the respective bacteria.Vitamin D supplement use of Breast feeding infantsvitamin D supplementationbacteria&nunadjusted b (95% ci)#adjusted b (95% ci)no use bifidobacterium spp.']	[('SUPERFICIAL_RELATIONSHIP', 836)]	1	[('GO_0007567', 'parturition', 315, 'delivery'), ('GO_0007565', 'female pregnancy', 428, 'pregnancy'), ('UBERON_0000178', 'blood', 478, 'blood'), ('CHEBI_28384', 'vitamin K', 605, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 671, 'vitamin D'), ('UBERON_0000104', 'life cycle', 737, 'life'), ('CHEBI_27300', 'vitamin D', 856, 'vitamin D'), ('UBERON_0000104', 'life cycle', 918, 'life'), ('CHEBI_27300', 'vitamin D', 1194, 'vitamin D'), ('UBERON_0001988', 'feces', 1266, 'feces'), ('GO_0007567', 'parturition', 1306, 'breast'), ('UBERON_0000310', 'breast', 1306, 'breast'), ('GO_0007631', 'feeding behavior', 1313, 'fed'), ('CHEBI_28384', 'vitamin K', 1374, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1374, 'Vitamin'), ('UBERON_0000310', 'breast', 1402, 'Breast'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1432, 'D')]
S0-PMC5685050	PMC5685050	10/2014	S0-PMC5685050	['vitamin D deficiency in thailand☆\nvitamin D deficiency has received INCREASED ATTENTION over the past several years since Vitamin D MAY play an IMPORTANT ROLE not ONLY in bone Metabolism but also in a variety of non-Skeletal diseases such as diabetes mellitus, Autoimmune diseases, infectious diseases, Cardiovascular diseases and cancer1,2,3.']	[('INCOMPLETE_EVIDENCE', 68), ('INCOMPLETE_EVIDENCE', 132), ('IMPORTANT_CONSIDERATION', 144), ('SUPERFICIAL_RELATIONSHIP', 154), ('INCOMPLETE_EVIDENCE', 163)]	5	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 8, 'D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 42, 'D'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('GO_0008152', 'metabolic process', 176, 'metabolism'), ('UBERON_0004288', 'skeleton', 216, 'skeletal'), ('UBERON_0001442', 'skeleton of manus', 261, 'autoimmune'), ('UBERON_0004535', 'cardiovascular system', 303, 'cardiovascular')]
S18-PMC5706533	PMC5706533	11/2017	S18-PMC5706533	['beyond its established INFLUENCE on bone growth and Calcium Homeostasis,1vitamin D and its RELATED Metabolites have HYPOTHESISED EFFECTS on the risk of Cardiovascular diseases,2cancer,3respiratory infections,4asthma,5conditions RELATED to Pregnancy (such as pre-eclampsia, Gestational diabetes), and Birth outcomes.6concern that Vitamin D deficiency is a global PUBLIC HEALTH PROBLEM HAS BEEN sparked by numerous REPORTS of the high proportion of Individuals in studies throughout the world who have relatively low Serum/Plasma concentrations of 25-hydroxyvitamin d (25(Oh)D),7the conventional circulating BIOMARKER of Vitamin D status.8there HAS BEEN particular ATTENTION to the high prevalence of vitamin d deficiency in Pregnant women and newborns.7\nin 2010, dietary reference intakes for Vitamin D for canada and the us from the institute of medicine were based solely on bone health—particularly in young children (for instance, rickets) and older Adults (for instance, osteoporosis).1considerable SKEPTICISM was cast onto the LINK between Vitamin D and Extraskeletal health conditions or the POTENTIAL benefits (versus risks) of intakes larger than the recommended dietary allowance (600 iu/day for MOST children and Adults).1THE institute’s report DID NOT RECOMMEND higher intakes during Pregnancy and Lactation.1a 2016 update of the cochrane collaboration systematic review and meta-analysis of trials of Vitamin D in Pregnancy (versus placebo or no Supplement), HOWEVER, TENTATIVELY CONCLUDED that Prenatal Vitamin D supplementation “MAY reduce the risk of pre-eclampsia, low birthweight and Preterm Birth.”6other RECENT systematic reviews that included trials with active control arms (in which participants received Vitamin D) ACKNOWLEDGED the POTENTIAL EFFECT of Vitamin D on fetal growth910but DID NOT FIND evidence of EFFECTS on OTHER maternal, fetal, or infant outcomes.91011citing the 2016 cochrane review,6the world health organization guidelines for Antenatal care ADVISE against routine Vitamin D supplementation in Pregnancy.12dietary and supplementation RECOMMENDATIONS, HOWEVER, vary widely across other professional organisations (appendix 1), and there REMAINS a LACK OF CONSENSUS on target health outcomes, indications for Prenatal supplementation, or EVIDENCE BASED regimens for supplement dose (or fortification STRATEGIES).']	[('SUPERFICIAL_RELATIONSHIP', 23), ('SUPERFICIAL_RELATIONSHIP', 91), ('INCOMPLETE_EVIDENCE', 116), ('SUPERFICIAL_RELATIONSHIP', 129), ('SUPERFICIAL_RELATIONSHIP', 228), ('IMPORTANT_CONSIDERATION', 362), ('IMPORTANT_CONSIDERATION', 376), ('PROBLEM_COMPLICATION', 376), ('INCOMPLETE_EVIDENCE', 384), ('INCOMPLETE_EVIDENCE', 413), ('SUPERFICIAL_RELATIONSHIP', 606), ('INCOMPLETE_EVIDENCE', 643), ('IMPORTANT_CONSIDERATION', 663), ('INCOMPLETE_EVIDENCE', 663), ('IMPORTANT_CONSIDERATION', 1003), ('SUPERFICIAL_RELATIONSHIP', 1032), ('INCOMPLETE_EVIDENCE', 1098), ('PROBABLE_UNDERSTANDING', 1205), ('INCOMPLETE_EVIDENCE', 1231), ('INCOMPLETE_EVIDENCE', 1255), ('FUTURE_WORK', 1263), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1471), ('INCOMPLETE_EVIDENCE', 1480), ('INCOMPLETE_EVIDENCE', 1492), ('INCOMPLETE_EVIDENCE', 1543), ('INCOMPLETE_EVIDENCE', 1623), ('INCOMPLETE_EVIDENCE', 1738), ('PROBABLE_UNDERSTANDING', 1738), ('INCOMPLETE_EVIDENCE', 1755), ('SUPERFICIAL_RELATIONSHIP', 1765), ('INCOMPLETE_EVIDENCE', 1807), ('SUPERFICIAL_RELATIONSHIP', 1832), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1843), ('FUTURE_WORK', 1983), ('FUTURE_WORK', 2075), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2092), ('ANOMALY_CURIOUS_FINDING', 2092), ('INCOMPLETE_EVIDENCE', 2177), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2187), ('INCOMPLETE_EVIDENCE', 2187), ('INCOMPLETE_EVIDENCE', 2277), ('FUTURE_WORK', 2339)]	42	[('GO_0055073', 'cadmium ion homeostasis', 52, 'calcium homeostasis'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 81, 'D'), ('CHEBI_25212', 'metabolite', 99, 'metabolites'), ('UBERON_0004535', 'cardiovascular system', 152, 'cardiovascular'), ('GO_0007565', 'female pregnancy', 239, 'pregnancy'), ('GO_0007565', 'female pregnancy', 273, 'gestational'), ('GO_0007567', 'parturition', 300, 'birth'), ('CHEBI_27300', 'vitamin D', 329, 'vitamin D'), ('NCBITaxon_1', 'root', 447, 'individuals'), ('UBERON_0001977', 'blood serum', 515, 'serum'), ('UBERON_0001969', 'blood plasma', 521, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 567, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 619, 'vitamin D'), ('GO_0007565', 'female pregnancy', 723, 'pregnant'), ('CHEBI_27300', 'vitamin D', 792, 'vitamin D'), ('UBERON_0007023', 'adult organism', 953, 'adults'), ('CHEBI_27300', 'vitamin D', 1045, 'vitamin D'), ('UBERON_0001431', 'distal carpal bone 2', 1059, 'extraskeletal'), ('UBERON_0007023', 'adult organism', 1223, 'adults'), ('GO_0007565', 'female pregnancy', 1295, 'pregnancy'), ('GO_0007595', 'lactation', 1309, 'lactation'), ('CHEBI_27300', 'vitamin D', 1413, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1426, 'pregnancy'), ('CHEBI_16158', 'steroid sulfate', 1458, 'supplement'), ('GO_0007565', 'female pregnancy', 1507, 'prenatal'), ('CHEBI_27300', 'vitamin D', 1516, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1601, 'preterm birth'), ('CHEBI_27300', 'vitamin D', 1727, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1775, 'vitamin D'), ('GO_0007567', 'parturition', 1968, 'antenatal'), ('CHEBI_27300', 'vitamin D', 2006, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2035, 'pregnancy'), ('GO_0007565', 'female pregnancy', 2248, 'prenatal')]
S46-PMC5706533	PMC5706533	11/2017	S46-PMC5706533	['when multiple comparisons from the same trial were included in the same meta-analysis, we divided the control group sample size corresponding to each comparison by the number of intervention arms to avoid double counting participants.14\nwe conducted subgroup meta-analyses according to a priori defined sources of potential clinical and methodological heterogeneity17: control arm type (Placebo versus Vitamin D containing active control); dosing frequency (regular versus bolus); baseline Vitamin D status categorised as low (mean 25(Oh)D <30 nmol/l) versus sufficient (≥30 nmol/l), based on maternal mean 25(Oh)D in the control group at enrolment (“initial baseline”) or at/near delivery (“modified baseline,” which THEORETICALLY takes into account the effect of active control supplementation); intervention dose (among regular dose trials), defined as low (<2000 iu/day) versus high (≥2000 iu/day).']	[('INCOMPLETE_EVIDENCE', 718)]	1	[('CHEBI_26130', 'biological pigment', 387, 'placebo'), ('CHEBI_27300', 'vitamin D', 402, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 490, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 532, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 538, 'D'), ('CHEBI_71657', 'versiconol acetate', 607, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 613, 'D')]
S89-PMC5706533	PMC5706533	11/2017	S89-PMC5706533	['no published trials were conducted in africa, THOUGH one large trial in tanzania (n=2300) is ongoing and projected to be completed and published before 2024\n\ncaption (fig)\n\nfig 3 \xa0effective equivalent daily Vitamin D dose (iu/day) versus maternal baseline mean 25-Hydroxyvitamin D (25(Oh)D) concentration (nmol/l) in published Prenatal Vitamin D supplementation trials with regular dosing regimens (29 trials; 36 comparisons).']	[('ANOMALY_CURIOUS_FINDING', 46)]	1	[('CHEBI_27300', 'vitamin D', 207, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 261, '25-hydroxyvitamin D'), ('CHEBI_30778', 'gallic acid', 282, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 288, 'D'), ('GO_0007565', 'female pregnancy', 327, 'prenatal'), ('CHEBI_27300', 'vitamin D', 336, 'vitamin D')]
S166-PMC5707701	PMC5707701	11/2017	S166-PMC5707701	['SOME nutritional, obstetric, and socio-economic factors HAVE BEEN IMPLICATED as being ASSOCIATED with the Vitamin A and E concentrations in milk [36,39,60].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 56), ('SUPERFICIAL_RELATIONSHIP', 66), ('SUPERFICIAL_RELATIONSHIP', 86)]	4	[('CHEBI_27300', 'vitamin D', 106, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 120, 'E')]
S170-PMC5707701	PMC5707701	11/2017	S170-PMC5707701	['these inverse CORRELATIONS between SOME of the Carotenoids and current bmi MAY BE due TO the underlying mechanism that an excess of body fat increases the consumption of all antioxidant elements in the diet [63], SO that Lactating women with a higher bmi and more body fat consumed more Vitamins A and E than those with lower bmi, resulting in lower Carotenoids in Human Milk.']	[('SUPERFICIAL_RELATIONSHIP', 14), ('INCOMPLETE_EVIDENCE', 35), ('INCOMPLETE_EVIDENCE', 75), ('QUESTION_ANSWERED_BY_THIS_WORK', 86), ('PROBABLE_UNDERSTANDING', 213)]	5	[('CHEBI_50815', 'norgestimate', 47, 'carotenoids'), ('GO_0007594', 'puparial adhesion', 221, 'lactating'), ('CHEBI_27300', 'vitamin D', 287, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 296, 'A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 302, 'E'), ('CHEBI_50815', 'norgestimate', 350, 'carotenoids'), ('NCBITaxon_9606', 'Homo sapiens', 365, 'human'), ('UBERON_0001913', 'milk', 371, 'milk')]
S177-PMC5707701	PMC5707701	11/2017	S177-PMC5707701	['HOWEVER, our results INDICATED that neither Vitamin A nor E intakes from one 24-h dietary Recall was associated with Vitamin A and E in Human milk, which MAY BE DUE TO the inherent Intake variability of one single 24-h dietary Recall questionnaire, which DID NOT ALLOW for estimations of an Individual’s usual diet, and THEREFORE, it is LIKELY to under- OR overestimate some Nutrient intakes.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 154), ('PROBLEM_COMPLICATION', 161), ('DIFFICULT_TASK', 255), ('ANOMALY_CURIOUS_FINDING', 259), ('PROBABLE_UNDERSTANDING', 320), ('PROBABLE_UNDERSTANDING', 337), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 354)]	9	[('CHEBI_27300', 'vitamin D', 44, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 58, 'E'), ('GO_0060033', 'anatomical structure regression', 90, 'recall'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 131, 'E'), ('NCBITaxon_9606', 'Homo sapiens', 136, 'human'), ('GO_0007631', 'feeding behavior', 181, 'intake'), ('GO_0060033', 'anatomical structure regression', 227, 'recall'), ('NCBITaxon_1', 'root', 291, 'individual'), ('CHEBI_33284', 'nutrient', 375, 'nutrient')]
S183-PMC5707701	PMC5707701	11/2017	S183-PMC5707701	['secondly, LITTLE IS KNOWN about the levels of Vitamins A and E in maternal Plasma ASSOCIATED with the corresponding Milk, which would be better than dietary Intake to assess maternal Nutrient status, DUE TO the IMPOSSIBILITY to collect such samples in our research.']	[('FULL_UNKNOWN', 10), ('SUPERFICIAL_RELATIONSHIP', 82), ('PROBLEM_COMPLICATION', 200), ('PROBLEM_COMPLICATION', 211)]	4	[('CHEBI_27300', 'vitamin D', 46, 'vitamins A'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 46, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 61, 'E'), ('UBERON_0001969', 'blood plasma', 75, 'plasma'), ('UBERON_0001913', 'milk', 116, 'milk'), ('GO_0007631', 'feeding behavior', 157, 'intake'), ('CHEBI_33284', 'nutrient', 183, 'nutrient')]
S184-PMC5707701	PMC5707701	11/2017	S184-PMC5707701	['thirdly, SINCE our design was a cross-sectional study, we COULD NOT collect DIRECT EVIDENCE about changes in Vitamins A and E with Lactation stages.']	[('PROBLEM_COMPLICATION', 9), ('DIFFICULT_TASK', 58), ('ANOMALY_CURIOUS_FINDING', 64), ('INCOMPLETE_EVIDENCE', 76), ('INCOMPLETE_EVIDENCE', 83)]	5	[('CHEBI_27300', 'vitamin D', 109, 'vitamins A'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 109, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 124, 'E'), ('GO_0007595', 'lactation', 131, 'lactation')]
S0-PMC5758521	PMC5758521	1/2018	S0-PMC5758521	['vitamin a and e nutritional status in RELATION to leptin, adiponectin, Igf-I and Igf-Ii in early Life - a Birth cohort study\n\nabstract\nthe Metabolic health EFFECTS of Vitamin A and E nutritional status in early Life are largely UNKNOWN.']	[('SUPERFICIAL_RELATIONSHIP', 38), ('SUPERFICIAL_RELATIONSHIP', 156), ('FULL_UNKNOWN', 228)]	3	[('PR_000008919', 'interferon alpha-6', 71, 'IGF-I'), ('PR_000002046', 'interferon regulatory factor 4', 81, 'IGF-II'), ('UBERON_0000104', 'life cycle', 97, 'Life'), ('GO_0007567', 'parturition', 106, 'Birth'), ('GO_0008152', 'metabolic process', 139, 'metabolic'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 181, 'E'), ('UBERON_0000104', 'life cycle', 211, 'life')]
S9-PMC5758521	PMC5758521	1/2018	S9-PMC5758521	['however, the Metabolic health EFFECTS of Vitamin A and E nutritional status in early Life remain largely UNKNOWN.']	[('SUPERFICIAL_RELATIONSHIP', 30), ('FULL_UNKNOWN', 105)]	2	[('GO_0008152', 'metabolic process', 13, 'metabolic'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 55, 'E'), ('UBERON_0000104', 'life cycle', 85, 'life')]
S15-PMC5758521	PMC5758521	1/2018	S15-PMC5758521	['circulating Vitamin A and E concentrations HAVE BEEN inversely CORRELATED to adiposity and Insulin sensitivity in children11.']	[('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 63)]	2	[('CHEBI_27300', 'vitamin D', 12, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 20, 'A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 26, 'E'), ('PR_000045358', 'insulin family protein', 91, 'insulin')]
S19-PMC5758521	PMC5758521	1/2018	S19-PMC5758521	['taken TOGETHER, these OBSERVATIONS SUGGEST that Vitamins A and E MAY AFFECT Metabolic health.']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 35), ('INCOMPLETE_EVIDENCE', 65), ('SUPERFICIAL_RELATIONSHIP', 69)]	5	[('CHEBI_27300', 'vitamin D', 48, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 63, 'E'), ('GO_0008152', 'metabolic process', 76, 'metabolic')]
S20-PMC5758521	PMC5758521	1/2018	S20-PMC5758521	['HOWEVER, there is a LACK OF DATA on WHETHER Vitamin A and E nutritional status MAY BE ASSOCIATED with Metabolic health BIOMARKERS in early Life in Humans.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 20), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 36), ('INCOMPLETE_EVIDENCE', 79), ('SUPERFICIAL_RELATIONSHIP', 86), ('SUPERFICIAL_RELATIONSHIP', 119)]	7	[('CHEBI_27300', 'vitamin D', 44, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 58, 'E'), ('GO_0008152', 'metabolic process', 102, 'metabolic'), ('UBERON_0000104', 'life cycle', 139, 'life'), ('NCBITaxon_9606', 'Homo sapiens', 147, 'humans')]
S22-PMC5758521	PMC5758521	1/2018	S22-PMC5758521	['we HYPOTHESIZED that Vitamin A and E nutritional status MAY AFFECT fetal circulating leptin, adiponectin, Igf-I and Igf-Ii levels.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 56), ('SUPERFICIAL_RELATIONSHIP', 60)]	3	[('CHEBI_27300', 'vitamin D', 21, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 35, 'E'), ('PR_000008919', 'interferon alpha-6', 106, 'IGF-I'), ('PR_000002046', 'interferon regulatory factor 4', 116, 'IGF-II')]
S27-PMC5758521	PMC5758521	1/2018	S27-PMC5758521	['in the original Birth cohort, we had collected Cord Blood specimens in 255 infants, but 7 without sufficient Plasma specimen (0.5\u2009ml) available for assays of Vitamins A and E. the PRESENT STUDY included all 248 subjects with Cord Plasma specimens available for assays of Vitamins A and e. all newborns are free of Birth defects, infections and Respiratory Distress syndrome.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 180)]	1	[('GO_0007567', 'parturition', 16, 'birth'), ('UBERON_0002240', 'spinal cord', 47, 'cord'), ('UBERON_0000178', 'blood', 52, 'blood'), ('UBERON_0001969', 'blood plasma', 109, 'plasma'), ('CHEBI_27300', 'vitamin D', 158, 'vitamins A'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 158, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 173, 'E'), ('UBERON_0002240', 'spinal cord', 225, 'cord'), ('UBERON_0001969', 'blood plasma', 230, 'plasma'), ('CHEBI_27300', 'vitamin D', 271, 'vitamins A'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 271, 'vitamins A'), ('GO_0007567', 'parturition', 314, 'birth'), ('UBERON_0003495', 'respiratory system arteriole', 344, 'respiratory distress')]
S140-PMC5758521	PMC5758521	1/2018	S140-PMC5758521	['MOST STUDIES on Vitamins A and E in Pregnancy HAVE BEEN focused on the ASSOCIATION with fetal growth, and the FINDINGS HAVE BEEN INCONSISTENT33–35.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 46), ('SUPERFICIAL_RELATIONSHIP', 71), ('INCOMPLETE_EVIDENCE', 110), ('INCOMPLETE_EVIDENCE', 119), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 129)]	6	[('CHEBI_27300', 'vitamin D', 16, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 25, 'A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 31, 'E'), ('GO_0007565', 'female pregnancy', 36, 'pregnancy')]
S147-PMC5758521	PMC5758521	1/2018	S147-PMC5758521	['it is NOTEWORTHY that in OUR STUDY, Vitamin A and E measurements were pretty ROBUST (low intra- and inter-assay cvs), and that Birth weight was measured by research nurses using a reliable electronic weighing scale.']	[('ANOMALY_CURIOUS_FINDING', 6), ('QUESTION_ANSWERED_BY_THIS_WORK', 25), ('INCOMPLETE_EVIDENCE', 77)]	3	[('CHEBI_27300', 'vitamin D', 36, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 50, 'E'), ('GO_0007567', 'parturition', 127, 'birth')]
S155-PMC5758521	PMC5758521	1/2018	S155-PMC5758521	['it SHOULD be NOTED that the normal reference values for Vitamins A and E in Cord Blood are NOT AVAILABLE, and our OBSERVED ASSOCIATIONS were MOSTLY moderate.']	[('IMPORTANT_CONSIDERATION', 3), ('ANOMALY_CURIOUS_FINDING', 13), ('INCOMPLETE_EVIDENCE', 91), ('INCOMPLETE_EVIDENCE', 114), ('SUPERFICIAL_RELATIONSHIP', 123), ('PROBABLE_UNDERSTANDING', 141)]	6	[('CHEBI_27300', 'vitamin D', 56, 'vitamins A'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 56, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 71, 'E'), ('UBERON_0009472', 'axilla', 76, 'cord blood')]
S101-PMC5827025	PMC5827025	2/2018	S101-PMC5827025	['follow-up, SEVERAL randomized TRIAL of Vitamin D supplementation FOUND that the rate of Preterm Delivery is significant more lower in Pregnant women with Serum 25(Oh)D ≥40\u2009ng/ml COMPARED TO those with Serum 25(Oh)D ≤20\u2009ng/ml, SUGGESTING higher 25(Oh)D concentration was ASSOCIATED with an decreased risk of Preterm Delivery35–38.']	[('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 65), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 178), ('INCOMPLETE_EVIDENCE', 226), ('SUPERFICIAL_RELATIONSHIP', 270)]	5	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 88, 'preterm'), ('GO_0007567', 'parturition', 96, 'delivery'), ('GO_0007565', 'female pregnancy', 134, 'pregnant'), ('UBERON_0001977', 'blood serum', 154, 'serum'), ('CHEBI_63056', 'zinc cation', 160, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 166, 'D'), ('UBERON_0001977', 'blood serum', 201, 'serum'), ('CHEBI_71657', 'versiconol acetate', 207, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 210, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 213, 'D'), ('CHEBI_71657', 'versiconol acetate', 244, '25(OH)D'), ('GO_0007565', 'female pregnancy', 307, 'preterm'), ('GO_0008219', 'cell death', 315, 'delivery35')]
S78-PMC5838372	PMC5838372	3/2018	S78-PMC5838372	['discussion\nvitamin D deficiency LEADS TO IMPORTANT health PROBLEMS, NOT ONLY in mothers BUT ALSO in their infants, BECAUSE the Vitamin D store of the mother is the MAJOR source of Vitamin D for the fetus (9).']	[('PROBABLE_UNDERSTANDING', 32), ('SUPERFICIAL_RELATIONSHIP', 32), ('IMPORTANT_CONSIDERATION', 41), ('IMPORTANT_CONSIDERATION', 58), ('ANOMALY_CURIOUS_FINDING', 68), ('ANOMALY_CURIOUS_FINDING', 88), ('PROBABLE_UNDERSTANDING', 115), ('IMPORTANT_CONSIDERATION', 164)]	8	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 19, 'D'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D')]
S32-PMC5941617	PMC5941617	5/2018	S32-PMC5941617	['caption (table-wrap): table 2\n\ndefinition of Vitamin D status according to several societies and organizations in the last 10\xa0yearssociety/organizationyearsevere deficiencydeficiencyinsufficiencysufficiency/adequacycanadian pediatric society [8]2007–<\u2009 10\xa0ng/ml10–29\xa0ng/ml≥ 30\xa0ng/mllawson wilkins pediatric Endocrine society [9]2008<\u2009 5\xa0ng/ml5–14\xa0ng/ml15–19\xa0ng/ml≥ 20\xa0ng/mlinstitute of medicine [10]2011–<\u2009 12\xa0ng/ml12–20\xa0ng/mla≥ 20\xa0ng/mlthe Endocrine society [11]2011–<\u2009 20\xa0ng/ml21–29\xa0ng/ml≥ 30\xa0ng/mlbritish paediatric and adolescent bone group [12]2012–<\u200910\xa0ng/ml10–19\xa0ng/ml≥ 20\xa0ng/mlfrench society of paediatrics [13]2012–<\u2009 20\xa0ng/ml–≥ 20\xa0ng/mlasociación espanola de pediatría (spain) [14]2012–<\u2009 20\xa0ng/ml–≥ 20\xa0ng/mlfederal commission for nutrition (switzerland) [15]2012<\u200910\xa0ng/ml<\u2009 20\xa0ng/ml–≥ 20\xa0ng/mlnordic nutrition recommendations [16]2012–<\u2009 12\xa0ng/ml12–20\xa0ng/ml≥ 20\xa0ng/mlgerman nutrition society [17]2012–––≥ 20\xa0ng/mlhealth council of the netherlands [18]2012–––≥ 12\xa0ng/mleuropean society for paediatric gastroenterology hepatology and nutrition [19]2013<\u200910\xa0ng/ml<\u2009 20\xa0ng/ml–≥ 20\xa0ng/mlcentral europe [20]2013–< 20\xa0ng/ml20–29\xa0ng/ml≥ 30\xa0ng/mlsociety for adolescent health and medicine [21]2013–<\u2009 20\xa0ng/ml20–29\xa0ng/ml≥ 30\xa0ng/mlaustralia/new zealand [22]2013<\u2009 5\xa0ng/ml5–11\xa0ng/ml12–19\xa0ng/ml≥ 20\xa0ng/mlamerican academy of pediatrics [23]2014–<\u2009 20\xa0ng/ml–≥ 20\xa0ng/mljapanese society for bone and Mineral research, japan Endocrine societyb[24]2015–<\u2009 20\xa0ng/ml––scientific advisory committee on nutrition [25]2016–––≥ 10\xa0ng/mleuropean Food safety authority [26]2016–––≥ 20\xa0ng/mlunited arab emirates [27]2016–<\u2009 20\xa0ng/ml20–29\xa0ng/ml≥ 30\xa0ng/mlglobal consensus for rickets [28]2016–<\u2009 12\xa0ng/ml12–19\xa0ng/ml≥ 20\xa0ng/mljapanese society for bone and Mineral research, japan Endocrine societyc[29]2017–<\u2009 20\xa0ng/ml20–29\xa0ng/ml≥ 30\xa0ng/mleuropean academy of pediatrics [30]2017definition of Vitamin D status is UNCLEAR DUE TO a lack OF consensus\navitamin D inadequacy\nbdiagnostic criteria for rickets\ncassessment criteria for Vitamin D deficiency/insufficiency (authors REPORTED that DIFFERENT criteria MAY BE needed for children)\nsevere Vitamin D deficiency is DEFINED as 25(Oh)d levels <\u200910\xa0ng/ml by SEVERAL authors and societies BECAUSE the risk of rickets is high below this cut-off also in presence of an adequate Calcium intake [31–33] (see chapter “nutritional rickets”).']	[('FULL_UNKNOWN', 1894), ('PROBLEM_COMPLICATION', 1902), ('ANOMALY_CURIOUS_FINDING', 1916), ('ANOMALY_CURIOUS_FINDING', 1916), ('INCOMPLETE_EVIDENCE', 2053), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2067), ('INCOMPLETE_EVIDENCE', 2086), ('PROBABLE_UNDERSTANDING', 2145), ('INCOMPLETE_EVIDENCE', 2185), ('PROBABLE_UNDERSTANDING', 2215)]	10	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('UBERON_0005063', 'left ventricular compact myocardium', 307, 'Endocrine'), ('UBERON_0005063', 'left ventricular compact myocardium', 441, 'Endocrine'), ('CHEBI_46662', 'mineral', 1396, 'Mineral'), ('GO_0009790', 'embryo development', 1420, 'Endocrine'), ('UBERON_0005063', 'left ventricular compact myocardium', 1420, 'Endocrine'), ('CHEBI_33290', 'food', 1533, 'Food'), ('CHEBI_46662', 'mineral', 1738, 'Mineral'), ('GO_0009790', 'embryo development', 1762, 'Endocrine'), ('UBERON_0005063', 'left ventricular compact myocardium', 1762, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 1874, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1938, 'D'), ('CHEBI_27300', 'vitamin D', 2009, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 2121, 'vitamin D'), ('CHEBI_30778', 'gallic acid', 2156, '25(OH)'), ('CHEBI_22313', 'alkaline earth metal atom', 2302, 'calcium')]
S59-PMC5941617	PMC5941617	5/2018	S59-PMC5941617	['hypovitaminosis D and Vitamin D deficiency, independently from cut-off definitions, have a higher PREVALENCE worldwide in any age.']	[('IMPORTANT_CONSIDERATION', 98)]	1	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 16, 'D'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin D')]
S71-PMC5941617	PMC5941617	5/2018	S71-PMC5941617	['caption (table-wrap): table 4\n\nprevalence of hypovitaminosis d in healthy children and adolescents living in italystudyperiod of enrolmentnumberm (%)age (range or as specified)city/region (latitude)% overweight% obese% receiving Vitamin D% not caucasian25(Oh)D assaysevere deficiency, % [25(Oh)D\u2009<\u200910\xa0ng/ml]deficiency, % [25(Oh)D\u2009<\u200920\xa0ng/ml]insufficiency, % [25(Oh)D: 20–29.9\xa0ng/ml]hypovitaminosis D, % [25(Oh)D\u2009<\u200930\xa0ng/ml]FACTORS for ASSOCIATED with Serum 25(Oh)D levelslippi g et al.']	[('SUPERFICIAL_RELATIONSHIP', 423), ('SUPERFICIAL_RELATIONSHIP', 435)]	2	[('CHEBI_27300', 'vitamin D', 229, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 255, '(OH)D'), ('CHEBI_71657', 'versiconol acetate', 288, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 322, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 359, '25(OH)D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 398, 'D'), ('CHEBI_71657', 'versiconol acetate', 404, '25(OH)D'), ('UBERON_0001977', 'blood serum', 451, 'serum'), ('CHEBI_71657', 'versiconol acetate', 457, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 457, '25 ... OH ... D')]
S110-PMC5941617	PMC5941617	5/2018	S110-PMC5941617	['Vitamin D supplementation\n\n0–12\xa0months\nvitamin D supplementation in the first year of Life is ESSENTIAL to ensure an adequate Vitamin D status and to prevent nutritional rickets.']	[('IMPORTANT_CONSIDERATION', 94)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 47, 'D'), ('UBERON_0000104', 'life cycle', 86, 'life'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D')]
S117-PMC5941617	PMC5941617	5/2018	S117-PMC5941617	['ON THE CONTRARY, Vitamin D supplementation at higher dosages SEEMED TO BE ASSOCIATED with increased RISK of hypervitaminosis D with hypercalciuria and hypercalcemia [62].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 7), ('ANOMALY_CURIOUS_FINDING', 7), ('ANOMALY_CURIOUS_FINDING', 61), ('SUPERFICIAL_RELATIONSHIP', 74), ('IMPORTANT_CONSIDERATION', 100)]	6	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 125, 'D')]
S199-PMC5941617	PMC5941617	5/2018	S199-PMC5941617	['particularly, Vitamin D status SHOULD BE monitored AT LEAST yearly in subjects that REQUIRE supplementation during the whole year BECAUSE AFFECTED from pathological conditions or receiving Drugs AFFECTING vitamin D Metabolism (table\xa07) (see “Extraskeletal actions of Vitamin D” for specific RECOMMENDATIONS).']	[('FUTURE_WORK', 31), ('IMPORTANT_CONSIDERATION', 31), ('PROBABLE_UNDERSTANDING', 51), ('IMPORTANT_CONSIDERATION', 84), ('PROBABLE_UNDERSTANDING', 130), ('SUPERFICIAL_RELATIONSHIP', 138), ('SUPERFICIAL_RELATIONSHIP', 195), ('FUTURE_WORK', 291)]	8	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('CHEBI_23888', 'drug', 189, 'drugs'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 213, 'D'), ('GO_0018977', '1,1,1-trichloro-2,2-bis-(4-chlorophenyl)ethane metabolic process', 213, 'D metabolism'), ('UBERON_0001431', 'distal carpal bone 2', 242, 'Extraskeletal'), ('CHEBI_27300', 'vitamin D', 267, 'vitamin D')]
S435-PMC5941617	PMC5941617	5/2018	S435-PMC5941617	['a recent meta-analysis SHOWED that patients with crohn’s disease ( n \u2009=\u2009129808, age 11–48\xa0years) had lower Serum 25(Oh)D concentrations compared with healthy controls, with an overall prevalence of Vitamin D deficiency [25(Oh)D\u2009<\u2009\xa020\xa0ng/ml] of 57.7% and an inverse CORRELATION between Serum 25(Oh)D levels and the severity of disease [399].']	[('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 265)]	2	[('UBERON_0001977', 'blood serum', 107, 'serum'), ('CHEBI_63056', 'zinc cation', 113, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 119, 'D'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 220, '25(OH)D'), ('UBERON_0001977', 'blood serum', 285, 'serum'), ('CHEBI_71657', 'versiconol acetate', 291, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 291, '25(OH ... D')]
S449-PMC5941617	PMC5941617	5/2018	S449-PMC5941617	['FOUND that two regimens of weekly Vitamin D3Administration (5000\xa0iu/10 kg/week, maximum weekly dose of 25000\xa0iu and maximum cumulative dose of 150000\xa0iu vs. 10000\xa0iu/10 kg/week, maximum weekly dose of 50000\xa0iu and maximum cumulative dose of 300000\xa0iu) for 6\xa0weeks were SAFE and EFFECTIVE in normalizing Vitamin D status in ibd children and adolescents with hypovitaminosis D [411].']	[('INCOMPLETE_EVIDENCE', 0), ('IMPORTANT_CONSIDERATION', 269), ('SUPERFICIAL_RELATIONSHIP', 278)]	3	[('CHEBI_63455', 'tetronic acid derivative', 34, 'vitamin D3administration'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 34, 'vitamin D3administration'), ('CHEBI_27300', 'vitamin D', 303, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 373, 'D')]
S517-PMC5941617	PMC5941617	5/2018	S517-PMC5941617	['AT PRESENT, CONSIDERING that obese italian children have higher prevalence of Vitamin D deficiency and insufficiency then normal weight Individuals, we SUGGEST in obese children and adolescents vitamin D supplementation at higher doses THAN those RECOMMENDED for age (1000–1500\xa0iu/day) from the end of fall to the beginning of spring (november–april) to ensure an adequate Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 12), ('INCOMPLETE_EVIDENCE', 152), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 236), ('FUTURE_WORK', 247)]	5	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('NCBITaxon_1', 'root', 136, 'individuals'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 202, 'D'), ('CHEBI_27300', 'vitamin D', 373, 'vitamin D')]
S576-PMC5941617	PMC5941617	5/2018	S576-PMC5941617	['a RECENT RCT in children (2–5\xa0years) with Vitamin D deficiency SHOWED that treatment with oral 4000\xa0iu/day or 30000\xa0iu/week for 12\xa0weeks or a single intramuscular dose of 300000\xa0iu of Vitamin D3Followed by a maintenance dose of 400\xa0iu/day increased and maintained Serum 25(Oh)D concentration\u2009>\u200930\xa0ng/ml after 1\xa0year [516].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 63)]	2	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('CHEBI_83261', 'pyribencarb', 184, 'vitamin D3followed'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 184, 'vitamin D3followed'), ('UBERON_0001977', 'blood serum', 264, 'serum'), ('CHEBI_30778', 'gallic acid', 270, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 276, 'D')]
S615-PMC5941617	PMC5941617	5/2018	S615-PMC5941617	['DEPENDING ON 25(Oh)D levels, Vitamin D status can be defined as follows:\nsufficiency ≥30\xa0ng/ml\ninsufficiency 20–29\xa0ng/ml\ndeficiency <\u200920\xa0ng/ml\nsevere deficiency <\u200910\xa0ng/ml\nthe term hypovitaminosis D refers to Serum 25(Oh)D levels <\u200930\xa0ng/ml.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0)]	1	[('CHEBI_71657', 'versiconol acetate', 13, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 197, 'D'), ('UBERON_0001977', 'blood serum', 209, 'serum'), ('CHEBI_71657', 'versiconol acetate', 215, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 215, '25(OH)D')]
S151-PMC5952272	PMC5952272	5/2018	S151-PMC5952272	['on the community level, it was NOTICED that diet plays a MAJOR ROLE in the manifestation of anaemia and Vitamin E and D deficiency; HOWEVER, OTHER factors MAY interfere to make such a deficiency multifactorial.']	[('ANOMALY_CURIOUS_FINDING', 31), ('IMPORTANT_CONSIDERATION', 57), ('SUPERFICIAL_RELATIONSHIP', 63), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 132), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 141), ('INCOMPLETE_EVIDENCE', 155)]	6	[('CHEBI_27300', 'vitamin D', 104, 'vitamin E'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 118, 'D')]
S62-PMC5956785	PMC5956785	5/2018	S62-PMC5956785	['defining Vitamin D status\nvitamin D deficiency is DEFINED AS a Serum 25(Oh)D concentration less than 30\xa0nmol/l, a 25(Oh)D concentration between 30 and 50\xa0nmol/l IS CONSIDERED insufficient, greater than 50\xa0nmol/l IS CONSIDERED sufficient and a 25(Oh)D status greater than 125\xa0nmol/l IS CONSIDERED AT RISK of adverse EFFECTS [19].']	[('PROBABLE_UNDERSTANDING', 50), ('PROBABLE_UNDERSTANDING', 58), ('INCOMPLETE_EVIDENCE', 161), ('INCOMPLETE_EVIDENCE', 212), ('INCOMPLETE_EVIDENCE', 282), ('IMPORTANT_CONSIDERATION', 296), ('SUPERFICIAL_RELATIONSHIP', 315)]	7	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 34, 'D'), ('UBERON_0001977', 'blood serum', 63, 'serum'), ('CHEBI_71657', 'versiconol acetate', 69, '25(OH)D'), ('CHEBI_30778', 'gallic acid', 114, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 120, 'D'), ('CHEBI_71657', 'versiconol acetate', 243, '25(OH)D')]
S22-PMC5995352	PMC5995352	6/2018	S22-PMC5995352	['hypovitaminosis D MAY BE defined as Vitamin D deficiency or insufficiency (Serum-25-Hydroxyvitamin D (25Ohd) < 25 nmol/l and 25–50 nmol/l, respectively) [3], ALTHOUGH the most APPROPRIATE cut points are STILL UNDER DEBATE [4,5].']	[('INCOMPLETE_EVIDENCE', 18), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 158), ('IMPORTANT_CONSIDERATION', 176), ('IMPORTANT_CONSIDERATION', 203), ('IMPORTANT_CONSIDERATION', 209), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 215)]	6	"[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 16, 'D'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('UBERON_0001977', 'blood serum', 75, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 81, '25-hydroxyvitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 102, '25OHD')]"
S92-PMC5995352	PMC5995352	6/2018	S92-PMC5995352	['compared to children in the highest Cord 25Ohd quartile, children in the lowest quartile were more often Born during winter and spring and more LIKELY had mothers of non-western ethnicity, mothers with pre-Gestational bmi above 25 kg/m2, mothers with parity above three children, mothers who took less than the recommended Vitamin D supplement of 10 μg/day, or mothers who Smoked during Pregnancy,table 1.10.1371/journal.pone.0198724.t001\n\ncaption (table-wrap): table 1\nbasic characteristics of the 2010 participants.nquartiles of Cord 25Ohd, nmol/lp-value*< 30.730.8–45.145.2–60.6> 60.7 maternal characteristics maternal height, cm2010168.3 ± 6.51168.0 ± 6.6168.2 ± 6.1168.5 ± 6.10.7maternal pre-Gestational weight, kg201069 [60–80]266 [60–74]66 [59–75]65 [59–73]<0.001 Pregestational bmi, kg/m2201024.3 [21.8–28.1]23.3 [21.4–26.0]23.5 [21.1–26.2]22.8 [21.0–25.6]<0.001 Gestational weight gain, kg87315.1 ± 6.315.0 ± 5.615.5 ± 5.614.5 ± 5.20.4maternal age, y201029.8 ± 4.630.4 ± 4.330.3 ± 4.330.0 ± 4.60.1smoking in Pregnancy, n (%) <0.001 \u2003smoker9843 (8.6)18 (3.6)19 (3.8)18 (3.6)\u2003non-smoker1912460 (91.4)484 (96.4)484 (96.2)484 (96.4)maternal educational level, n (%)0.2\u2003lower25274 (19.5)64 (16.3)54 (13.7)60 (17.7)\u2003intermediate908218 (57.5)230 (58.7)245 (62.2)215 (63.2)\u2003higher34587 (23.0)98 (25.0)95 (24.1)65 (19.1)ethnicity, n (%) <0.001 \u2003western1918459 (93.2)482 (95.8)486 (98.6)491 (97.1)\u2003non-western9244 (6.8)20 (4.2)17 (1.4)11 (2.9)skin-type**, n (%)0.2\u2003i/ii white29986 (22.6)84 (21.3)66 (16.7)63 (18.4)\u2003iii darker white889207 (54.3)239 (60.5)249 (62.8)194 (56.7)\u2003iv brown30982 (21.5)67 (16.9)78 (19.7)82 (23.9)\u2003v/vi dark brown176 (1.6)5 (1.3)3 (0.6)3 (1.0)parity, n (%) <0.001 \u2003first child1109230 (45.7)282 (56.2)295 (58.7)302 (60.2)\u2003second child679204 (40.6)164 (32.7)156 (31.0)155 (30.9)\u2003third child or more22269 (13.7)56 (11.1)52 (10.3)45 (8.9)time spent outdoors, mother, n (%) 0.002 \u2003never/rarely3111 (2.9)7 (1.8)7 (1.8)6 (1.8)\u2003sometimes29595 (24.9)84 (21.2)62 (15.7)54 (15.8)\u2003often920204 (54.4)252 (63.6)256 (64.7)208 (60.8)\u2003most of the time27072 (18.8)53 (13.4)71 (17.8)74 (21.6)Vitamin D supplementation in Pregnancy, mother, n (%) <0.001 \u2003≤10 μg/day15764 (23.4)33 (10.7)36 (11.4)24 (8.5)\u2003>10 μg/day1023210 (76.6)275 (89.3)281 (88.6)257 (91.5) paternal characteristics paternal height, cm1223182.6 ± 6.7182.5 ± 7.0183.2± 6.6182.3± 6.70.3 child characteristics Gestational age (ga) at Birth, w201040 [39–41]40 [39–41]40 [39–41]40 [39–41]0.6season of Birth n (%) <0.001 \u2003winter (dec-feb)489190 (37.7)143 (28.5)107 (21.3)49 (9.8)\u2003spring (mar-may)496158 (31.4)144 (28.7)106 (21.1)88 (17.5)\u2003summer (jun-aug)47729 (5.8)78 (15.5)135 (26.8)235 (46.8)\u2003autumn (sep-nov)548126 (25.1)137 (27.3)155 (30.8)130 (25.9)child sex, n (%)0.6\u2003girls948241 (47.9)228 (45.4)247 (49.1)232 (46.2)\u2003boys1062262 (52.1)274 (54.6)256 (50.9)270 (53.8)child age at 18 months examination, m135018.7 [18.3–19.4]18.8 [18.2–19.4]18.0 [18.4–19.6]19.0 [18.4–19.5]0.03 duration of exclusive breastfeeding, w123018 [6–34]19 [11–24]20 [10–24]20 [12–24]0.06intake of infant formula after 8 weeks of age0.06\u2003yes9219 (6.5)21 (6.2)34 (10.3)18 (5.2)\u2003no1219275 (93.5)319 (93.8)297 (89.7)328 (94.8)dietary intake of Calcium, mg/day1243489 [213–756]495 [230–751]495 [224–757]489 [211–747]0.06dietary intake of Vitamin D, μg/day11851.14 ± 1.011.18 ± 1.661.04 ± 0.900.98 ± 1.00.2vitamin D supplementation, μg/day9433.47 ± 2.213.98 ± 1.363.88 ± 1.454.03 ± 1.59 0.002\nanova was used for comparing means of numerical, normally distributed variables.']	[('PROBABLE_UNDERSTANDING', 144)]	1	"[('UBERON_0002240', 'spinal cord', 36, 'cord'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 41, '25OHD'), ('GO_0007567', 'parturition', 105, 'born'), ('GO_0007565', 'female pregnancy', 206, 'gestational'), ('CHEBI_27300', 'vitamin D', 323, 'vitamin D'), ('GO_0007601', 'visual perception', 373, 'smoked'), ('GO_0007565', 'female pregnancy', 387, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 531, 'cord'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 536, '25OHD'), ('GO_0007565', 'female pregnancy', 697, 'gestational'), ('GO_0007565', 'female pregnancy', 771, 'Pregestational'), ('GO_0007565', 'female pregnancy', 871, 'Gestational'), ('GO_0007565', 'female pregnancy', 1017, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 2097, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 2126, 'pregnancy'), ('GO_0007565', 'female pregnancy', 2379, 'Gestational'), ('GO_0007567', 'parturition', 2403, 'birth'), ('GO_0007567', 'parturition', 2468, 'birth'), ('CHEBI_22313', 'alkaline earth metal atom', 3186, 'calcium'), ('CHEBI_27300', 'vitamin D', 3279, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 3354, 'D')]"
S64-PMC6011374	PMC6011374	6/2018	S64-PMC6011374	['caption (table-wrap): table 1\n\nparticipant characteristics and comparison of characteristics between women recruited at the adelaide and auckland scope centresall women (n = 2800)adelaide (n = 1156)auckland (n = 1644) p value*age yrs , mean (sd)28 (6)23.73 (5.11)30.44 (4.82)<0.0001bmi kg/m2, mean (sd)25.8 (5.44)27.04 (6.56)24.88 (4.26)<0.0001ethnicity<0.0001\u2003caucasian2449 (87)1060 (92)1389 (84)\u2003non caucasian351 (13)96 (8)255 (16)smoking status, n (%)<0.0001\u2003no2152 (77)704 (61)1448 (88)\u2003quit during Pregnancy306 (11)175 (15)131 (8)\u2003smoking342 (12)277 (24)65 (4)Alcohol consumption, n (%)<0.0001\u2003no1480 (53)708 (61)772 (47)\u2003stopped during pregnancy1185 (42)397 (34)788 (48)\u2003consuming Alcohol135 (5)51 (4)84 (5)fruit intake, n (%)<0.0001\u2003≥1x per day2032 (73)586 (51)1446 (88)\u20033-6x per week405 (14)272 (24)133 (8)\u20031-2x per week223 (8)181 (16)42 (3)\u20031-3x per month or less140 (5)117 (10)23 (1)recreational walking<0.0001\u2003never428 (15)265 (23)163 (10)\u20031-3 times/week1773 (63)668 (58)1105 (68)\u2003≥4 times/week590 (22)221 (19)369 (23)time watching tv<0.0001\u2003<5 hours per day2404 (86)901 (78)1503 (92)\u2003≥5 hours per day387 (14)253 (22)134 (8)season Serum was sampled0.3213\u2003summer636 (23)278 (24)358 (22)\u2003autumn705 (25)273 (24)432 (26)\u2003winter727 (26)300 (26)427 (26)\u2003spring732 (26)305 (26)427 (26)Serum 25(Oh)D nmol/l , mean (sd)68.09 (27.14)60.06 (23.68)73.74 (27.99)<0.0001vitamin D status<0.0001\u2003<25 nmol/l99 (4)48 (4)51 (3)\u200325-50 nmol/l673 (24)375 (32)298 (18)\u200350-75 nmol/l928 (33)422 (37)506 (31)\u2003>75 nmol/l1098 (39)311 (27)787 (48)\n* p values for continuous variables were determined using a welch’s t-test and categorical variables a fisher’s exact test comparing adelaide and auckland women\n\nstandardising Serum 25(Oh)D based on seasonal variation\nAS EXPECTED, there was a seasonal INFLUENCE on Serum 25(Oh)D and THUS, “standardised” Vitamin D concentrations were calculated to account for the month of Serum collection.']	[('INCOMPLETE_EVIDENCE', 1748), ('SUPERFICIAL_RELATIONSHIP', 1782), ('PROBABLE_UNDERSTANDING', 1813)]	3	[('GO_0007602', 'phototransduction', 503, 'pregnancy306'), ('CHEBI_30879', 'alcohol', 565, 'Alcohol'), ('CHEBI_78635', 'fatty alcohol 16:1', 687, 'alcohol135'), ('UBERON_0001977', 'blood serum', 1142, 'serum'), ('UBERON_0001977', 'blood serum', 1289, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 1295, '25(OH)D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1375, 'D'), ('UBERON_0001977', 'blood serum', 1706, 'serum'), ('CHEBI_71657', 'versiconol acetate', 1712, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1712, '25(OH)D'), ('UBERON_0001977', 'blood serum', 1795, 'serum'), ('CHEBI_71657', 'versiconol acetate', 1801, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1801, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 1834, 'vitamin D'), ('UBERON_0001977', 'blood serum', 1903, 'serum')]
